Biomarkers of Nutrition for Development—
Folate Review1–5

Lynn B Bailey,6* Patrick J Stover,7 Helene McNulty,8 Michael F Fenech,9 Jesse F Gregory III,10 James L Mills,11 Christine M Pfeiffer,12 Zia Fazli,12 Mindy Zhang,12 Per M Ueland,13 Anne M Molloy,14 Marie A Caudill,15 Barry Shane,15 Robert J Berry,16 Regan L Bailey,17 Dorothy B Hausman,6 Ramkripa Raghavan,11 and Daniel J Raiten11*

6Department of Foods and Nutrition, University of Georgia, Athens, GA; 7Division of Nutritional Sciences, Cornell University, Ithaca, NY; 8Northern Ireland Centre for Food and Health, Biomedical Sciences Research Institute, University of Ulster, Londonderry, United Kingdom; 9Genome Health Nutrigenomics Laboratory, Food, Nutrition, and Bioproducts Flagship, Commonwealth Scientific and Industrial Research Organization, Adelaide, Australia; 10Food Science and Human Nutrition Department, University of Florida, Gainesville, FL; 11Eunice Kennedy Shriver National Institute of Child Health and Human Development, NIH, Bethesda, MD; 12National Center for Environmental Health, CDC, Atlanta, GA; 13Department of Clinical Science, University of Bergen, Bergen, Norway; 14Institute of Molecular Medicine, Trinity College, Dublin, Ireland; 15Department of Nutritional Sciences and Toxicology, University of California–Berkeley, Berkeley, CA; 16National Center on Birth Defects and Developmental Disabilities, CDC, Atlanta, GA; and 17Office of Dietary Supplements, NIH, Bethesda, MD

Abstract

The Biomarkers of Nutrition for Development (BOND) project is designed to provide evidence-based advice to anyone with an interest in the role of nutrition in health. Specifically, the BOND program provides state-of-the-art information and service with regard to selection, use, and interpretation of biomarkers of nutrient exposure, status, function, and effect. To accomplish this objective, expert panels are recruited to evaluate the literature and to draft comprehensive reports on the current state of the art with regard to specific nutrient biology and available biomarkers for assessing nutrients in body tissues at the individual and population level. Phase I of the BOND project includes the evaluation of biomarkers for 6 nutrients: iodine, iron, zinc, folate, vitamin A, and vitamin B-12. This review represents the second in the series of reviews and covers all relevant aspects of folate biology and biomarkers. The article is organized to provide the reader with a full appreciation of folate’s history as a public health issue, its biology, and an overview of available biomarkers (serum folate, RBC folate, and plasma homocysteine concentrations) and their interpretation across a range of clinical and population-based uses. The article also includes a list of priority research needs for advancing the area of folate biomarkers related to nutritional health status and development. J Nutr 2015;145:1636S–80S.

Keywords: BOND, folate biomarkers, serum folate, RBC folate, homocysteine

Introduction

Folate’s key role in ensuring normal development, growth, and maintenance of optimal health is the focus of the background section of this article, which begins with historical highlights and continues with capstones of clinical, chronic disease, and developmental disorder considerations. Public health applications follow with global intake recommendations coupled with the payment of page charges. This publication must therefore be hereby marked "advertisement" in accordance with 18 USC section 1734 solely to indicate this fact. The opinions expressed in this publication are those of the authors and are not attributable to the sponsors or the publisher, Editor, or Editorial Board of The Journal of Nutrition.

The BOND project was funded in part by the Bill & Melinda Gates Foundation; PepsiCo; the Office of Dietary Supplements (ODS, NIH); the Division of Nutrition Research Coordination (DNRC, NIH); and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD, NIH). The Folate Review was written in response to an invitation from the NICHD of the NIH within the US Department of Health and Human Services (DHH). This is a free access article, distributed under terms (http://www.nutrition.org/publications/guidelines-and-policies/licensed) that permit unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

2 The BOND project was funded in part by the Bill & Melinda Gates Foundation; PepsiCo; the Office of Dietary Supplements (ODS, NIH); the Division of Nutrition Research Coordination (DNRC, NIH); and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD, NIH). The Folate Review was written in response to an invitation from the NICHD of the NIH within the US Department of Health and Human Services (DHH). This is a free access article, distributed under terms (http://www.nutrition.org/publications/guidelines-and-policies/licensed) that permit unrestricted noncommercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

3 Author disclosures: LB Bailey, PJ Stover, H McNulty, MF Fenech, JF Gregory III, JL Mills, CM Pfeiffer, Z Fazli, M Zhang, PM Ueland, AM Molloy, MA Caudill, B Shane, RJ Berry, RL Bailey, DB Hausman, R Raghavan, and DJ Raiten, no conflicts of interest.

4 The content represents the views of the Folate Expert Panel and other invited contributors and does not necessarily represent the official views or positions of the NIH, the CDC/Agency for Toxic Substances and Disease Registry, or the DHHS. In addition, individual members of the expert panel may not endorse all statements in this report.

DOI: 10.3945/jn.114.206599

status estimates and the impact of fortification with a focus on neural tube defect (NTD)\textsuperscript{18} risk reduction. An overview of folate’s chemistry, metabolism, and critically important role in one-carbon metabolism precedes the biomarker-specific sections of the review. After the identification of “priority” biomarkers for folate status assessment, the characteristics of pertinent analytical methods and technical considerations of each are presented (in general in the body of the article and in detail in Supplemental Table 1). Assay-specific issues are addressed for each priority biomarker and advantages and disadvantages summarized. Guidance to the most appropriate choice of method for the purpose and setting including laboratory infrastructure is provided in conjunction with how best to optimize specific analytical methods. In addition to analytical considerations, the review addresses the important issues on interpretation of folate status assessment data with the use of defined cutoff values determined by specific methods. After the method-specific sections, new directions and technologies, including the use of technology as research tools, are addressed. Concluding the review is a summary of research gaps and needs that present challenges and opportunities for research scientists with the interest and expertise to advance the field related to folate biomarkers for nutrition and development.

**Background**

**Historical overview**

Beginning with the observations by Lucy Wills in 1931 (1) of a factor in marmite that produces a cure of macrocytic anemia in pregnant women, a number of events have occurred to reinforce the role of folate as a key nutrient for human health (Table 1). This review will cover what we have learned over the years about this role and how best to assess folate status of humans across a range of developmental and environmental circumstances. The recent reviews by Shane (8) and Pfeiffer et al. (9) provide a perspective of the evolution of methods used to assess folate in both physiologic fluids and foods.

**Clinical considerations and the role of folate in health and disease**

**Clinical stages of folate insufficiency.** Because the Biomarkers of Nutrition for Development (BOND) project is intended to serve the breadth of users involved in the nutrition enterprise, including clinicians, it is useful to appreciate the clinical stages of folate insufficiency in order to inform that community. Inadequate intake is a leading cause of folate deficiency. Other major causes include increased requirements due to pregnancy or neoplastic diseases, malabsorptive conditions, and antifolate drugs or other metabolic inhibitors (10, 11). In Western societies, alcoholism (which affects both folate intake and absorption) is a common cause of low folate status, whereas in developing countries malabsorptive conditions such as tropical sprue are more common causative factors (10). Body stores of folate generally represent a 2- to 3-mo supply, and folate deficiency can develop in persons of any age with an inadequate intake and/or increased requirement for the vitamin (11). The clinical presentation of folate deficiency covers a wide range of symptoms, the basic progression of which is highlighted in Table 2.

### Increased folate requirements for maternal health and fetal development.

Although essential throughout life, folate is particularly critical during early stages of human development. Since the first report of amelioration of macrocytic anemia by exposure to folate-rich food sources (1), pregnancy has been recognized as a time when folate requirements are increased to sustain the demand for rapid cell replication and growth of fetal, placental, and maternal tissue, relating to the critical role it plays in DNA, RNA, and protein synthesis. Maintaining an adequate folate status throughout pregnancy is important not only for the mother’s health but also for the developing infant because folate inadequacy in pregnancy has been associated with a number of adverse outcomes (21). These include folate-responsive NTDDs and neural crest disorders (e.g., congenital heart defects), fetal growth retardation, low birth weight, preterm delivery, and neonatal folate deficiency. It is also notable that folate requirements are increased during lactation in order to meet both maternal and neonatal needs (21).

### Folate and disease.

Increased folate requirements in clinical settings have been linked with some anemias, malignancy, and in patients undergoing renal dialysis (22). In addition, folate status may become an issue in the context of therapeutic drug use including the following:

- anticonvulsant drugs (phenytoin, primidone);
- sulfasalazine (used in the treatment of inflammatory bowel disease);
- trimethoprim (a diuretic); and
- metformin (used in type 2 diabetes).

Some malabsorptive conditions can lead to folate deficiency (22). These include extensive inflammatory bowel disease (Crohn disease and ulcerative colitis), tropical sprue, and celiac disease, a genetically determined chronic inflammatory intestinal condition involving gluten-sensitive enteropathy and associated deficiency of iron, folate and other vitamins due to impaired absorption. In this condition, megaloblastic anemia is commonly encountered at the time of diagnosis, and subclinical deficiency is found in patients reported to have persistent mucosal damage (23).

Chronic alcoholism is associated with severe folate deficiency linked to poor dietary intake, intestinal malabsorption, impaired hepatic uptake with reduced storage of endogenous folates, and increased renal excretion (24). Hepatic methionine metabolism is also impaired in chronic alcoholism (24).
TABLE 1 Landmark events in folate history and critical points in assessment

Landmark events
- 1931, Lucy Wills, working in India, published an article on “The treatment of ‘pernicious anemia of pregnancy’ and ‘tropical anemia’” in which she reported curing tropical macrocytic anemia with marmite. She was not able to identify the specific factor that produced the cure, noting that “at present it is only possible to state that in marmite, and probably in other yeast extracts, there appears to be a curative agent for this dread disease...” (1)
- 1941 Mitchell et al. (2) described “folic acid” extracted from 4 tons of spinach. The name was derived from the Latin word folium for leaf. They also noted that “folic acid” stimulated the growth of Lactobacillus casei.
- 1945 Spies (3) demonstrated that folic acid produced a prompt hematologic response in macrocytic anemia; among the patients he treated were some patients with pernicious anemia, providing one of the first reports of masking of pernicious anemia by folic acid.

Critical points in folate assessment (4)
- Assessing folate status is complicated by the large number of folate forms that may be readily interconverted.
- Microbiological assays have been used for many decades due to the ability of some bacteria to grow in the presence of many different forms of folate (e.g., L. casei, now known as Lactobacillus rhamnosus, responds to all active monoglutamate forms). Microbiological assays are viewed by many researchers as the “gold standard.”
- Subsequently, assays using competitive protein binding became common because of their simplicity (4).
- In recent years the use of LC-MS/MS1 has been recommended to quantitate individual folate forms which may be useful to:
  - Characterize metabolic alterations due to the common polymorphism in methylenetetrahydrofolate reductase (677 C>T) capable of reducing blood folate (5) and causing alterations in the proportion of folate forms in RBCs (6).
  - Identify blood folate resulting from food fortification and use of folic acid containing supplements.

1 LC-MS/MS, liquid chromatography–tandem mass spectrometry.

Role of folate in chronic disease risk. Metabolic changes associated with impaired folate status have been linked to increased risk of chronic diseases including cancer and cardiovascular disease and cognitive dysfunction. As described in detail later in the review, folate is required for remethylation of homocysteine to methionine and DNA synthesis and cell proliferation in addition to methylation reactions that affect critical processes such as methylation of cytosine in DNA for control of gene expression and neurotransmitter synthesis. The types of chronic diseases linked to folate status and folate-related metabolic abnormalities are summarized below.

Cancer. Several cancers such as leukemia, lymphoma, and colorectal, breast, and prostate cancer have been associated epidemiologically with low folate status (25–28). Carcinogenesis has been linked with poor folate status because of the induction of DNA breaks by uracil incorporation in DNA (29). These deleterious genomic events lead to chromosome fragmentation and rearrangements, causing the generation of cells with aberrant karyotypes and altered gene dosage from which cancers have a higher probability of evolving (30). Hypomethylation of DNA associated with poor folate status may lead to inappropriate expression of genes that potentially predispose to cancer (e.g., uncontrolled expression of proto-oncogenes) (31). Although the prevention of folate deficiency has been linked to diminished cancer initiation, it has been hypothesized that excessive folate intake may fuel the growth of initiated cancers (32, 33). A recent meta-analysis with data on 50,000 individuals concluded that folic acid supplementation does not significantly increase or decrease site-specific cancer during the first 5 y of treatment (34).

Cardiovascular disease. As outlined later, one of the key folate-dependent pathways is associated with the generation of homocysteine. Hyperhomocysteinemia, which may result from poor folate intake or impaired folate metabolism as well as vitamin B-12 deficiency, has been associated with an increased risk of hypertension, cardiovascular disease, and cerebrovascular disease in epidemiologic studies (35–38). Although these observational findings do not support a causal effect, several mechanisms have been proposed by which hyperhomocysteinemia may mediate the risk of these diseases (38, 39).

Results of placebo-controlled intervention studies of folic acid supplementation, with or without vitamin B-12, have not yielded evidence of a strong protective effect against the incidence or progression of cardiovascular disease or cerebrovascular disease in the short term (<2 y). The evidence from these intervention studies does not support the previously hypothesized causal relation between homocysteine and cardiovascular disease that was based on observational studies.

Neurological conditions. Recent trials with longer intervention time frames using multiple B vitamins including folic acid suggest potential benefits against stroke, brain shrinkage, cognitive decline, and depression, particularly in those with above-average concentrations of homocysteine within the cohorts studied (40–43). In contrast, a recent meta-analysis of 11 trials on the effects of homocysteine lowering with B vitamins found no significant effect on individual cognitive domains or global cognitive function or on cognitive aging (44). However, meta-analyses on the effect of B vitamins on cognition (44, 45) included trials in which any effect would be difficult to detect because of the low sample size, short trial duration, or inclusion of healthy subjects not experiencing cognitive decline, subjects with already excellent B vitamin status, or severely demented patients in whom the treatment comes too late for any meaningful effect.

TABLE 2 Stages of folate insufficiency

- Events in the blood (12)
  - a decrease in plasma folate concentration followed by
  - an increase in plasma homocysteine concentration and
  - a reduction in RBC folate
- At the morphologic level, megaloblastic changes in the bone marrow and other rapidly dividing tissues becomes evident (13)
- Megaloblastic cells are abnormally large cells with large nuclei (characterized by a finely stippled lacy pattern of nuclear chromatin) and apparently normal cytoplasm, which give rise to the classic morphologic finding of nuclear-cytoplasmic dissociation
- Other abnormal nuclear changes may also occur: these include hypersegmentation of nuclei in neutrophils or generation of micronuclei in lymphocytes, which are a biomarker of chromosome breakage or loss; when found in RBCs, these are also known as Howell-Jolly bodies (14–18)
- The incapacitation of erythroblast replication results in reduced and abnormal erythrocyte production leading to anemia and reduced oxygen-carrying capacity of the blood, which may lead to symptoms of weakness, fatigue, irritability, and shortness of breath (19, 20)
Genetic considerations. An emerging body of evidence and research effort point to the potential for genetics to significantly affect folate metabolism and disease risk. Common polymorphisms in genes that code for proteins/enzymes required for folate uptake [e.g., glutamate carboxypeptidase II (GCPII; 1561 C>T), reduced folate carrier (RFC; 80 G>A)] and metabolism [e.g., methylenetetrahydrofolate reductase (MTHFR; 677C>T), methionine synthase (MTR; 2756 A>G)] have been shown to alter the catalytic activity or expression of these proteins, which can have a substantial influence on developmental or degenerative disease risk, providing further support for the central role of this key vitamin in health maintenance (46). Because some of these enzymes require other dietary cofactors for their function (e.g., vitamin B-12 and riboflavin as cofactors for MTR and MTHFR, respectively), it is important to take into account not only nutrient-gene interactions but also interactions of folate with other nutrients on health effects.

Role of folate in birth defects. A major driver of much of the recent public health attention to the importance of folate has been its link to a specific set of serious development disorders associated with defects in the closure of the neural tube. These disorders lead to an extremely serious set of disorders called “neural tube defects.” Although considerable epidemiologic and experimental evidence links folate status to NTD risk, occurrence, and recurrence (47), the metabolic mechanisms by which folate promotes neural tube closure and reduces NTD risk are yet to be delineated. Because folate functions as an essential cofactor for the de novo synthesis of purine and thymidine nucleotides and for the remethylation of homocysteine to methionine, it has been suggested that folate can influence NTD risk by impairing nucleotide biosynthesis and cell division, elevating homocysteine, or altering the cellular methylation potential and gene expression (48). However, it is unlikely that one mechanism will suffice to explain the link between folate status and NTD risk. It is more likely to be an outcome of the complex interactions between folate nurture, genetic, and environmental factors (49, 50).

Despite our lack of clarity with regard to the etiology of NTDs, a series of reports culminating in 2 landmark clinical trials that showed that folic acid taken periconceptually could dramatically reduce the risk of NTDs (51, 52) led the US Public Health Service (USPHS) to recommend that all women of childbearing age capable of becoming pregnant take 400 µg folic acid daily (53). The approach and impact of this decision will be covered in greater detail in the section below.

Public health approaches

Low dietary intake remains the most common cause of folate inadequacy, both in developed and developing countries, and generally those of lower socioeconomic status do not consume high-folate-content foods. Furthermore, although the diets of many people worldwide may be adequate in preventing clinical deficiency (i.e., megaloblastic anemia), they may be insufficient to achieve a biomarker status of folate that is associated with optimal health and fetal development (i.e., NTD risk reduction). Accordingly, folate intakes of such diets would be considered suboptimal. This widespread underprovision of folate is generally attributed to the poor stability and incomplete bioavailability of natural food folates when compared with the synthetic vitamin folic acid (54). As a consequence, a large public health effort has gone into addressing the folate needs of the global population. The following is coverage of the key elements of those efforts.

Folate intake recommendations

Table 3 provides select examples of the folate intake recommendations across the world, including the US Institute of Medicine’s (IOM’s) DRIs. The FAO/WHO Expert Consultation adopted the RDAs set by the IOM (55) as the basis for the Recommended Nutrient Intakes (56). Other countries/regions with specific guidance include the following: Australia and New Zealand (57); the United Kingdom (58); Ireland (59); Germany, Austria, and Switzerland (60); The Netherlands (61); Denmark, Sweden, Norway, Iceland, and Finland (62); and Southeast Asia, encompassing Indonesia, Malaysia, The Philippines, Singapore, Thailand, and Vietnam (63). The basis of these recommendations and how they compare with the IOM DRIs have been reviewed (65).

The IOM recommendations consist of several categories (55). Of most relevance to folate are the following:

- Estimated Average Requirement: the median usual intake of the nutrient that meets the requirements of 50% of the population
- RDA: based on the Estimated Average Requirement, corrected for population variance, and represents the average daily dietary intake level sufficient to meet the nutrient requirement of ~98% of the population
- Adequate Intake: the quantity of a nutrient consumed by a group with no evidence of inadequacy
- Tolerable Upper Intake Level: defined as the “maximum daily intake levels at which no risk of adverse health effects is expected for almost all individuals in the general population, including sensitive individuals, when the nutrient is consumed over long periods of time” (66)

Table 4 provides some key points with regard to the derivation of DRIs for folate.

Folic acid intake recommendation for NTD risk reduction.

For NTD risk reduction, the IOM (55) recommends that all women capable of becoming pregnant consume 400 µg folic acid/d from supplements or fortified foods in addition to folate from a varied diet. This recommended intake for NTD risk reduction is consistent with that of the USPHS (53) and is not the same as the RDA (400 µg dietary folate equivalents (DFEs), equivalent to 235 µg folic acid), a common misconception. The implications and impact of this policy are discussed in detail in the section below entitled “A case study in public health intervention: folic acid and NTDs.”

Folate/folic acid intake and adequacy in the United States.

The USDA Food and Nutrient Database for Dietary Studies (69) can be used to estimate dietary folate intake (µg/d) in specific categories including the following:

- naturally occurring food folate;
- folic acid, including that in enriched cereal-grain products (140 µg/100 g flour) and in folic acid–fortified ready-to-eat cereals, including those with ~100 to 400 µg/serving (70);
- total folate in µg/d; and
- total folate in µg/d DFEs.

Yang et al. (71) estimated folic acid intake provided by different food intake categories for the nonpregnant adult US population aged ≥19 y from NHANES 2003–2004 and 2005–2006. These results confirmed those of other studies that consumption of ready-to-eat cereals and/or supplements contributes significantly to intakes of folic acid. Table 5 provides some additional detail with regard to folic acid exposure in the United States.
### TABLE 3  Selected examples of folate intake recommendations worldwide

<table>
<thead>
<tr>
<th>Category</th>
<th>United States and Canada (59), µg/d DFE</th>
<th>FAO/WHO (56), µg/d DFE</th>
<th>Australia, New Zealand (57), µg/d folate</th>
<th>United Kingdom (58), µg/d folate</th>
<th>Ireland (59), µg/d folate</th>
<th>Germany, Switzerland, Austria (60), µg/d DFE</th>
<th>The Netherlands (61), µg/d DFE</th>
<th>Nordic countries (62), µg/d folate</th>
<th>Southeast Asia (63), µg/d folate</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>RDA/AI</td>
<td>RNI</td>
<td>RDI/AI</td>
<td>RNI</td>
<td>RDA</td>
<td>RI</td>
<td>RDA/AI</td>
<td>RI</td>
<td>RDA</td>
</tr>
<tr>
<td>Infants</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0–6 mo</td>
<td>65²</td>
<td>80</td>
<td>65²</td>
<td>50</td>
<td>50</td>
<td>(&lt;4 mo) 60</td>
<td>50 (0–5 mo) 50²</td>
<td>None set</td>
<td>(0–5 mo) 80</td>
</tr>
<tr>
<td>7–12 mo</td>
<td>80²</td>
<td>80</td>
<td>80²</td>
<td>50</td>
<td>50</td>
<td>(4–11 mo) 80</td>
<td>(6–11 mo) 60²</td>
<td>50</td>
<td>(6–11 mo) 80</td>
</tr>
<tr>
<td>Children</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1–3 y</td>
<td>150</td>
<td>160</td>
<td>150</td>
<td>70</td>
<td>100</td>
<td>(1–4 yr) 200</td>
<td>85²</td>
<td>(12–23 mo) 60</td>
<td>160</td>
</tr>
<tr>
<td>4–8 y</td>
<td>200 (4–6 y)</td>
<td>200</td>
<td>(7–9 y)</td>
<td>300</td>
<td>200</td>
<td>(4–6 yr) 100; (7–10 yr) 150</td>
<td>(4–9 yr) 300</td>
<td>150²</td>
<td>(2–5 yr) 80; (6–9 yr) 130</td>
</tr>
<tr>
<td></td>
<td>(all ages)</td>
<td>(4–8 y)</td>
<td>(all ages)</td>
<td>(14–18 y) 300; (≥19 y) 300</td>
<td>(≥14 y) 300</td>
<td>(≥10 y) 400</td>
<td>(15–20 y) 300; (21–30 y) 500</td>
<td>(≥19 y) 500</td>
<td>(14–18 y) 300; (≥19 y) 300</td>
</tr>
<tr>
<td>Males</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9–13 y</td>
<td>300</td>
<td>(≥10 y) 400</td>
<td>300</td>
<td>(≥11 y) 200</td>
<td>(≥11 y) 300</td>
<td>(≥10 y) 400</td>
<td>225²</td>
<td>(10–13 y) 200</td>
<td></td>
</tr>
<tr>
<td>≥14 y</td>
<td>400</td>
<td>400</td>
<td>400</td>
<td>300</td>
<td>(14–18 y) 300; (≥19 y) 300</td>
<td>(≥14 y) 300</td>
<td>(≥14 y) 300</td>
<td>(≥10 y) 400</td>
<td></td>
</tr>
<tr>
<td>Females</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9–13 y</td>
<td>300</td>
<td>(≥10 y) 400</td>
<td>300</td>
<td>(≥11 y) 200</td>
<td>(≥11 y) 300</td>
<td>(≥10 y) 400</td>
<td>225²</td>
<td>(10–13 y) 200</td>
<td></td>
</tr>
<tr>
<td>≥14 y</td>
<td>400</td>
<td>400</td>
<td>400</td>
<td>300</td>
<td>(14–18 y) 300; (≥19 y) 300</td>
<td>(14–17 y) 300; (18–30 y) 400; (≥30 y) 300</td>
<td>(≥10 y) 400</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pregnancy</td>
<td>600</td>
<td>600</td>
<td>600</td>
<td>300</td>
<td>(Second half) 500</td>
<td>600</td>
<td>400²</td>
<td>500</td>
<td></td>
</tr>
<tr>
<td>(all ages)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lactation</td>
<td>500</td>
<td>500</td>
<td>500</td>
<td>260</td>
<td>(First 6 mo) 500</td>
<td>600</td>
<td>400²</td>
<td>500</td>
<td>(First 6 mo) 500; (second 6 mo) 500</td>
</tr>
</tbody>
</table>

1 Note that units used to express intake recommendations differ among countries. AI, Adequate Intake; DFE, dietary folate equivalent; RI, recommended intake; RNAI, recommended nutrition intake. Adapted from reference 64 with permission.

2 Indicates AI, which is believed to cover the needs of all individuals in the group, but lack of data or uncertainty in the data prevents being able to specify with confidence the percentage of individuals covered by this intake.
TABLE 4  Key points with regard to IOM folate recommendations

- Primary biomarker used for DRI was RBC folate concentration, an index of tissue stores and long-term status.
- Ancillary biomarkers included serum folate and Hcy concentrations.
- The EAR for adults was based primarily on data from controlled metabolic studies in which folate response to defined diets was determined.
- Additional supporting evidence included data from epidemiologic studies in which folate intake was estimated in conjunction with status indicators.
- The DRIs are expressed in DFEs, defined as micrograms of naturally occurring food folate plus 1.7 times the micrograms of synthetic folic acid. The use of DFEs is intended to
  - account for differences in bioavailability between synthetic folic acid in fortified foods and naturally occurring dietary folate and
  - establish equivalency of all forms of folate, including folic acid in fortified foods.
  The 1.7 multiplier for converting micrograms of folic acid to DFEs was based on the assumption that added folic acid (consumed with a meal) is ~85% available (67) and food folate is ~50% available (68); thus, the ratio 85:50 yielded the multiplier of 1.7 in the DFE calculation.
- UL for adults (≥19 y) for folic acid is 1000 μg/d. There is no UL for naturally occurring food folate.
- UL for folic acid is based on case reports in patients treated for vitamin B-12 deficiency treated with high doses of folic acid (>5 mg/d in most cases) and the observation that hematologic but not neurological symptoms were reversed in the majority of cases with the folic acid treatment.
- UL for children
  - No direct data available for children aged 1–18 y
  - Used adult UL and adjusted by weight: 300–800 μg/d, depending on the age group
  - No UL established for infants

TABLE 5  Folic acid intake in the United States

- Based on NHANES data (2003–2004 and 2005–2006), the estimated usual median folic acid (μg/d) intakes provided by different food intake categories were as follows:
  - 139 from ECGPs only,
  - 274 from ECGPs plus RTECs,
  - 479 from ECGPs plus supplements, and
  - 635 from ECGPs + RTECs + supplements (71).
- An estimated 60% of US adults consumed folic acid from RTECs and/or supplements and 15% from both (71).
- Regular consumption of RTECs with folic acid was associated with an ~100% higher usual intake.
- Use of folic acid–containing supplements was associated with >200% higher intake compared with consumption of ECGPs only (71).
- Folic acid intake exceeding the UL was reported in NHANES (71).
  - Overall, <3% of US adults exceeded the UL
  - Among the 60% of adults who did not take supplements postfortification (NHANES 2003–2004 and 2005–2006), 0% exceeded the UL for folic acid.
  - Among the 34% and 6% of adults who consumed supplements with an average of ≤400 or >400 μg/d folic acid, <1% and 47.8% (95% CI: 39.6%, 56.0%) consumed more than the UL, respectively.

Folate status estimates

Folate status in the United States based on specified biomarkers and the effect of fortification.

Serum and RBC folate. Serum and RBC folate have been assessed for the US population as part of the NHANES, first (1988–2006) with the Bio-Rad radioassay, and later (2007–2010) with the microbiological assay (MBA) (4). Population-based reference data for serum and RBC folate concentrations from the 2003–2006 NHANES were recently summarized (72) (Figures 1–3, Table 6). In the most recent NHANES folate status report of the 2007–2010 time period, previously published data generated with the Bio-Rad assay (1988–2006) were adjusted by using statistical models to a microbiologic equivalent value to bridge known assay differences, thus enabling time trend evaluations (73) (Table 6).

Homocysteine. Because of its reputed impact on health, as discussed above, plasma homocysteine was assessed as a nonspecific “functional” indicator of folate status in NHANES (72). Elevated plasma homocysteine concentrations (>13 μmol/L) were found in ~8% of the population aged ≥20 y and in 19% of persons aged ≥60 y participating in NHANES 2003–2006 (72). Pfeiffer et al. (74) estimated a 10% decrease in plasma homocysteine when comparing prefortification (1991–1994) to postfortification (1999–2004) concentrations in a national sample of the US population.

Folate status in countries other than the United States based on specified biomarkers and guidelines in current use. Because folic acid in foods is more stable and bioavailable than naturally occurring food folates, the biomarker status of folate tends to be highest in countries with mandatory folic acid fortification, followed by those countries with voluntary fortification. Voluntary fortification of a wide variety of foods is practiced in many countries worldwide (75, 76). Because of the variability in the number of foods fortified and subsequently consumed, folate status (and related health outcomes) in countries with voluntary fortification is more disparate than in countries with mandatory fortification (77). Mandatory fortification may not reach all women of reproductive age adequately; however, the lowest folate status in population groups is found in those countries without access to folic acid–fortified foods, even on a voluntary basis (78). As of November 2012, 75 countries have passed regulations for mandatory fortification of staple foods with folic acid and iron (79). Features of the mandatory fortification can be found in Table 7. Figure 4 shows a map of the global efforts to actualize folic acid fortification of foods.
A recent review of folate deficiency worldwide compared surveys of folate status published between 1995 and 2005 (84) and highlighted many of the challenges confronting the global community (Table 8). The overall conclusion of the report was that to gain a better understanding of the magnitude of folate deficiency worldwide, there was a need for more population-based studies specifically designed to assess folate status, consensus on the best indicators for assessing folate status, and agreement on the appropriate biomarker cutoff point to define the severity of deficiency (84).

The European Community has been addressing this issue in a variety of ways and several points can be made about these efforts:

- Although nationally representative dietary surveys are available for several European countries (85), such surveys are often conducted without the inclusion of corresponding blood samples for determination of biomarker status, thereby preventing biomarker concentrations to be examined in relation to population intakes of folate.
- Observed variability in folate status among European countries is primarily due to differences in exposure to folic acid–fortified foods:
  - National fortification policy varies considerably throughout the European Union.
  - Many European countries (e.g., the United Kingdom and Ireland) permit the addition of folic acid and other nutrients to foods on a voluntary basis (i.e., at the manufacturer’s discretion); others (e.g., Denmark) prohibit fortification of any kind or specifically limit fortification with folic acid (e.g., The Netherlands).
  - The United Kingdom and Ireland have voluntary, relatively liberal, fortification policies that permit folic acid and other micronutrients to be added to various foods (e.g., breakfast cereals), thus allowing the consumer to have ready access to fortified foods. Under these conditions, studies show that typically ~75% of the population will consume fortified foods on a regular basis.
  - The impact of voluntary fortification was examined in a convenience sample of 441 healthy adults aged 18–92 y who were not taking folic acid supplements in Northern Ireland (86):
  - Fortified foods were associated with significantly higher total folate and folic acid intakes.
Although age-adjusted or race/ethnicity: NHANES 1988–2006. Values are age-adjusted geometric means; error bars represent 95% CIs. Within a demographic group, bars not sharing a common letter differ ($P < 0.05$). To convert μg/L to nmol/L, multiply by 2.266. Adapted from reference 72 with permission.

RBC folate concentrations were 387 nmol/L higher, and plasma homocysteine concentrations were 2 μmol/L lower, in the group in the highest tertile of fortified food intake (median intake of 208 μg/d folic acid) compared with nonconsumers of fortified foods (0 μg/d folic acid).

Although a comprehensive review of efforts to address folate status globally is beyond the scope of this article, a comparison of folate intake recommendations by different countries provides insight into global efforts to establish folate intake recommendations to maintain adequate folate status. Table 3 presents a comparison of these country- or region-specific folate intake recommendations, which have been previously reviewed (65).

**Folate status in children.** As will be discussed in further detail below, folate biology and subsequent requirements are developmentally sensitive. As noted, the bulk of surveillance has focused on the folate status of adults. However, some effort has gone into the assessment of status of children. Two prime examples are published data from population-based surveys conducted in the United Kingdom (87) (Figure 5) and the United States (88). Both reports describe a decline in folate status biomarkers with age from childhood to adolescence; these observations in British and American children are consistent with findings from Belgian, Dutch, and Greek children (albeit not population-based cohorts but convenience samples) (89–91), also showing age-related decreases in folate concentrations. Of particular note, where dietary intakes were also measured by using validated methodologies (87, 88, 91), the data showed that dietary folate intakes in general compared favorably with dietary reference values across all age groups and were not lower in the older children after adjustment for total energy. The mechanism for the decline in folate status biomarkers with age in children and adolescents, despite no corresponding decline in dietary folate intakes, is not clear but may be an indication that folate requirements of older children are increased due to higher metabolic demands for growth from childhood to adolescence (Table 9).

**Major causes of folate inadequacy in developed and underdeveloped countries.** Folate inadequacy is not uncommon, even in otherwise well-nourished populations. As with any nutrient, a low or deficient status of folate can arise in any situation in which requirements are increased or availability is decreased or both, with the clinical manifestation of folate deficiency (i.e., megaloblastic anemia) more likely to be present when both occur simultaneously. The major causes of folate inadequacy are shown in Table 9. The biology of folate, including increased demands from a life stage and clinical perspective, will be covered in the subsequent sections. The assessment of these factors linked to folate inadequacy requires accurate and reliable measures of folate exposure. The following section addresses our current tools to evaluate that need.

**Determining adequacy of folate intake/status.** As discussed in greater detail below, RBC folate, widely considered the most robust biomarker of long-term status, is found to be moderately correlated with habitual folate intake when the latter is expressed as DFEs (as is done in the United States), thus accounting for the greater bioavailability of folic acid compared with naturally occurring food folates (86) (Figure 6). This conversion factor is not applied in most European countries, where folate intakes are expressed as total folate in micrograms per day (Table 3). As a result, the relation between folate

---

**TABLE 6** Summary of key findings of folate status in the US population after initiation of mandatory fortification in 1998

- Serum and RBC folate concentrations followed a U-shaped age pattern, with the lowest concentrations seen in adolescents and young adults, respectively (Figure 1) (72).
- Serum folate concentrations more than doubled and RBC folate concentrations increased by ~50% (Figures 2 and 3) (72).
- Small decreases (<10%) in serum and RBC folate concentrations were observed from the earlier (1999–2002) to the later (2003–2006) postfortification period (Figures 2 and 3) (72).
- Based on microbiologically equivalent blood folate data for 6 prefortification (1988–1994) and 12 postfortification (1999–2010) years, the prevalence of low serum (<10 nmol/L) or RBC (<340 nmol/L) folate concentrations was ≤1% postfortification, regardless of demographic subgroup, compared with 24% for serum folate and 3.5% for RBC folate prefortification (72).
TABLE 7 Features of mandatory fortification

- Mandatory fortification of ≥1 food products is carried out under specific regulations or laws that are country-specific (80).
- Mandatory fortification can include many food products or be limited to only 1 staple food product.
- The level of folic acid fortification should be determined by the average daily consumption of the chosen food product and the mean target intake of folic acid desired in the target population (81).
- In the United States and Canada, all cereal-grain food products labeled as enriched are fortified through a standard of identity regulation at 1.4 mg/kg flour or cereal-grain product (70).
- Case study: Chile
  - Only bread is fortified with folic acid based on the goal of providing an average of 400 μg/d folic acid to women 15–44 y of age.
  - Food consumption patterns were used to support the decision to fortify bread flour with 220 μg folic acid per 100 g of bread flour (82).

biomarkers and dietary intake is found to be weaker, i.e., for RBC vs. natural food folates \( r = 0.290 \) (\( P < 0.001 \)) and for RBC vs. food folic acid \( r = 0.416 \) (\( P < 0.001 \)) (86). The contrasting approaches to expressing dietary folate intakes make any evaluation of adequacy of dietary folate intake in relation to biomarker status, or comparison of folate recommendations between countries, inherently complicated.

Folic acid in circulation: what does it mean? Concerns have been raised about the low concentrations of fasting unmetabolized circulating folic acid (0–2 nmol/L) found in subjects consuming fortified foods and/or folic acid–containing supplements (92). The concern about folic acid is primarily because folic acid is not a naturally occurring form of the vitamin. The “absence” of unmetabolized folic acid in plasma at lower folic acid doses in some studies most likely reflects limitations of the assay methods used to detect very low concentrations of folic acid.

A review of the extant literature revealed a single human study in postmenopausal women that reported what the authors concluded was a potential adverse effect of folic acid (93). Unmetabolized folic acid, but not total folate, in plasma was related to a decrease in NK cell cytotoxicity. Many of the elderly subjects in the study were obese, and it is possible they had conditions that influenced the concentration of soluble folate-binding protein (FBP) in plasma. If so, plasma folic acid concentrations would be merely reporting on the concentrations of soluble FBP (folic acid has a very high affinity for FBP), which, in turn, would be reporting on an underlying condition, and neither would be causative for the decrease in NK cell cytotoxicity. Other studies showed no effect of folic acid on NK cell cytotoxicity (94).

The effect of folic acid supplements on human-milk folate content was assessed in women who had received a folic acid prenatal supplement (750 μg/d) and who consumed 400 μg/d dietary folate during the third trimester of pregnancy (95). In this study, the prenatal folic acid dose did not increase human-milk total folate, but the proportion of folic acid increased to 40% of total breast-milk folate. A possible concern was raised about the effect of prenatal folic acid supplements on breast-milk folic acid concentrations; however, folic acid has been added to infant formula for many years without any apparent adverse effect. Aside from the results reported above, no confirmed metabolic effects have been found for plasma folic acid that would not be mimicked by the much higher concentrations of reduced folate in plasma. Thus, it is difficult to envisage a scenario in which the very low concentrations of circulating folic acid could have a specific adverse effect.

A case study in public health intervention: folic acid and NTDs. Two landmark clinical trials (51, 52) showed that folic acid, taken periconceptionally, could reduce the risk of both recurrent (51) and the first occurrence of (52) NTDs dramatically and led the USPHS to recommend that all women of childbearing age who are capable of becoming pregnant take 400 μg folic acid daily. Only a minority of women followed this recommendation, prompting the FDA to mandate that enriched cereal grain products (e.g., bread, pasta, rice) be fortified with 140 μg folic acid per 100 g grain in order to reach the population at risk.

The impact of this effort has not been easy to measure. In the United States, most NTDs are diagnosed prenatally and pregnancies may be terminated without being identified in vital records. Thus, determining the prevalence of NTDs reported on birth certificates results in many missed cases (78). Fortunately, in Canada, which has a very similar fortification program, more information is available on prenatally diagnosed cases (96). Comparing the impact of fortification between US and Canadian studies showed that the decrease in prevalences was greater in areas where ascertainment was more complete (97). However, the percentage reduction in prevalence was greater in Canada because the baseline prevalence was higher than in the United States, whereas the NTD prevalence postfortification was lower in the United States than in Canada. Because percentage reduction is a function of the baseline prevalence (98) it should only be used to monitor progress within a population and not be used to compare the impact of folic acid intervention on NTDs among countries.

The lowest achievable NTD prevalence in response to folic acid intervention is estimated to be ~5–6 per 10,000 pregnancies and consists of largely folate-insensitive NTDs. Other causes of NTDs are not preventable by folic acid (e.g., drug exposure, other genetic conditions) and these are thought to contribute to ~5 NTDs per 10,000 births because folic acid fortification results in reductions to approximately this rate in multiple population settings (78).

Can folate status biomarkers be used to assess NTD risk? The number of NTDs that could be prevented in a population has been shown to be dependent on folate status; specifically,

FIGURE 4 All countries shown in black fortify flour with at least iron and folic acid, except for Australia, which does not include iron, and Venezuela, the United Kingdom, the Philippines, and Trinidad and Tobago, which do not include folic acid. Reproduced from reference 88 with permission.
TABLE 8 Key points regarding the extant global folate survey data

- Folate status was most frequently assessed in
  - women of reproductive age (34 countries) and
  - in adults generally (27 countries).
- Surveys of preschool-aged children and pregnant women, those likely to be at
greatest risk of deficiency, are greatly lacking.
- The majority of the 145 studies examined (78%) assessed folate status by serum (or
plasma) folate; far fewer reported RBC folate (45%).
- Few nationally representative studies were available for investigation; but, on the
basis of evidence from countries with such survey data, deficient folate status (i.e.,
>5% of the population with a serum folate value below the normal range) was
identified in specific age groups in 6 of 8 countries, most notably in preschool-aged
children in Venezuela, pregnant women in Costa Rica (before mandatory fortification)
and Venezuela, and the elderly in the United Kingdom.

1 Data from reference 84.

RBC folate concentration has been shown to be a reasonable biomarker of NTD risk (99, 100). Daly et al. (100) found that the prevalence of NTD in an Irish population was <8 per 10,000 when RBC folate concentrations were ≥906 nmol/L. The dose-response between RBC folate concentrations and NTD risk in the Irish study (100) agreed with data modeled from Chinese folate intervention studies by Crider et al. (99). Crider et al. (99) reported that the NTD risk was substantially attenuated at RBC folate concentrations >1000 nmol/L. Their results indicated that an RBC folate concentration of ~1000–1300 nmol/L may achieve optimal prevention of folate-sensitive NTDs, with a resulting overall risk of NTDs of ~6 per 10,000 births. On the basis of distributions of RBC folate concentration (88, 99), the US population level of NTDs prefortification was estimated to be 10.1–16.4 per 10,000 births and postfortification prevalence to be in the range of 4.2–7.7 per 10,000 births (99). The WHO has developed new guidelines for optimal RBC folate concentrations associated with NTD risk reduction on the basis of published findings (101).

Has food fortification with folic acid prevented all folate-related NTDs in the United States? In 2 studies (102, 103), investigators collected data on folate/folic acid exposure in women who had NTD pregnancies and women who had unaffected pregnancies. They found that women who had an affected child were not significantly less likely to have used folate acid supplements. The data from these 2 epidemiologic studies suggest that because folic acid supplement use was not determined to significantly affect NTD risk, the amount of folic acid in fortified food alone in the United States may be sufficient to prevent a large percentage of folate-related NTDs. Conclusions from these studies are not definitive because the numbers of affected cases may have been insufficient to detect a true difference. The small sample sizes prevented subgroup analysis, which may have revealed racial/ethnic differences because a smaller decline in NTDs was detected in Hispanics during the postfortification period relative to non-Hispanic whites. In addition, recall bias cannot be ruled out because of the long period of time between interview and neural tube formation (up to 3 y).

A subgroup of US women who are non-supplement users may still be at increased risk of folic acid–preventable NTDs. This conclusion is based on the following facts: 1) folic acid supplements are taken infrequently by women of childbearing age in the United States (~30%) (104), 2) there is a high rate of unplanned pregnancies in the United States (~50%) (105), and

3) the neural tube closes by day 28 of gestation, before most women know they are pregnant (106).

Because NTDs are known to have a strong genetic component, there has been an extensive search for folate gene variants that increase the risk of NTDs. The results have been mixed, which may relate to the mitigating effect that folic acid intake has on genetic risk. Thus, although many genetic variants in folate enzyme genes have been identified, a relatively small number have been shown to influence folate or homocysteine concentrations (107). Nonetheless, MTHFR 677 C>T has been shown to be a risk factor for NTDs in most studies and in a large meta-analysis (108).

The question of whether birth abnormalities other than NTDs are significantly affected by maternal folic acid intake has been investigated (109–113). There is, however, a lack of consistent evidence that the risk of birth defects other than NTDs is positively affected by folic acid in the amount consumed in supplements and/or fortified foods (109–113).

FIGURE 5 RBC folate and plasma homocysteine concentrations in
a representative sample of British children aged 4–18 y. Differences
between groups were assessed by using 1-factor ANOVA (with
Tukey’s post hoc tests), adjusted for sex, smoking, breakfast cereal
consumption, and supplement use (ANCOVA: P < 0.05). Bars not
sharing a common letter differ, P < 0.05. Adapted from reference 87
with permission.
**TABLE 9** Primary causes of folate inadequacy

- Reduced dietary intake (e.g., low intake of folic acid–fortified foods, dark-green leafy vegetables, legumes, select fruit such as orange juice)
- Increased requirement
  - Increased physiologic requirement (e.g., pregnancy, lactation, rapid growth in adolescence; see section on folate status in children)
  - Pathological conditions (e.g., malignancy, inflammatory conditions, certain anemias)
  - Drugs (e.g., anticonvulsants, methotrexate, sulfasalazine)
- Decreased availability
  - Impaired folate absorption (e.g., celiac disease, use of drugs such as sulfasalazine)

**Folate Biology and Homeostasis**

The ability to discover and develop biomarkers, particularly those reflecting nutrient function or effect, is contingent on an appreciation of the role of nutrients within relevant biological systems. To provide some perspective on the folate expert panel recommendations, the following sections describe the specific roles and interrelations of the folates.

**Current understanding of the biology: dependent systems**

**Structure, function, and absorption.** The tetrahydrofolates (THFs), a family of structurally related, water-soluble vitamins composed of a fully reduced pterin ring, a p-aminobenzoyl group, and a polyglutamate peptide containing up to 9 glutamate residues linked by unusual γ-peptide linkages, have been well described (114) and are represented in Figure 7. The key elements of folate metabolism are highlighted in Table 10.

**Overview of folate-mediated one-carbon metabolism.** The intracellular functions of folate are interconnected through competition for a limiting pool of folate cofactors within the network, because the concentration of folate enzymes exceeds intracellular folate concentrations (114). More recent studies indicate that the activity of these pathways is also regulated by dynamic physical compartmentation and formation of multi-enzyme complexes that are required for pathway function. The dynamic assembly of metabolic complexes adds additional dimensions and complexity to the regulation of these pathways, including the necessity for regulated trafficking of folate cofactors among compartmentalized pathways (115). Figure 8 summarizes the essential components of THF-related pathways. The key elements of those pathways are as follows:

- In the mammalian cell, one-carbon metabolism occurs in the cytosol, mitochondria, and nucleus.
- THF polyglutamates are found in the lysosome where they are converted to THF monoglutamates through the activity of γ-glutamyl hydrolase (121).
- Folate-mediated one-carbon metabolism in the cytosol is a network of 3 interdependent biosynthetic pathways that catalyze the de novo synthesis of purine nucleotides, deoxythymidylate (dTMP), and remethylation of homocysteine to methionine.
- In the nucleus, THF is required for the synthesis of thymidylate at the replication fork (122) and may function in histone demethylation catalyzed by lysine-specific demethylase 1 (LSD1) (123).

- Formate is the primary source of one-carbon units for nuclear and cytosolic one-carbon metabolism and is generated through mitochondrial one-carbon metabolism (120), although one-carbons carried by THF can be derived directly in the cytosol from the catabolism of histidine, purines, and serine (114).

**Methionine.** The importance of these folate-dependent pathways is exemplified by the role of methionine in numerous pathways including serving as a precursor for protein biosynthesis. Methionine can be converted to S-adenosylmethionine (SAM), which, in the decarboxylated form, participates in polyamine synthesis and can serve as a cofactor and methyl group donor for numerous methylation reactions including the methylation of chromatin (CpG islands in DNA) and histone proteins, RNA, and numerous proteins and synthesis of neurotransmitters, phosphatidylcholine, and other small molecules. SAM-dependent methylation regulates fundamental biological processes including nuclear transcription, mRNA translation, cell signaling (124), protein localization (125), and the degradation of small molecules (126). The essential elements of the 3 primary folate-dependent pathways are shown in Figure 8 and Figure 9 and are described in Table 11.

Each of these pathways highlights the important role of folates in critical metabolic systems. Although the purine pathway has no folate relevant biomarkers, the other 2 offer implications for potential biomarkers to assess folate. In the context of thymidylate biosynthesis, uracil accumulation in DNA is a biomarker of impaired de novo thymidylate biosynthesis (131). Uracil has been suggested to be a biomarker of folate (132) and vitamin B-12 status (133), but not all studies agree (134). In mice, distinct tissues have different levels of uracil incorporation into DNA (135).

Implications of homocysteine remethylation for folate assessment/biomarkers include the following:

- Biomarkers of impaired homocysteine remethylation include depressed SAM concentrations and elevations in plasma homocysteine and S-adenosylhomocysteine (SAH) concentrations (136, 137), leading to hypomethylated DNA

![Figure 6](image-url)

**FIGURE 6** Relation between dietary intake and biomarker status of folate. Correlations were carried out on log-transformed data and were calculated by using Pearson correlation coefficients (r). Correlations for which P < 0.05 were considered significant. Total folate intake was expressed as DFEs, which were introduced in the United States to account for the higher bioavailability of synthetic folic acid added to food compared with natural food folate. DFEs were calculated as micrograms of natural folate plus 1.7 × μg added folic acid. DFE, dietary folate equivalent. Adapted from reference 86 with permission.
One-carbon metabolism in mitochondria. THF monoglutamates are transported into mitochondria by the mitochondrial folate transporter (143), where they constitute as much as 40% of total cellular folate (144, 145). Folate monoglutamates must be converted to THF polyglutamates to be retained in mitochondria and become a distinct cofactor pool that is not in equilibrium with THF polyglutamates in the cytosol (145). One-carbon metabolism in mitochondria is essential for glycine synthesis from serine, N-formylmethionine-transfer RNA synthesis for mitochondrial protein synthesis initiation and the generation of formate from the amino acids serine, glycine, dimethylglycine, and sarcosine for cytosolic one-carbon metabolism (120) (Figure 9). Mitochondria-derived formate traverses to the cytosol where it is a major source of one-carbon units for cytosolic one-carbon metabolism. More recently, mitochondria have been shown to synthesize d TMP for mitochondrial DNA replication (146). Whereas synthesis of dTMP for nuclear DNA replication is cell cycle regulated, mitochondrial DNA replication is not linked to cell cycle or nuclear DNA replication and occurs in proliferating and nonproliferating cells (147).

All mammalian cells, with the exception of RBCs, can convert serine to glycine and formate, whereas the generation of formate from glycine, sarcosine, and dimethylglycine is restricted to liver, kidney, and stem cells and other undifferentiated cell types. The disruption of glycine cleavage to formate, as well as the generation of formate from 10-formyltetrahydrofolate (10-formyl-THF) catalyzed by methylene-THF dehydrogenase (MTHFD) 1L, in mouse models and human subjects is associated with increased risk of NTD-affected pregnancies (148–150). The THF-dependent catalysis of amino acids generates 5,10-methylene-THF (5,10-methylene-THF), which is oxidized to 10-formyl-THF by the bifunctional enzymes MTHFDC2 (151, 152) and MTHFDC2L (153). MTHFDLC1 hydrolyzes 10-formyl-THF to formate in an ATP-generating reaction (154, 155). Formate traverses to the cytosol for cytosolic and nuclear one-carbon metabolism (120). There are no established biomarkers for impaired mitochondrial one-carbon metabolism.

Homeostatic control of metabolism/nutrient-nutrient interactions

Overview—homeostatic controls of one-carbon metabolism. Research over the past ~10 y has shown that strong homeostatic controls exist to reduce fluctuation in folate-dependent metabolic processes (8, 115). Were it not for homeostatic controls, the rates of many of these biochemical reactions would be very sensitive to fluctuation in dietary intakes of folate, vitamins B-6 and B-12, and choline and to postprandial fluctuations in cellular concentrations of macronutrient substrates such as serine, glycine, and methionine. Elements of folate homeostasis are described in Table 11. These regulatory processes have been investigated by mathematical modeling studies (127, 156–160) and by many biochemical and genetic approaches. Controlled nutritional studies that use stable-isotopic tracers also have provided evidence of strong homeostatic regulation (161–167). Severe deficiency of folate and vitamin B-12 as well as genetic disorders clearly lead to impaired homeostasis of one-carbon metabolism with reduced thymidylate and pyrimidine synthesis, impaired homocysteine remethylation, and decreased SAM:SAH ratio associated with reduced methylation capacity.

TABLE 10 Essentials of folate absorption and metabolism

- THF polyglutamates are the form of the vitamin present in cells and in food from natural sources.
- THF polyglutamates must be hydrolyzed to THF monoglutamates in the gastrointestinal tract before absorption across the intestinal epithelium of the duodenum by the PCTF (116).
- THF monoglutamates circulate in serum and are transported into cells through either the reduced folate carrier or through receptor-mediated endocytosis of the folate receptors (117, 118).
- Intracellular THF monoglutamates are processed into functional metabolic cofactors through the re-establishment of the polyglutamate peptide (119).
- The glutamate polypeptide is essential to retain the vitamin within cells and to increase its affinity for folate-dependent enzymes (114).
- Folic acid, a chemically stable and fully oxidized pro-vitamin that is found in fortified foods and vitamin supplements
  - is readily transported across the intestinal epithelium by PCTF,
  - must be reduced to THF by the enzyme dihydrofolate reductase, and
  - converted to a polyglutamate form to function as a metabolic cofactor.
- There are 5 one-carbon substituted forms of THF cofactors in cells. The one-carbon moiety is covalently attached to the N5 and/or N10 position of the cofactor at the oxidation level of formate (e.g., 10-formyl-THF), formaldehyde (5,10-methylene-THF) or methanol (5-methyl-THF) (Figure 7).
- Intracellular THF cofactors function as a family of metabolic cofactors that chemically activate and either accept or donate single carbons for a network of interconnected metabolic pathways referred to as one-carbon metabolism (114, 120) (Figure 8).

1 PCFT, proton coupled folate transporter; THF, tetrahydrofolate.
Other nutrient linkages with folate. As outlined above, folate’s role in a myriad of critical biochemical pathways occurs in close association with other essential nutrient cofactors. The potential for interactions among these nutrients demands an appreciation of these interrelations and their implications. Table 12 summarizes the nature of these interactions.

Specific considerations about absorption and metabolism of follic acid. As discussed earlier (Table 10), folie acid is not naturally found in food but is the more stable form of the vitamin used in food fortification and supplements. In light of the extent of its use, a brief review of essential components of follic acid absorption and metabolism is warranted, particularly in light of unknown implications of circulating free folic acid. Most of the follic acid absorbed in the gut is rapidly converted to reduced folic acid, primarily 5-methyl-THF during its passage across the intestinal mucosa and during first-pass metabolism in the liver. Some folic acid may appear in the peripheral circulation, the amount depending on the dose. Folate retention by tissues requires their conversion to long-chain-length polyglutamate forms. Folic acid and 5-methyl-THF are poor substrates for conversion to retainable polyglutamates. Incomplete conversion to polyglutamates by tissues such as intestinal mucosa and liver leads to the release of folate, mainly as methylfolate, into plasma. The utilization of folic acid differs from that of dietary folates primarily in that it has to be reduced

FIGURE 8 Folate- and vitamin B-12–mediated one-carbon metabolism. One-carbon metabolism is required for the synthesis of purines, thymidylate (dTMP), and methionine. The hydroxymethyl group of serine is a major source of one-carbon units, which are generated in the mitochondria in the form of formate via SHMT2 or in the cytosol through the activity of SHMT1 or SHMT2α. Mitochondria-derived formate can enter the cytoplasm and function as a one-carbon unit for folate metabolism. The synthesis of dTMP occurs in the nucleus and mitochondria. At the S phase, the enzymes of the thymidylate (dTMP) synthesis pathway undergo SUMO-dependent translocation to the nucleus. The remethylation of homocysteine to methionine by MTR requires vitamin B-12. The one-carbon is labeled in bold type. The inset shows the thymidylate synthesis cycle, which involves the enzymes SHMT1, SHMT2α, TYMS, and DHFR. AdoHcy, S-adenosylhomocysteine; AdoMet, S-adenosylmethionine; AICAR Tfase, glycaminde ribonucleotide transformylase and aminomimidazolecarboxamide ribonucleotide transformylase; DHF, dihydrofolate; DHFR, dihydrofotolate reductase; dTMP, deoxythymidine monophosphate; dUMP, deoxyuridine monophosphate; GAR Tfase, glycaminde ribonucleotide transformylase; GCS, glycine cleavage system; MTHFD1, methylenetetrahydrofolate dehydrogenase 1; MTHFR, methylenetetrahydrofolate reductase; MTR, methionine synthase; SARDH, sarcosine dehydrogenase; SHMT, serine hydroxymethyltransferase; Sumo, small ubiquitin-like molecule; THF, tetrahydrofolate; TYMS, thymidylate synthase. Adapted from reference 118 with permission.
to THF via dihydrofolate (DHF) by DHF reductase (DHRF) (Figure 10). The first step, the reduction of folic acid to DHF, is quite slow and may be influenced by individual variations in DHRF activity (221). Folic acid would be poorly transported by many peripheral tissues. The limited peripheral tissue uptake may be explained by folic acid’s very poor affinity for the RFC transporter, so transport would primarily be into tissues that express the proton coupled folate transporter (PCFT) and the limited number of tissues that express folate receptors (membrane-associated FBPs). The clearance of folate from plasma is very fast. After a single oral dose of folic acid, plasma folate (which would be mainly 5-methyl-THF) peaks after ~2 h and then falls, with a mean residence time of ~10 min (222). Plasma folate concentrations decrease with a similar half-life after an intravenous injection of folic acid (223). This rapid clearance indicates that fasting plasma folate concentrations primarily reflect reduced folates released by tissues. Why unmetabolized folic acid should still be present in plasma after fasting is less clear.

The concentrations of unmetabolized folic acid in fasting plasma are very low, representing at most a small percentage of total folate, and, somewhat unexpectedly, are poorly correlated with total folate (7, 92). These folic acid concentrations are very similar to those reported for soluble FBP in serum (224, 225). Folic acid has a very high affinity for FBP and binding to this protein would explain the persistence of low concentrations of folic acid in plasma in the fasted state. Human serum contains primarily FBP-γ, derived from neutrophil granulocytes, and some FBP-α, with total concentrations ranging from 0.5 to 1.5 nmol/L (225). Early studies, before the identification of FBP, indicated a high-affinity folic acid binder in serum that was increased in folate deficiency (up to 1 nmol/L), pregnancy, and in some cancers (226). These early studies probably measured unligated FBP rather than total binding capacity. There is little known about conditions that influence the concentrations of soluble plasma FBP.

As stated above, the Folate Expert Panel is not aware of any toxic or abnormal effects of circulating folic acid. Folic acid has been added to supplements for many years and in larger amounts than are obtained by food fortification in the United States without any apparent adverse effects.

Clearly, the family of folates is intimately and inextricably involved in numerous biological systems with significant implication for health and disease. As we learn more about these interrelations the need for better tools to assess folate status assumes even greater importance. The following section on folate biomarker overview summarizes the Folate Expert Panel’s evaluation of the currently available biomarkers of folate covering a range of uses.

### Folate Biomarker Overview

The usefulness, advantages, disadvantages, and analytical considerations for the folate priority biomarkers (serum, RBC folate, and homocysteine) have been summarized for all users by the Folate Expert Panel (Table 13). Later sections and Supplemental Table 1 include specific details for the priority biomarkers identified by the Folate Expert Panel as being most useful for the range of uses covered by the BOND community.

### Biomarker-Specific Issues

This section is an overview of the conclusions of the Folate Expert Panel with regard to those biomarkers that were deemed

---

**TABLE 11** Homeostatic controls of folate metabolism

<table>
<thead>
<tr>
<th>Control</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>SAM</td>
<td>an allosteric activator of cystathionine β-synthase and an allosteric inhibitor of MTHFR.</td>
</tr>
<tr>
<td>5-Methyl-THF (in polyglutamyl form), which inhibits GNMT and the use of SAM and glycine to produce sarcosine (N-methylglycine) and SAH.</td>
<td></td>
</tr>
<tr>
<td>Homeostatic regulation also occurs under conditions of high folate intake and the accompanying high intracellular folate concentration.</td>
<td></td>
</tr>
<tr>
<td>Many of the folate-dependent enzymes also exhibit induction by nonglutathione polyglutamyl forms of THFs such as THF, 5-methyl-THF, and 5-formyl-THF (128–130).</td>
<td></td>
</tr>
<tr>
<td>Shifts in the concentration of certain metabolites tend to maintain flux through metabolic pathways. These concurrent effects strongly support homeostasis (Figure 9).</td>
<td></td>
</tr>
</tbody>
</table>

---

1 GNMT, glycine N-methyltransferase; MTHFR, methylenetetrahydrofolate reductase; SAH, S-adenosylhomocysteine; SAM, S-adenosylmethionine; THF, tetrahydrofolate.
TABLE 12  Summary of folate: nutrient interactions

<table>
<thead>
<tr>
<th>Nutrient</th>
<th>Implicated enzymes/metabolic pathways</th>
<th>Key features of interactions</th>
<th>Effect of nutrient deficiency on folate biomarkers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vitamin B-12 (cobalamin)</td>
<td>● Vitamin B-12 (as methylcobalamin) serves as a coenzyme in the methionine synthase reaction. ● Vitamin B-12 is necessary for the methione synthase-based conversion of 5-methyl-THF to THF and subsequent entry into other phases of one-carbon metabolism.</td>
<td>Via its role in methionine synthase, vitamin B-12 is intimately associated with the function of folate-dependent one-carbon metabolism needed for homocysteine regulation, cellular methylation reactions, and nucleotide synthesis. Insufficiency of vitamin B-12 leads to an accumulation of methylmalonyl-CoA, which undergoes hydrolysis to MMA, which provides a functional biomarker of vitamin B-12 deficiency (169). Despite the elevation of MMA and homocysteine due to vitamin B-12 deficiency, little is known about the functional impact of the changes in flux. Severe vitamin B-12 deficiency, as occurs in untreated pernicious anemia, perturbs homoeostasis of one-carbon metabolism through reduced flux of the MS reaction. Because the only metabolic function of 5-methyl-THF is as a substrate in the MS reaction for homocysteine remethylation, reduced MS activity causes 5-methyl-THF to accumulate in the &quot;methyl trap&quot; (170, 171). Because 5-methyl-THF monogluta-mate is a poor substrate for elongation by folate polyglutamate synthetase, the accumulated 5-methyl-THF readily diffuses from the cell, leading to a progressive reduction in vivo folate pool size and thus indirect induction of intracellular folate deficiency.</td>
<td>Because vitamin B-12 is required for folate retention in developing RBCs, RBC folate concentrations are dependent on vitamin B-12 as well as folate availability, and low concentrations may reflect vitamin B-12 deficiency as well as folate deficiency. A case study of a patient with vitamin B-12 deficiency and the MTHFR C677T SNP indicated higher Hcy, lower RBCs, and a higher percentage of 5-methyl-THF in RBCs before as compared with after vitamin B-12 supplementation, providing evidence of &quot;methyl trapping&quot; in vitamin B-12 deficiency (172). In infants, vitamin B-12 rather than folate status predicts Hcy (173, 174), and high serum folate is attributed to methyl folate trapping as demonstrated by reduction in both Hcy and serum folate after vitamin B-12 supplementation (173). Likewise, adults with pure vitamin B-12 deficiency (pernicious anemia) also have falsely increased serum folate concentrations, which return to baseline only after vitamin B-12 replacement (175–178). Insufficiency of vitamin B-12, folate, or both leads to an accumulation of homocysteine. In population groups who consume folic acid–fortified foods or folic acid supplements, Hcy is considered a more reliable biomarker of vitamin B-12 status than of folate status (179).</td>
</tr>
<tr>
<td>Iron</td>
<td>● Both nutrients are intimately involved in the erythropoiesis process. ● Heme carrier protein 1, also called the PCFT, constitutes a physiologic interaction of iron and folate because PCFT serves as a major intestinal folate absorption mechanism while also serving as a heme transporter (115). Ferritin has been reported to catalyze a single-turnover cleavage of 5-formyl-THF to a pentadiene and para-aminobenzoylglutamate; this has been proposed as a mechanism contributing to folate turnover (180, 181). Heavy-chain ferritin also has been shown to increase SHMT expression and favor thymidilate synthesis in cultured cells (181), an effect shown to be mediated by a ferritin-responsive internal ribosome entry site that is not dependent on iron availability (182).</td>
<td>Iron is not directly involved in folate metabolism or metabolic functioning associated with one-carbon metabolism. However, metabolic and physiologic interactions exist between iron and folate. Insufficient iron impairs heme production, whereas folate and/or vitamin B-12 deficiency leads to impaired nucleotide synthesis needed for the maturation of the RBCs, which leads to macrocytic anemia. The observed greater incidence of neutrophil hypersegmentation in iron deficiency anemia concurrent with folate and/or vitamin B-12 deficiency implies interactive effects on the erythropoietic process (183, 184). PCFT expression analysis suggests that the PCFT also serves along with other folate transporters in delivering folate to tissues such as the placenta and brain (185). Overexpression of ferritin in cultured cells lowered the intracellular folate concentration, although alternative mechanisms of folate breakdown and turnover do exist (186, 188). Oxidative stress associated with iron overload may also be proven to contribute to nonspecific oxidative turnover of folates.</td>
<td>Iron and folate deficiencies often occur simultaneously, with the prevalence most common among pregnant women and individuals suffering from gastrointestinal disorders and intestinal parasites (187). Some investigators suggest that iron deficiency can alter folate metabolism, inducing a functional deficiency, whereas others propose that the 2 conditions develop independently (187, 188). The impact of iron status on folate biomarkers may depend on contributing physiologic influences and severity of iron and folate deficiencies. Patients suffering from iron deficiency due to intestinal parasites and gastrointestinal disorders often have no evidence of impaired folate intake or absorption but present with megaloblastic dysplasia and other signs of compromised folate status, including low serum folate but normal or elevated RBC folate (187, 188). These symptoms, caused by impaired DNA synthesis, can be reversed by iron repletion alone (188). In contrast, treatment of uncomplicated iron deficiency anemia with iron alone may &quot;unmask&quot; folate deficiency, manifesting morphologic and hematologic changes, despite normal serum and RBC folate concentrations (187). In rodent models, it is well established that maternal iron deficiency decreases milk folate content and retards neonatal growth, independent of maternal folate status (188). Although the impact of iron deficiency on folate status during lactation has not been well studied in humans, a study from Mexico indicated that milk folate secretions were not impaired during maternal iron deficiency associated with altered neonatal growth (189).</td>
</tr>
</tbody>
</table>

(Continued)
TABLE 12  Continued

<table>
<thead>
<tr>
<th>Nutrient</th>
<th>Implicated enzymes/metabolic pathways</th>
<th>Key features of interactions</th>
<th>Effect of nutrient deficiency on folate biomarkers</th>
</tr>
</thead>
</table>
| Choline   | - Does not directly participate in folate metabolism, but interactions exist which affect folate metabolism and homoeostasis.  
- FAD-dependent choline dehydrogenase catalyzes oxidation of choline to betaine aldehyde, which is further oxidized by NAD-dependent betaine aldehyde dehydrogenase to form betaine trimethylglycine.  
- Betaine acts as a methyl donor for BHMT, which catalyzes a folate-independent alternative remethylation mechanism to form methionine and dimethylglycine.  
- In contrast to widely distributed methionine synthase, BHMT exists only in the liver, kidney, and the lens of the eye.  
- Dimethylglycine is further oxidized with concurrent transfer of the methyl groups to the folate cycle by the sequential action of NAD-dependent dimethylglycine dehydrogenase forming N-methylglycine (sarcosine) and sarcosine dehydrogenase forming glycine. Both of these utilize THF as the one-carbon acceptor to form 5,10-methylene-THF. | Although the oxidation pathway is intimately linked to one-carbon metabolism, quantitative aspects of such interactions with folate homeostasis remain unclear.  
- Because adequate choline intake provides a supply of betaine to allow non-folate-dependent homocysteine remethylation, choline can partially compensate in maintaining methylation despite dietary folate insufficiency (190).  
- Folate, but not choline, modified NTD risk in an Smmt knockout mouse model (33), whereas dietary choline intake and variants in choline metabolizing genes associate with NTDs in human populations (191–193) and the amount of folate intake has been shown to modulate choline metabolism in mice (194).  
- Choline intake appears to be an ameliorative factor affecting human NTD risk, but the literature is not consistent (191, 192, 195).  
- Common genetic polymorphisms of one-carbon metabolism also influence the susceptibility to effects of low choline intake (196) and men with the MTHFR677TT (vs. 677CC) genotype use more choline as a methyl donor (197). The effect of the MTHFD1 polymorphism is stronger than that of MTHFR and other SNPs in the folate pathway (198).  
- In controlled studies, healthy young adults exhibited no evidence of impaired folate-dependent remethylation or total remethylation during either mild folate restriction (164, 198) or vitamin B-6 restriction (162), and folate-dependent remethylation (i.e., via methionine synthase) accounted for nearly all of the whole-body remethylation flux in both studies.  
- In contrast, population studies indicated that betaine may be a significant determinant of plasma homocysteine (199). | Dietary choline inadequacy may also affect biomarkers of folate status (200).  
- Short-term (<3 wk) administration of a choline-deficient diet to rats depleted hepatic folate content, decreased tissue concentrations of SAM, diminished global DNA methylation, and/or increased homocysteine (201–205).  
- In chronically (12 mo) choline-deficient rats, hepatic total folate concentration was not altered; however, polyglutamation was elevated, possibly due to increased conservation of the folate coenzymes (206).  
- In humans, dietary choline inadequacy elevated plasma homocysteine (after a methionine load) but did not influence circulating concentrations of folate (203). |
| Vitamin B-6 (pyridoxine) | - PLP, the coenzyme form of vitamin B-6, functions as a cofactor in:  
  - the glycine cleavage system and SHMT, both of which mediate the supply of 5,10-methylene-THF  
  - the transsulfuration pathway enzymes cystathionine β-synthase and cystathionine γ-lyase, which mediate the disposal of homocysteine and synthesis of cysteine.  
- Regulatory mechanisms exist to buffer the components of one-carbon metabolism against the effects of marginal vitamin B-6 deficiency, primarily via increases in substrate concentrations for key PLP-dependent enzymes as a result of reduced activity of the glycine cleavage system, SHMT, and cystathionine γ-lyase associated with reduced intracellular PLP availability (163, 167, 207).  
- Consequently, the supply of 5,10-methylene-THF, 10-formyl-THF, and 5-methyl-THF remain adequate to support the demands for nucleotide synthesis and methylation over a wide range of vitamin B-6 intakes, whereas cellular and plasma homocysteine are only weakly affected by vitamin B-6 insufficiency (208, 209).  
- Homocysteine and glycine are relatively weak biomarkers of vitamin B-6 status, and cystathionine is a more sensitive functional indicator of low vitamin B-6 status (162, 165, 210). | Vitamin B-6 deficiency weakly affects plasma homocysteine concentration (208).  
- Cell culture studies and mathematical modeling suggest that the proportions of formyl-, methyl-, and unsubstituted THFs can be altered by vitamin B-6 deficiency (211). |
**TABLE 12 Continued**

<table>
<thead>
<tr>
<th>Nutrient</th>
<th>Implicated enzymes/metabolic pathways</th>
<th>Key features of interactions</th>
<th>Effect of nutrient deficiency on folate biomarkers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Riboflavin (vitamin B2)</td>
<td>FAD as a coenzyme for MTHFR</td>
<td>• Insufficient riboflavin can impair one-carbon metabolism, as indicated by elevated plasma homocysteine, particularly under conditions of low folate status.</td>
<td>• When folate or riboflavin status is low, individuals with the homozygous mutant TT genotype typically present with low serum and RBC folate (5, 218), along with elevated homocysteine concentrations (219).</td>
</tr>
</tbody>
</table>

1 BHMT, betaine-homocysteine methyltransferase; MMA, methylmalonic acid; MS, methionine synthase; MTHFD1, methyltetrahydrofolate dehydrogenase 1; MTHFR, methylene tetrahydrofolate reductase; NTD, neural tube defect; PCFT, proton coupled folate transporter; PLP, pyridoxal-5'-phosphate; SAM, S-adenosylmethionine; SHMT, serine hydroxymethyltransferase; SNP, single nucleotide polymorphism; TCA, tricarboxylic acid; THF, tetrahydrofolate.

---

**Dietary folate/acid folic intake assessment**

As highlighted in earlier sections, folate (THF) polyglutamate is predominantly found in food. The predominant form of folate typically used to assess overall folate intake, including food and dietary intake, is over a longer period of time. The following sections cover the core elements of the dietary folate intake assessment.

**Assessment of the diet can be done on a short- or long-term basis.** Short-term assessments aim to capture data on recent dietary folate intake, whereas long-term assessments aim to capture data over a longer period of time. Diet assessment methodologies are discussed in Section 5.2. The following sections cover the core elements of dietary folate intake assessment.

**Dietary/Supplemental intake assessment**

Assessment of the diet can be done on a short- or long-term basis. Short-term assessments aim to capture data on recent dietary folate intake, whereas long-term assessments aim to capture data over a longer period of time. Diet assessment methodologies are discussed in Section 5.2. The following sections cover the core elements of dietary folate intake assessment.

**Dietary folate/acid folic intake assessment**

As highlighted in earlier sections, folate (THF) polyglutamate is predominantly found in food. The predominant form of folate typically used to assess overall folate intake, including food and dietary intake, is over a longer period of time. The following sections cover the core elements of the dietary folate intake assessment.

**Assessment of the diet can be done on a short- or long-term basis.** Short-term assessments aim to capture data on recent dietary folate intake, whereas long-term assessments aim to capture data over a longer period of time. Diet assessment methodologies are discussed in Section 5.2. The following sections cover the core elements of dietary folate intake assessment.

**Dietary/Supplemental intake assessment**

Assessment of the diet can be done on a short- or long-term basis. Short-term assessments aim to capture data on recent dietary folate intake, whereas long-term assessments aim to capture data over a longer period of time. Diet assessment methodologies are discussed in Section 5.2. The following sections cover the core elements of dietary folate intake assessment.

**Dietary folate/acid folic intake assessment**

As highlighted in earlier sections, folate (THF) polyglutamate is predominantly found in food. The predominant form of folate typically used to assess overall folate intake, including food and dietary intake, is over a longer period of time. The following sections cover the core elements of the dietary folate intake assessment.

**Assessment of the diet can be done on a short- or long-term basis.** Short-term assessments aim to capture data on recent dietary folate intake, whereas long-term assessments aim to capture data over a longer period of time. Diet assessment methodologies are discussed in Section 5.2. The following sections cover the core elements of dietary folate intake assessment.

**Dietary/Supplemental intake assessment**

Assessment of the diet can be done on a short- or long-term basis. Short-term assessments aim to capture data on recent dietary folate intake, whereas long-term assessments aim to capture data over a longer period of time. Diet assessment methodologies are discussed in Section 5.2. The following sections cover the core elements of dietary folate intake assessment.

**Dietary folate/acid folic intake assessment**

As highlighted in earlier sections, folate (THF) polyglutamate is predominantly found in food. The predominant form of folate typically used to assess overall folate intake, including food and dietary intake, is over a longer period of time. The following sections cover the core elements of the dietary folate intake assessment.

**Assessment of the diet can be done on a short- or long-term basis.** Short-term assessments aim to capture data on recent dietary folate intake, whereas long-term assessments aim to capture data over a longer period of time. Diet assessment methodologies are discussed in Section 5.2. The following sections cover the core elements of dietary folate intake assessment.

**Dietary/Supplemental intake assessment**

Assessment of the diet can be done on a short- or long-term basis. Short-term assessments aim to capture data on recent dietary folate intake, whereas long-term assessments aim to capture data over a longer period of time. Diet assessment methodologies are discussed in Section 5.2. The following sections cover the core elements of dietary folate intake assessment.

**Dietary folate/acid folic intake assessment**

As highlighted in earlier sections, folate (THF) polyglutamate is predominantly found in food. The predominant form of folate typically used to assess overall folate intake, including food and dietary intake, is over a longer period of time. The following sections cover the core elements of the dietary folate intake assessment.

**Assessment of the diet can be done on a short- or long-term basis.** Short-term assessments aim to capture data on recent dietary folate intake, whereas long-term assessments aim to capture data over a longer period of time. Diet assessment methodologies are discussed in Section 5.2. The following sections cover the core elements of dietary folate intake assessment.

**Dietary/Supplemental intake assessment**

Assessment of the diet can be done on a short- or long-term basis. Short-term assessments aim to capture data on recent dietary folate intake, whereas long-term assessments aim to capture data over a longer period of time. Diet assessment methodologies are discussed in Section 5.2. The following sections cover the core elements of dietary folate intake assessment.

**Dietary folate/acid folic intake assessment**

As highlighted in earlier sections, folate (THF) polyglutamate is predominantly found in food. The predominant form of folate typically used to assess overall folate intake, including food and dietary intake, is over a longer period of time. The following sections cover the core elements of the dietary folate intake assessment.

**Assessment of the diet can be done on a short- or long-term basis.** Short-term assessments aim to capture data on recent dietary folate intake, whereas long-term assessments aim to capture data over a longer period of time. Diet assessment methodologies are discussed in Section 5.2. The following sections cover the core elements of dietary folate intake assessment.

**Dietary/Supplemental intake assessment**

Assessment of the diet can be done on a short- or long-term basis. Short-term assessments aim to capture data on recent dietary folate intake, whereas long-term assessments aim to capture data over a longer period of time. Diet assessment methodologies are discussed in Section 5.2. The following sections cover the core elements of dietary folate intake assessment.

**Dietary folate/acid folic intake assessment**

As highlighted in earlier sections, folate (THF) polyglutamate is predominantly found in food. The predominant form of folate typically used to assess overall folate intake, including food and dietary intake, is over a longer period of time. The following sections cover the core elements of the dietary folate intake assessment.

**Assessment of the diet can be done on a short- or long-term basis.** Short-term assessments aim to capture data on recent dietary folate intake, whereas long-term assessments aim to capture data over a longer period of time. Diet assessment methodologies are discussed in Section 5.2. The following sections cover the core elements of dietary folate intake assessment.

**Dietary/Supplemental intake assessment**

Assessment of the diet can be done on a short- or long-term basis. Short-term assessments aim to capture data on recent dietary folate intake, whereas long-term assessments aim to capture data over a longer period of time. Diet assessment methodologies are discussed in Section 5.2. The following sections cover the core elements of dietary folate intake assessment.

**Dietary folate/acid folic intake assessment**

As highlighted in earlier sections, folate (THF) polyglutamate is predominantly found in food. The predominant form of folate typically used to assess overall folate intake, including food and dietary intake, is over a longer period of time. The following sections cover the core elements of the dietary folate intake assessment.

**Assessment of the diet can be done on a short- or long-term basis.** Short-term assessments aim to capture data on recent dietary folate intake, whereas long-term assessments aim to capture data over a longer period of time. Diet assessment methodologies are discussed in Section 5.2. The following sections cover the core elements of dietary folate intake assessment.

**Dietary/Supplemental intake assessment**

Assessment of the diet can be done on a short- or long-term basis. Short-term assessments aim to capture data on recent dietary folate intake, whereas long-term assessments aim to capture data over a longer period of time. Diet assessment methodologies are discussed in Section 5.2. The following sections cover the core elements of dietary folate intake assessment.

**Dietary folate/acid folic intake assessment**

As highlighted in earlier sections, folate (THF) polyglutamate is predominantly found in food. The predominant form of folate typically used to assess overall folate intake, including food and dietary intake, is over a longer period of time. The following sections cover the core elements of the dietary folate intake assessment.

**Assessment of the diet can be done on a short- or long-term basis.** Short-term assessments aim to capture data on recent dietary folate intake, whereas long-term assessments aim to capture data over a longer period of time. Diet assessment methodologies are discussed in Section 5.2. The following sections cover the core elements of dietary folate intake assessment.

**Dietary/Supplemental intake assessment**

Assessment of the diet can be done on a short- or long-term basis. Short-term assessments aim to capture data on recent dietary folate intake, whereas long-term assessments aim to capture data over a longer period of time. Diet assessment methodologies are discussed in Section 5.2. The following sections cover the core elements of dietary folate intake assessment.
Supplement Ingredient Database uses a complex sampling program to ensure that products represent the US market for products. The folic acid content in children’s and adults’ MVM products was determined by using an MBA with the National Institute of Standards and Technology (NIST) standard reference material (SRM) 3280 to evaluate product content for folic acid. For both children (≥4 y) and adults, the most common label dose of folic acid in an MVM product is 400 μg, and the measured content was ~13% higher in the supplement than on the label. For products intended for children aged 1 to <4 y, the most common labeled dose of folic acid was 200 μg and the actual content was ~16% higher in the supplement than on the label.

Usual dietary and total intakes. Dietary recommendations are intended to be met over time (236). Many procedures have been described to adjust the dietary estimates from 24-h recalls to reduce within-person variation to produce usual intakes (237–241). To produce total usual intakes, it is recommended to first adjust the dietary folic acid estimates by using one of these methods and then add the daily estimate of folic acid from dietary supplements to the usual dietary intakes (242).

Food-composition tables. The most current national database for the folic acid/folate content of foods is the USDA National Nutrient Database for Standard Reference, release 25. The Standard Reference values are the basis for USDA Food and Nutrient Database for Dietary Studies values. The National Food and Nutrition Analysis Program is a federally funded research program to enhance the analytical estimates of the nutrient content of foods and dietary supplements. The folate content of foods is determined by a tri-enzyme microbiological procedure (243), which is appropriate for the estimation of total folate content, not the specific forms. To determine the amount of folic acid added to foods, an additional microbiological procedure without enzymes is used to estimate the amount of added folic acid; food folate then is assumed to be the remainder after the folic acid contribution is subtracted from the total (243). The DFE is then calculated by multiplying the amount of folic acid by 1.7 and adding that to the value for food folate. There are 7042 foods with values for total folate and 6381 foods with values for DFEs present in the Standard Release 25.

Measuring the folate/folic acid content in foods. Estimates of dietary intakes rely on the accuracy of the food-composition databases. Estimates of the folate and folic acid content of foods can be determined by MBAs and by LC. The MBA with enzyme extraction is unable to differentiate among the various forms of folate in foods. The LC techniques can differentiate among the folate forms but have been reported to have difficulties measuring all folates [summarized in (244)]. The variability in results obtained for folate/folic acid in foods can be attributed to agricultural variability, heat processing, pH, food matrix, extraction procedure, failure to account for all or different folate vitamins, incubation time, and number of enzyme extractions (244, 245).

Priority folate biomarkers

Serum folate concentration. The measurement of serum folate is the earliest indicator of altered folate exposure and reflects recent dietary intake (i.e., short-term status) (9). However, recurrent measures of serum folate in the same individual over time can reveal chronic folate deficiency. Serum folate is highly responsive to intervention with folic acid, with natural food folates typically resulting in a poorer serum folate response. Likewise, population data show that irrespective of whether they are from regions with mandatory or voluntary fortification, serum folate concentrations are highly reflective of exposure to folic acid, with the highest concentrations observed in persons who consume folic acid in both supplements and fortified foods (71, 246, 247).

RBC concentration. RBC folate is a sensitive indicator of long-term folate status, which represents the amount of folate that accumulates in RBCs during erythropoiesis, thereby reflecting folate status during the preceding 120 d (i.e., the half-life of RBCs) (248, 249). Moreover, RBC folate parallels liver concentrations (accounting for ~50% of total body folate) and is thus considered to reflect tissue folate stores (250). Similar to serum folate, RBC folate is highly responsive to intervention with folic acid, with natural food folates typically resulting in a poorer RBC folate response than folic acid at similar intervention amounts. Likewise, population data show that RBC folate concentrations are highly reflective of exposure to folic acid, with the highest concentrations observed in persons who consume folic acid in both supplements and fortified foods, in regions with mandatory or voluntary-only fortification (71, 99, 247).

Plasma homocysteine concentration. The measurement of plasma homocysteine provides a sensitive functional biomarker of folate status. As described in detail in the section on Folate Biology and Homeostasis, folate-mediated one-carbon metabolism is a network of 3 interdependent biosynthetic pathways including the remethylation of homocysteine to methionine. When the status of folate is low or deficient, plasma homocysteine is invariably found to be elevated. However, the folate-dependent remethylation of homocysteine to methionine is catalyzed by the vitamin B-12–dependent enzyme MTR and involves a number of other nutritional cofactors. Thus, plasma homocysteine is not a specific marker of folate status, because it will also be elevated with other B-vitamin deficiencies, lifestyle factors, renal insufficiency, and drug treatments (179, 251). In population groups who consume folic acid–fortified foods or folic acid supplements, homocysteine is considered to be a more reliable biomarker of vitamin B-12 than folate status (179).

Plasma homocysteine is inversely related to folate status (whether measured as serum or RBC folate). Plasma homocysteine is also highly responsive to intervention with folate, alone or in combination with the other methyl donors involved in...
TABLE 13 Relative strengths and weaknesses of folate biomarkers

<table>
<thead>
<tr>
<th>Biomarker name</th>
<th>Population groups</th>
<th>Usefulness for purpose</th>
<th>Advantages</th>
<th>Disadvantages</th>
<th>Analytical considerations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serum folate</td>
<td>All individuals</td>
<td>Measurement of serum folate provides information on the short-term folate status of the individual. Population data indicate that serum folate concentrations are highly reflective of exposure to folic acid, with the highest concentrations observed in persons who consume folic acid in both supplements and fortified foods. Serum folate is the earliest indicator of altered folate exposure, will reflect recent dietary intake, and is highly responsive to intervention. Serum folate requires less processing at the time of blood collection vs. RBC folate. Natural food folates typically result in a poorer serum folate response than does folic acid at similar intervention levels. The inconsistent use of cutoff values over time to assess the proportion of the population with low serum folate concentrations has led to confusion. Contrasting approaches to expressing dietary folate intakes makes any evaluation of adequacy of dietary folate intake in relation to biomarker status, or comparison of folate recommendations between countries, inherently complicated. The measurement of folate forms circulating in serum may further elucidate the role of folate vitamers relative to various health outcomes; however, to date, no cutoff values for either low or high concentrations or desirable ranges have been identified. Fasting blood samples are recommended when using serum folate to assess folate status. Natural food folates typically result in a poorer RBC folate response than does folic acid at similar intervention levels. If the DFE conversion is not made, the relation between folate intake and status is weak. Contrasting approaches to expressing dietary folate intakes makes any evaluation of adequacy of dietary folate intake in relation to biomarker status, or comparison of folate recommendations between countries, inherently complicated. The measurement of folate forms present in RBCs may further elucidate the role of folate vitamers relative to various health outcomes; however, to date, no cutoff values for either low or high concentrations or desirable ranges have been identified. Natural food folates typically result in a poorer serum folate response than does folic acid at similar intervention levels. The inconsistent use of cutoff values over time to assess the proportion of the population with low serum folate concentrations has led to confusion. Contrasting approaches to expressing dietary folate intakes makes any evaluation of adequacy of dietary folate intake in relation to biomarker status, or comparison of folate recommendations between countries, inherently complicated. The measurement of folate forms present in RBCs may further elucidate the role of folate vitamers relative to various health outcomes; however, to date, no cutoff values for either low or high concentrations or desirable ranges have been identified. Measurement of serum folate cannot be done in the field and requires at minimum a mediocre laboratory infrastructure with uninterrupted electrical power. Methods to assess serum folate have not yet reached the point where they produce sufficiently comparable results across methods or laboratories. Folate is the least stable of the B vitamins; careful sample handling and use of antioxidants are required to maintain sample integrity. Because RBCs contain much higher folate concentrations than serum, the presence of hemolysis will inflate serum folate values, regardless of technique used for measurement.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RBC folate</td>
<td>All individuals</td>
<td>RBC folate is a sensitive indicator of long-term folate status. RBC folate represents the amount of folate that accumulates in blood cells during erythropoiesis and reflects folate status during the preceding 120 d, i.e., the half-life of RBCs. RBC folate parallels liver concentrations (accounting for ~50% of total body folate) and is thus considered to reflect tissue folate stores. Population data indicate that RBC folate concentrations are highly reflective of exposure to folic acid, with the highest concentrations in persons who consume folic acid in both supplements and fortified foods. RBC folate is highly correlated with habitual folate intake when the latter is expressed as DFEs.</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

(Continued)
TABLE 13

<table>
<thead>
<tr>
<th>Biomarker name</th>
<th>Population groups</th>
<th>Advantages</th>
<th>Disadvantages</th>
<th>Analytical considerations</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hcy</td>
<td>All individuals</td>
<td>When folate status is low or deficient plasma Hcy provides a sensitive measurement of plasma folate status. Plasma Hcy is highly responsive to intervention with folate, either alone or in combination with folic acid or folate-rich foods. Plasma Hcy is not influenced by variation in inter- and intracellular folate status. Plasma Hcy is highly comparable across different populations. Plasma Hcy is a reliable biomarker of folate status. It also responds within 1 wk of folate treatments. Although folate intake (253, 256), urinary folate excretion exhibits a large degree of inter- and intrahost variability (257). Because of this variability and because little intact folate is excreted at doses up to the RDA, urinary folate would not be a sensitive biomarker for folate intake or status.</td>
<td>The measurement of Hcy in plasma is catalyzed by the vitamin B-12-dependent enzyme MTHFR, which may be subject to variation across different populations. Measurement of Hcy provides highly comparable results across different populations. Plasma Hcy is not influenced by variation in inter- and intracellular folate status. Plasma Hcy is a reliable biomarker of folate status. It also responds within 1 wk of folate treatments. Although folate intake (253, 256), urinary folate excretion exhibits a large degree of inter- and intrahost variability (257). Because of this variability and because little intact folate is excreted at doses up to the RDA, urinary folate would not be a sensitive biomarker for folate intake or status.</td>
<td>Requires specialized laboratory equipment and trained technicians. Results are highly comparable across different populations. Measurement of Hcy provides highly comparable results across different populations. Plasma Hcy is not influenced by variation in inter- and intracellular folate status. Plasma Hcy is a reliable biomarker of folate status. It also responds within 1 wk of folate treatments. Although folate intake (253, 256), urinary folate excretion exhibits a large degree of inter- and intrahost variability (257). Because of this variability and because little intact folate is excreted at doses up to the RDA, urinary folate would not be a sensitive biomarker for folate intake or status.</td>
</tr>
</tbody>
</table>

**Other biomarkers—general descriptions**

Although the focus of this section is on a detailed coverage of the key issues specific to the priority biomarkers selected, the Folate Expert Panel concluded that it would be useful to provide brief summaries of those biomarkers that, although not chosen as priorities for immediate widespread use, nevertheless offer either 1) some utility under defined circumstances or 2) potential for eventual widespread application.

**Serum folic acid.** As discussed in earlier sections, unmetabolized folic acid in serum or plasma may be considered as a biomarker of exposure, status, function, and/or effect. The appearance and quantity of unmetabolized folic acid in circulation have been associated with folic acid exposure via fortified foods, dietary supplements, and a combination of both (7, 252, 253). Greater concentrations of unmetabolized folic acid are associated with higher serum folate concentrations (7, 254), suggesting that the amount of folic acid in blood is related to whole-body folate status. However, there is large variation in folic acid concentrations and the dose response relation between folic acid exposure and unmetabolized folic acid in circulation is not entirely clear. Any effect of unmetabolized folic acid in blood on cellular function and/or health remains to be elucidated.

**Urinary folate/folic acid.** Although not commonly used, in research settings 24-h urinary folate excretion in combination with serum or RBC folate can provide unique information about folate status and metabolism. Twenty-four-hour urinary folate excretion captures the rise and fall of circulating folate concentrations in response to feeding and fasting and thus may be considered an indicator of “average” folate exposure and status over that 24-h period (95). Although responsive to folate intake (253, 256), urinary folate excretion exhibits a large degree of inter- and intra-individual variability (257). Because of this variability and because little intact folate is excreted at doses up to the RDA, urinary folate would not be a sensitive biomarker for folate intake or status.

**Urinary and serum para-aminobenzoic acid (pABG) and para-acetaminobenzoic acid (apABG).** The oxidative folate catabolites para-aminobenzoic acid (pABG) and para-acetaminobenzoic acid (apABG) are biomarkers of folate status and turnover. Although pABG and apABG are found in blood, urinary pABG and apABG are studied most often. Urinary pABG and apABG reflect turnover in endogenous folate pools (258). Total urinary catabolite excretion is positively correlated with serum total folate, RBC folate, and folate intake (259); however, it is not as sensitive to folate intake as urinary folate excretion (260), serum folate (261), and plasma homocysteine (261).

**Genomic biomarkers of folate status.** The following genomic biomarkers for folate status are used exclusively in research settings and are associated with problems due to lack of specificity, equivocal results, and methodologic challenges.

**DNA cytosine methylation.** Folate plays an important role in DNA metabolism because it is required as a methyl donor for one-carbon metabolism: vitamins B-12, B-6, and B-2 (riboflavin) and betaine (or choline). Plasma homocysteine responds within 3–4 wk of folate depletion (increases) and subsequent repletion (declines) in healthy subjects (251). The fast response probably reflects that methyl groups for homocysteine remethylation are dependent on “small” folate pool(s) with a fast turnover rate (186).
the synthesis of methionine and SAM and for the synthesis of phosphorylated nucleotides such as deoxothytmidine triphosphate (dTTP) (262). SAM is required as a methyl donor for the maintenance or induction of cytosine methylation, which is essential for silencing of genes or structural integrity of specific regions of the chromosomes (131, 263). When SAM is depleted and/or the enzyme DNA methyltransferase is defective, it becomes increasingly probable that the maintenance of DNA methylation is compromised, leading to hypomethylation of cytosine and structural changes in chromatin (264). Some studies suggest that global DNA methylation status is reduced when folate is deficient and plasma homocysteine is elevated (263–272). However, folate depletion-repletion studies have produced differing results with regard to DNA methylation (273–276).

**Uracil misincorporation into DNA.** Uracil content in DNA has been explored as a biomarker of folate deficiency. dTTP synthesis requires adequate amounts of 5,10-methylene-THF to donate methyl groups to deoxyuridines monophosphate (deoxuryridylate; dUMP). If 5,10-methylene-THF is limiting as a substrate of thymidylate synthase (TYMS) and/or TYMS is defective, dUMP accumulates, the deoxuryridine triphosphate (dUTP)/dTTP ratio increases, and it becomes more probable that uracil is incorporated into DNA instead of thymidine during DNA synthesis (131, 262). The conversion of dUMP to dTTP is entirely dependent on one-carbon donation by 5,10-methylene-THF. In contrast, methylation of CpG is dependent on the supply of SAM and its precursor methionine, the synthesis of which is influenced not only by folate but also by the availability of choline and methionine (131, 262). Therefore, uracil accumulation into DNA may be more specific than DNA cytosine methylation as a potential genomic biomarker of folate status.

**Micronuclei.** Excessive uracil incorporation into DNA and hypomethylation of pericentromeric DNA can lead to lagging chromosomes or chromosome fragments that form micronuclei (14, 131, 132, 277). Micronuclei have the same morphologic features as normal nuclei with the exception that they are much smaller, usually one-third to one-sixteenth in diameter. Cross-sectional studies have shown that micronuclei in lymphocytes or in erythrocytes are inversely associated with dietary folate intake and/or RBC folate and positively with plasma homocysteine (132, 278–285). Four intervention studies (284–287) reported on the effect of folic acid supplementation on micronuclei in lymphocytes, 3 of which showed a significant reduction in micronuclei frequency.

Because micronuclei frequency is also associated with intakes of other vitamins and minerals (279, 282) and exposure to lifestyle or environmental genotoxins (288, 289), it is not specific to folate status and therefore cannot be used on its own as an indicator of folate deficiency. It is, however, very sensitive to folate deficiency within the physiologic range and in combination with uracil and DNA methylation measurements has the potential to provide a reliable assessment of genome pathology resulting from inadequate folate. It is also important to note that it is now possible to score micronuclei automatically and reliably by using a wide range of image cytometry platforms (290, 291), making this technique amenable to mass screening.

**Assay-Specific Queries**

The previous section covered the physiologic aspects of each biomarker reviewed by the Folate Expert Panel. This section is focused principally on the priority biomarkers and in particular includes the following:

- an overview of the analytical methods;
- tools used to ensure the quality of the biomarker measurement; and
- a coverage of preanalytical considerations relevant to sample collection, processing, and storage.

Because the technical issues for serum and RBC folate are generally similar, these 2 biomarkers are presented together, pointing out differences where appropriate. Information on plasma homocysteine is presented separately.

**Measurement of serum and RBC folate**

**Introduction.** The essentials of folate as pertains to its measurement in serum/RBCs are outlined in Table 14. Folates are susceptible to interconversions and oxidative degradation (Figure 11) (295, 296), and their oxidation and breakdown products can also be found in serum. Some of these products no longer exhibit folate activity, yet one needs to ensure that they do not interfere with the measurement of folate vitamers. Understanding folate interconversions and degradations helps to better understand what different methods measure.

- 5-Methyl-THF is relatively stable at different pH values, with and without heat treatment, but it can undergo mild reversible oxidation to 5-methyl-5,6-dihydrofolate (5-methyl-5,6-DHF). This compound undergoes spontaneous cleavage of the C9-N10 bond in acidic solution (297). Under prolonged or severe oxidative conditions, 5-methyl-THF or 5-methyl-5,6-DHF can convert to 4α-hydroxy-5-methyl-THF, an intermediate product also called 4α-hydroxy-5-methyltetrahydrofolic acid (hmTHF) (298). In the absence of a reducing agent, hmTHF undergoes structural rearrangement to form a pyrazino-s-triazine derivative, which is no longer biologically active (299). This stable oxidation product of 5-methyl-THF is also known as pyrazino-s-triazine derivative of hmTHF (MeFox) (293, 300).

- Under heat and/or low pH conditions, THF can oxidize to folic acid via the highly unstable DHF intermediate. Assays measuring unmetabolized folic acid in serum should therefore verify that this compound is not an artifactual result of THF oxidation due to analytical steps. THF and DHF can also degrade to the biologically inactive catabolite pABG (301).

- There is a pH-driven equilibrium between 3 major formyl-folate vitamers: 10-formyl-THF is present at neutral and alkaline pH, folinic acid (5-formyl-THF) at slightly acidic pH, and 5,10-methenyl-THF at acidic pH. Heat accelerates the conversion of 10-formyl-THF to 5-formyl-THF at slightly acidic pH. Both 5-formyl-THF and 10-formyl-THF cyclize to 5,10-methenyl-THF at acidic pH. If the pH changes from acidic to slightly acidic or neutral, the equilibrium is pushed toward 10-formyl-THF (302).

- 10-Formyl-THF is readily oxidized to 10-formyl-folic acid (via 10-formyl-DHF), a stable form of the vitamin that was shown to exhibit folate activity (303).

- 5,10-methylene-THF is only stable at pH 10 and dissociates to formaldehyde and THF at physiologic pH values. On the other hand, heating samples in ascorbate-containing buffers in the absence of other reducing agent can also cause THF conversion to 5,10-methylene-THF via formaldehyde generated by the breakdown of ascorbate (295).
Analytical methods. Over the past 50 years, methods to assess serum and RBC folate concentrations have been continuously improved; however, they have not yet reached the point where they produce sufficiently comparable results across methods or laboratories. A comprehensive review article of analytical approaches and related issues (9) and 2 articles discussing issues pertaining to folate measurements in NHANES (4, 304) provide a wealth of information on this topic. Table 15 is a summary of the 3 main method types and their advantages and disadvantages.

MBAs. Historically considered the “gold standard” measurement procedure for serum and RBC total folate because it “fully measures the multiple forms of folate species that exhibit folate vitamin activity and does not measure folate species that lack vitamin activity” (304), the underlying principle of the MBA is that a folate-dependent microorganism, namely Lactobacillus rhamnosus (formerly called Lactobacillus casei), grows proportionally to the amount of folate present in serum or whole blood and that the folate concentration can be quantified by measuring the turbidity of the inoculated medium after a nearly 2-d incubation at 37°C. Some of the key advantages and disadvantages are itemized in Table 15. However, a few points are worth highlighting. The MBA has received renewed interest during the past decade because of improvements in efficiency and robustness, so that the assay can be reliably used in a high-throughput routine setting such as NHANES (305, 306). Important improvements introduced in the 1970s and 1980s included the development of a chloramphenicol-resistant strain of L. rhamnosus (307), the ability to cryopreserve the inoculum (308), and the introduction of automated microtitrater plate technology (309).

As a result, the need for sterilization or aseptic addition was eliminated, growth curves could be reproduced with much higher precision for hundreds of assays, and the assay was miniaturized by using disposable labware such as 96-well plates. Since then, 2 “variants” of the MBA have been adopted: 1) continued use of the wild-type organism (American Type Culture Collection 7469), but incorporation of the 96-well plate technology and cryopreservation, and 2) use of the chloramphenicol-resistant organism [American Type Culture Collection 27773 or National Collection of Industrial and Marine Bacteria (NCIMB) 10463] as well as incorporation of the 96-well plate technology and cryopreservation (310–312). A recent method comparison showed less than optimum correlation between these 2 “variants” (serum: r ~0.8; whole blood: r ~0.7) but very good correlation between 2 laboratories using the chloramphenicol-resistant organism (serum and whole blood: r > 0.9) (305).

The sensitivity of the MBA is a particular advantage when only small-sample volume is available, such as for samples collected from a fingerstick or as a dried blood spot (DBS). To date, no other folate assessment method has been applied successfully to DBS. The MBA method for DBS developed by O’Broin et al. (313, 314) and implemented at the CDC (315) is a suitable tool to assess folate status in a population when no venous sample can be collected (9). Despite the limitations outlined in Table 15, based on data from thousands of samples from NHANES, CDC analysts reported <1% of samples exhibited a pattern of interference due to the potential presence of antibiotics or antifolates (9). Some of the key factors that help to successfully perform the MBA are outlined in Table 16.

Protein-binding assays. Protein-binding assays (PBAs) were developed with the clinical laboratory in mind, to enable the diagnosis of folate deficiency. These assays use the highly specific FBP (mainly from milk or milk fractions, sometimes from porcine plasma or kidney) to “extract” folate from the sample. The strengths and weaknesses of PBAs are outlined in Table 15 and were recently reviewed by Pfeiffer et al. (9). A few key issues are highlighted below.

- PBA specificity comes with its own problems (9, 316), including that the various folate forms have different affinities to FBP (317) and slight deviations from the optimal pH of 9.3 (where folic acid and 5-methyl-THF show equivalent binding affinity to FBP) or in the protein content of the sample can lead to inaccurate measurements.
- PBAs are not sensitive to antibiotics, but they are influenced by certain antifolates such as methotrexate.
- If a person has consumed a diastereoisomeric supplement [e.g., (6R,5)-5-methyl-THF], the 6R form will readily bind to the FBP and the assay will give a spurious result (as will chromatographic assays because they also cannot distinguish between diastereoisomers).
- Folate polyglutamates generally exhibit a higher response than do monoglutamates, requiring a complete deconjugation of RBC folates (317). The conditions for the deconjugation step vary across assays and the preparation of whole-blood hemolysates needs to be performed off-line, potentially contributing to the larger assay differences noted for RBC folate than for serum folate (9).
- Additional shortcomings of PBAs are related to their limited dynamic range:
  - Potential problems with inaccurate dilution linearity, particularly if dilutions are not conducted in sample matrix.
  - Need to dilute and reanalyze a high percentage of samples from populations who are exposed to folic acid fortification, if the purpose of the analysis is to describe the distribution of folate concentrations.
- Other characteristics of PBAs include the following:
  - Different types of analytic binding; competitive (i.e., the sample and the labeled folate conjugate are mixed before the introduction of a limited amount of FBP, ensuring competition for the binding sites) or noncompetitive (i.e., an excess capacity of FBP is incubated with the sample before the addition of the labeled folate conjugate).

### TABLE 14 Folate essentials

<table>
<thead>
<tr>
<th>Type</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serum folate</td>
<td>The sum of several folate vitamins circulating in the blood stream, often referred to as “total folate.”</td>
</tr>
<tr>
<td>RBC folate</td>
<td>The analysis of these compounds is complicated by their appearance as pteroylmonoglutamates with variations in the oxidase state of the pteridine moiety and in the one-carbon substituent group at the N-5 and/or N-10 positions.</td>
</tr>
<tr>
<td>MBA</td>
<td>The main circulating folate vitamin is 5-methyl-THF (292), but incorporation of the 96-well plate technology and cryopreservation, and use of the chloramphenicol-resistant organism [American Type Culture Collection 27773 or National Collection of Industrial and Marine Bacteria (NCIMB) 10463] as well as incorporation of the 96-well plate technology and cryopreservation (310–312).</td>
</tr>
</tbody>
</table>

1. MTHFR, methylenetetrahydrofolate reductase; THF, tetrahydrofolate.
Different types of sample preparation: heterogeneous (i.e., excess unbound analyte or excess reaction components have to be removed, requiring that either the FBP or the folate conjugate be immobilized to a solid support) or homogeneous (i.e., no separation step is required).

Most current PBAs are competitive and heterogeneous. Generally, a pretreatment step on the instrument with alkaline reagent and antioxidant ensures the release of folate from endogenous FBP and its stabilization to prevent oxidation.

**Chromatography-based assays.** Chromatography-based methods provide information on individual folate forms and are based on either measurement of intact folates via HPLC or measurement of folate breakdown products as an indicator for total folate via GC. General characteristics of these 2 approaches are listed in Table 17.

Over the past decade, tandem mass spectrometers have become more affordable and user-friendly and smaller in footprint, and their performance in terms of sensitivity and linear dynamic range has greatly improved. They are now considered to be the preferred detectors for HPLC-based methods, at least for specialized laboratories. General characteristics of LC-tandem mass spectrometry (LC-MS/MS) are outlined in Table 18.

**Assay calibration for chromatographic assays.** Ensuring accurate calibration is a big task for chromatography-based methods, partially due to the number of folate forms, but also because of their instability. General recommendations and detailed procedures for the preparation and handling of folate standards are described elsewhere (9, 254). Fazili and Pfeiffer (293) recently reported that high-concentration stock solutions of 5-methyl-THF (100 mg/L) were stable for up to 9 y if stored at ~70°C in the presence of 1% ascorbic acid. However, mixed working calibrators have to be prepared freshly from frozen individual folate stock solutions for each analytical run and discarded after use.

**Key principles in sample extraction and preparation for chromatographic assays.** Chromatography-based analytical methods require sample extraction and cleanup, and some methods also use a sample concentration step to enable detection of minor folate forms. Pfeiffer et al. (9) provided a detailed table that summarizes features of LC-MS/MS methods used to measure serum and RBC folates. Most newer methods perform sample cleanup by use of solid-phase extraction (SPE) as an efficient way that can be easily automated for high throughput. Newer generation 96-probe SPE instruments allow fast sample cleanup (<1 h) with excellent folate recovery (300). Generally, reversed-phase cartridges are used in the SPE step, but strong anion-exchange cartridges have also been used. Because the latter require elution buffers with high salt content that can cause ion suppression and negatively influence analyte sensitivity, they are less favored by MS-based methods. Solid-phase affinity chromatography using FBP has also been used for sample cleanup by some methods. It has been shown that as long as the pH of the sample is low enough (<3.5) to prevent rebinding of 5-methyl-THF to the native proteins in the sample, the SPE step is sufficient, alleviating the need for a manual protein precipitation step (321). Yet, some investigators prefer to use heat, acid, or an organic solvent to precipitate proteins from either serum or whole blood. Regardless, internal standards should be added at the earliest possible time to account for procedural losses, and antioxidants have to be added to extraction buffers and reagents to protect labile reduced folates.

The extraction of folate polyglutamates from whole blood is complex and requires the hemolysis of erythrocytes (typically by diluting whole blood with ascorbic acid) as well as the deconjugation of polyglutamates to monogluta mates (typically through the action of the endogenous plasma conjugase at a slightly acidic pH and incubation at 37°C). Research is still ongoing to optimize conditions such that the LC-MS/MS method generates whole-blood total folate concentrations comparable to the MBA or to explain why the MBA measures ~20% higher (4). An alternative approach to the extraction of whole-blood folates at an acidic pH is to inactivate the endogenous plasma conjugase by heat in a high-pH borate buffer and to conduct in-line FBP affinity chromatography and HPLC-electrochemical detection analysis at a neutral pH (320). Although this preserves the folate polyglutamate pattern and prevents folate interconversions, it requires the quantitation of a large number of folate compounds, some of which have no commercially available calibrator materials. Furthermore, there are no appropriate internal standards available for this procedure and it is presently not amenable to LC-MS/MS.
TABLE 15 Main analytical method types used for the measurement of serum and RBC folate

<table>
<thead>
<tr>
<th>Method</th>
<th>Advantages</th>
<th>Disadvantages</th>
</tr>
</thead>
<tbody>
<tr>
<td>MBA for total folate</td>
<td>• Great sensitivity; small sample volume needed (∼50 μL)</td>
<td>• Manual assay; relatively laborious unless automated liquid handling is introduced</td>
</tr>
<tr>
<td></td>
<td>• Measures all biologically active forms approximately equally</td>
<td>• Lengthy assay; limited throughput (can only be performed 3 d/wk)</td>
</tr>
<tr>
<td></td>
<td>• Inexpensive, simple instrumentation, suited for low-resource settings</td>
<td>• Precision is relatively low (need for replicates)</td>
</tr>
<tr>
<td></td>
<td>• In-house control of performance</td>
<td>• Limited linear range (need multiple dilutions)</td>
</tr>
<tr>
<td></td>
<td>• Can be used with dried blood spot samples</td>
<td>• Not standardized (use of different calibrators, microorganisms)</td>
</tr>
<tr>
<td>PBA for total folate</td>
<td>• High sample throughput</td>
<td>• Prone to contamination issues</td>
</tr>
<tr>
<td></td>
<td>• Quick turnaround time to first result</td>
<td>• Inhibited by presence of antibiotics or antifolates</td>
</tr>
<tr>
<td></td>
<td>• Available in commercial kit form</td>
<td>• Folate forms have different affinities to the folate binding protein</td>
</tr>
<tr>
<td></td>
<td>• Minimum operator involvement</td>
<td>• Questionable accuracy when mixtures of folate are present</td>
</tr>
<tr>
<td></td>
<td>• Good precision for some assays</td>
<td>• Limited linear range</td>
</tr>
<tr>
<td></td>
<td>• Relatively low reagent cost</td>
<td>• Matrix effects when sample is diluted</td>
</tr>
<tr>
<td>Chromatography-based MS/MS</td>
<td>• Provides information on folate vitamers</td>
<td>• No control over lot-to-lot variability or assay recalibration/reformulation</td>
</tr>
<tr>
<td>assay for folate vitamers</td>
<td>• Use of stable-isotope-labeled internal standards compensates for procedural losses</td>
<td>• Requires expensive instrumentation, experienced operator, frequent technical service</td>
</tr>
<tr>
<td></td>
<td>• Highly selective and specific</td>
<td>• Manual assay; relatively laborious unless automated liquid handling is introduced</td>
</tr>
<tr>
<td></td>
<td>• Good sensitivity</td>
<td>• Complex sample extraction/cleanup</td>
</tr>
<tr>
<td></td>
<td>• Good precision</td>
<td>• Interconversions of folate forms need to be considered in the interpretation of data</td>
</tr>
<tr>
<td></td>
<td>• In-house control of performance</td>
<td>• Conversion of erythrocyte polyglutamates to monoglutamates needed for RBC folate</td>
</tr>
<tr>
<td></td>
<td></td>
<td>• Summation of folate forms to total folate</td>
</tr>
</tbody>
</table>

1 MBA, microbiological assay; MS/MS, tandem mass spectrometry; PBA, protein-binding assay.

As mentioned earlier, folates are susceptible to oxidative degradation during preanalytical sample handling and storage processes. Two recent LC-MS/MS methods showed that an oxidation product of 5-methyl-THF known as MeFox is present in serum at low concentrations and can interfere with the quantitation of 5-formyl-THF because it is an isobaric compound of 5-formyl-THF (293, 322). This shows that even the highly specific LC-MS/MS methods are not immune from interference problems.

**Choice of method.** The choice of method is contingent on the purpose and setting. For example, the aim of clinical laboratories is to determine whether a patient is folate deficient. As a result, clinical laboratories require inexpensive, automated, and high-throughput assays to be able to report results within a day or less of receiving a sample. They prefer ready-to-use reagents and supplies and generally do not have the technical staff to develop, validate, improve, or troubleshoot assays. Therefore, for clinical settings, PBA meet these criteria. However, as exemplified in the report by Raiten and Fisher (323), kit assays can change over time as a result of manufacturer recalibration or reformulation and may not be a good choice for a public health laboratory that needs to monitor trends in folate concentration distributions in a population over time.

Public health laboratories require stable assays, preferably where the method performance can be verified and controlled in-house. Either the MBA or LC-MS/MS may be suitable methods depending on the availability of resources (financial as well as staffing and instrumentation) and sample volume and whether total folate only or information on individual folate forms is of interest. By contrast, advantages of the MBA assay for low-resource settings include its relative low cost, its calibration and long-term performance can be controlled in-house, and it generates results that are generally in good agreement with higher-order LC-MS/MS methods. For the research setting, chromatographic assays that allow the determination of individual folate forms may be of greatest interest, but depending on the research question, other analytical approaches may also be appropriate.

**Serum/RBC cutoff values and interpretation of data.** The measurement of total folate provides information on the folate status of the individual, either short-term through serum folate or long-term through RBC folate. The inconsistent use of cutoff values over time to assess the proportion of the population with low blood folate concentrations has led to confusion. Some historical perspectives on the use of folate cutoffs are presented in Table 19. What unifies the various folate cutoff values is the fact that most were derived from data generated with the MBA. What is less clear is how the older MBA methods compare to today’s MBA.

Crider et al. (99) estimated that a reasonable cutoff for optimal prevention of NTDs would be population RBC folate concentrations of ∼1000 nmol/L, which is in agreement with the only prospective study that has been conducted to date (100), which found that the prevalence of NTD in an Irish population was lowest when RBC folate concentrations were ≥906 nmol/L (400 µg/L) (100). The WHO has estimated that the RBC folate concentration should be ≥400 µg/L (906 nmol/L) in women of reproductive age to achieve the greatest NTD risk reduction (101).

The presence of unmetabolized folic acid in serum is a result of folic acid intake from supplements or fortified foods in excess of ∼200 µg/m integral, which exceeds the capacity of the DHFR enzyme to reduce folic acid during intestinal absorption to the bioactive folate vitamer THF (328). The measurement of folate
<table>
<thead>
<tr>
<th>Suggestion</th>
<th>Rationale</th>
<th>Comment</th>
</tr>
</thead>
<tbody>
<tr>
<td>Use a liquid handler to dilute and dispense samples and reagents</td>
<td>Improves assay precision. Reduces manual labor and increases efficiency.</td>
<td>With manual pipetting four 96-well plates can be handled by an experienced analyst in an analytical run and the pipetting steps take ~3 h. If a liquid handler is used, the analytical run can be increased to seven 96-well plates/d and the pipetting steps only take half the time. This is important because the MBA can only be set up 3d/wk to avoid reading the plates on the weekend. Traditionally, most MBAs have used folic acid as a calibrator for convenience because of the greater stability of this folate form compared to reduced folates.</td>
</tr>
<tr>
<td>Select an appropriate calibrator</td>
<td>Because 5-methyl-THF constitutes the largest portion of total folate in both serum and whole-blood samples, it was recommended to use this folate form as a calibrator (305). The response of the chloramphenicol-resistant <em>L. rhamnosus</em> has been recently shown to be slightly greater for 5-methyl-THF than for folic acid, resulting in lower calculated concentrations by ~20% (9, 305). Because 5-methyl-THF constitutes the largest portion of total folate in both serum and whole-blood samples, it was recommended to use this folate form as a calibrator (305).</td>
<td>Folic acid is probably preferable for a novice laboratory until it establishes good proficiency with the assay. Most of the synthetic 5-methyl-THF forms commercially available are 6S,8S diastereomeric mixtures. Because in vivo vitamin activity of THFs and in vitro oxozymatic activity are only observed with the (SS)-THF isomers, the MBA will show 50% activity.</td>
</tr>
<tr>
<td>Handle calibrator with great care</td>
<td>5-Methyl-THF is sensitive to oxidation; therefore, stock solutions should be prepared with great care (use of antioxidants, purging solutions with nitrogen).</td>
<td>The concentration of the primary stock solution should be determined spectrophotometrically, and secondary stock solutions should be stored in small single-use aliquots at −70°C (9).</td>
</tr>
<tr>
<td>Prepare ready-to-use reagents</td>
<td>To reduce daily workload (e.g., preparation of additional reagents to be added to the medium). To reduce the chance of contamination.</td>
<td>Intermediate ready-to-use reagents can be prepared and stored at −70°C for up to 6 mo and easily added to the medium at the time of preparation.</td>
</tr>
<tr>
<td>Generate a “sensitive” <em>Lactobacillus rhamnosus</em> inoculum</td>
<td>To ensure good assay sensitivity (growth response per unit of folate).</td>
<td>Measure the turbidity of the culture regularly to identify the log phase growth (usually at ~20 h), stop the growth at that point, and freeze many inoculum aliquots at −70°C for subsequent sample analysis. Create each new inoculum from the original culture (freeze-dried organism); however, avoid generating more than 2 subsequent inoculi to avoid potential changes in the organism. Test the new inoculum before using it for sample analysis. Use a negative control (medium without the addition of folate) when preparing the inoculum to ensure that no organism is growing in the absence of folate.</td>
</tr>
<tr>
<td>Use appropriate sample dilution</td>
<td>The required sample dilution factor varies with the folate concentrations found in serum and whole-blood samples.</td>
<td>Samples from a population exposed to folic acid fortification require higher dilution (e.g., 1/100 for serum, 1/140 for hemolysate) than samples from a folate-deficient population (e.g., 1/20 for serum, 1/40 for hemolysate). A dilution linearity test over a relatively wide range (including lower and higher dilution than typically needed) should be carried out periodically to verify that the assay recovery (100 ± 15%) and precision (CV ≤15%) are adequate.</td>
</tr>
<tr>
<td>Prevent contamination</td>
<td>To ensure accurate results and minimize time to troubleshoot assay problems.</td>
<td>Use separate areas for the preparation of calibrator stock solutions and for the analysis of samples or preparation of reagents to avoid cross-contamination. Use disposable supplies when possible. Thoroughly clean durable supplies and dedicate their use to the same purpose to avoid cross-contamination.</td>
</tr>
<tr>
<td>Follow pre-established sample and run QC criteria</td>
<td>To ensure objective data review. To allow for automated (rule-based) result acceptance, rejection, and repeat analysis determination.</td>
<td>If an assay calls for 4 replicates (from 2 different dilutions) to calculate the final folate concentration for each sample: accept results if n = 4 and CV ≤15% or if n = 3 and CV ≤10%; reject a result if n ≤ 2 and repeat sample. If the result is outside the calibration range, repeat sample at higher or lower than regular dilutions.</td>
</tr>
<tr>
<td>Conduct regular calibration verification and instrument checks</td>
<td>Verify calibration accuracy of pipettes and automatic liquid handler. Ensure proper wavelength calibration of the microplate reader. Monitor temperature of the incubator, refrigerator, and freezer.</td>
<td>If run QC is outside of pre-established limits, repeat entire run.</td>
</tr>
</tbody>
</table>

1 MBA, microbiological assay; QC, quality control; THF, tetrahydrofolate
forms circulating in serum or present in RBCs may further elucidate the functional role of folate vitamins relative to various health outcomes; however, cutoff values for low or high concentrations or desirable ranges have yet to be identified. In conclusion, irrespective of what cutoff values are used, an earlier expert panel tasked to assess the folate methodology used in the NHANES III came to the still valid conclusion that “there is an inherent inadequacy in the reliance of single indices as sole determinants of inadequate folate nutriture” (323).

**Laboratory infrastructure.** Because of the technical and capacity requirements, measurements of serum and RBC folate cannot be conducted in the field. Table 20 outlines specific needs for each of the methods described above for assessment of serum/RBC folate.

**Measurement of plasma total homocysteine**

*Introduction.* Relevant information regarding homocysteine is itemized in Table 21.

*Analytical methods.* As described in detail by Ducros et al. (332) and Refsum et al. (179), various method types are available for homocysteine determination, from fully automated commercial kits (immunoassay or enzymatic method) to chromatographic assays with MS detection, overall providing comparable results and good assay performance. Table 22 presents a summary of the main method types and their advantages and disadvantages.

All methods require the reduction of the disulfide bonds to allow measurement of homocysteine (sum of the various disulfide forms and the reduced homocysteine form). The general characteristics and some specific features of commonly available methodologies for homocysteine assessment are outlined in Table 23.

**Choice of method.** Because the measurement of homocysteine produces fairly comparable results across different method types, the choice of method is mainly dependent on the availability of instrumentation and technical expertise. The following may help to inform this decision:

- The use of commercial kits (either immunoassay or enzymatic assay) on a fully automated clinical analyzer will provide the highest throughput and quickest turnaround time with the least effort; however, the relatively high reagent costs can make the measurements quite expensive, particularly for a large number of samples.
- If an HPLC system with fluorescence detector is available, setting up a manual assay may be the least expensive approach, particularly in settings with low labor costs.
- The disadvantage of the manual HPLC assay is the number of samples that can be run, likely limited to 50–70 unknown samples per analytical run.
- If a laboratory has access to an LC-MS/MS system and the required technical know-how, homocysteine can be measured in a high-throughput semiautomated manner, with quite low reagent costs.
- Because of the high initial cost, an LC-MS/MS system is economical only if a large number of samples are measured regularly.
- For the research setting, where other thiols besides homocysteine may be of interest, chromatographic assays are the method of choice.
- Gas chromatography–mass spectrometry (GC-MS) or GC-tandem MS (GC-MS/MS) have also been used in high-throughput research settings, particularly when the determination of both methylenalonic acid and methionine is of interest (343).

**TABLE 17** General characteristics of chromatography-based assays

<table>
<thead>
<tr>
<th>HPLC-based methods</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Older methods were HPLC-based and used fairly inexpensive detectors, such as UV, diode array, fluorescence, or electrochemical (295).</td>
<td></td>
</tr>
<tr>
<td>Folates were separated mainly on RP stationary materials.</td>
<td></td>
</tr>
<tr>
<td>To facilitate retention of negatively charged folates on RP columns, it was common to use low pH (&lt;4.0) mobile phases (phosphate buffer) with organic modifiers (typically acetonitrile), so-called ion suppression chromatography (318).</td>
<td></td>
</tr>
<tr>
<td>Due to the acidic mobile phase, this approach led to some folate interconversion of formyl forms.</td>
<td></td>
</tr>
<tr>
<td>Alternatively, folate forms were separated at a neutral pH after forming ion pairs with cationic surfactants (e.g., tetrabutylammonium phosphate), so-called ion-pair chromatography (319).</td>
<td></td>
</tr>
<tr>
<td>However, ion-pairing reagents were generally not used with electrochemical detection (320) and may negatively affect the robustness of the chromatography.</td>
<td></td>
</tr>
<tr>
<td>Both isocratic (typically shorter run times) and gradient (more flexible in resolving coeluting folate forms) elution methods were used.</td>
<td></td>
</tr>
<tr>
<td>Aside from having limited specificity, these methods also suffered from the lack of appropriate internal standards to correct for procedural losses (9).</td>
<td></td>
</tr>
<tr>
<td>GC-based methods</td>
<td></td>
</tr>
<tr>
<td>Developed for whole-blood samples before the availability of HPLC coupled to tandem MS (LC-MS/MS).</td>
<td></td>
</tr>
<tr>
<td>Used acid hydrolysis to break folate to pABA and used stable-isotope-labeled pABA as an internal standard for the MS detection.</td>
<td></td>
</tr>
<tr>
<td>Required lengthy multiphase preparation and were not widely used.</td>
<td></td>
</tr>
</tbody>
</table>

1. LC-MS/MS, liquid chromatography–tandem mass spectrometry; pABA, para-aminobenzoic acid; RP, reversed-phase.

**TABLE 18** General characteristics of LC-MS/MS

<p>| |</p>
<table>
<thead>
<tr>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Aside from offering great sensitivity, selectivity, and specificity, LC-MS/MS can also offer high throughput for routine measurements as long as the chromatographic separation is rapid and the sample preparation is mostly automated.</td>
</tr>
<tr>
<td>Sample preparation and automation can be facilitated by using UPLC, a technique that is becoming more established; but requires specific instrumentation and columns to withstand the higher pressure.</td>
</tr>
<tr>
<td>UPLC columns are less rugged than ordinary HPLC columns, requiring more frequent replacement.</td>
</tr>
<tr>
<td>An important advantage of LC-MS/MS compared with HPLC with conventional detection is that it can use stable-isotope-labeled internal standards that improve the accuracy and precision of the method by o behaving almost identically to the analyte of interest and o correcting for procedural losses, sample-to-sample ionization variations, and ion suppression issues (9).</td>
</tr>
<tr>
<td>Isotope dilution LC-MS/MS is now considered a state-of-the-art technology and is used by higher-order reference methods (4).</td>
</tr>
<tr>
<td>Most recent LC-MS/MS methods have used ESI (a softer ionization form preferred for folate analysis) and positive ion mode.</td>
</tr>
<tr>
<td>To enhance sample evaporation and ionization, MS-based methods require a mobile phase with high organic (acetonitrile or methanol) and low salt content.</td>
</tr>
<tr>
<td>Acid modifiers (acetic or formic acid) are most often used for positive ion mode, whereas volatile buffers (ammonium acetate or formate) are used for negative ion mode.</td>
</tr>
</tbody>
</table>

1. ESI, electrospray ionization; LC-MS/MS, liquid chromatography–tandem mass spectrometry; UPLC, ultra-high pressure liquid chromatography.
### TABLE 19  
**Historical perspectives on folate cutoffs**

- During the late 1980s, cutoff values for sequential stages of folate deficiency were established through depletion/repletion experiments.
- A serum folate concentration <7 nmol/L (3 μg/L) indicated negative folate balance at the time the blood sample was drawn (324).
- For RBC folate, concentrations of
  - o <363 nmol/L (180 μg/L) indicated the onset of folate depletion,
  - o <272 nmol/L (120 μg/L) marked the beginning of folate-deficient erythropoiesis, and
  - o <227 nmol/L (100 μg/L) marked folate-deficient anemia (324).
- More commonly, investigators used a single cutoff value of <317 nmol/L (140 μg/L) for RBC folate to designate deficiency (325).
- More recently, cutoff values for folate deficiency (serum folate <10 nmol/L and RBC folate <340 nmol/L) were defined on the basis of a metabolic indicator (increased plasma total homocysteine) (326). These cutoff values were derived from NHANES III data generated with the Bio-Rad radioassay and have been recommended by the 2005 WHO Technical Consultation on folate and vitamin B-12 deficiencies for the assessment of folate status of populations (327).

- GC-based methods provide better precision, higher resolution, and longer column life than do LC-based methods and are not subject to ion suppression issues, which can be a problem in LC-MS/MS methods.

**Interpretation of data.** As discussed above, abnormal plasma homocysteine concentrations are not specific for folate deficiency. They are found in persons whose folate and vitamin B-12, B-6, and or B-2 status is suboptimal (208, 344) and in persons with impaired renal function regardless of their B-vitamin status (345). Although elevated plasma homocysteine concentrations are associated with an increased risk of cardiovascular disease, clinical trials have shown that reducing homocysteine is not associated with a decrease in recurrence of cardiovascular disease (346). Furthermore, a recent meta-analysis on overall results from large unpublished data sets showed that lifelong moderate homocysteine elevation had little or no effect on coronary heart disease and that results from previously published studies may reflect publication bias or methodologic problems (347). The 2009 US National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines on “Emerging Biomarkers of Cardiovascular Disease and Stroke” categorized homocysteine concentrations (μmol/L) derived from standardized assays as follows: desirable, ≤10; intermediate (low to high), >10 to <15; high, ≥15 to <30; and very high, ≥30 (348).

**Laboratory infrastructure.** Measurements of homocysteine have to be conducted in a laboratory with uninterrupted electrical power supply for analytical instrumentation, freezers, refrigerators, and a water purification system for deionized water. Issues mentioned for folate PBA’s, such as the need for a certified service engineer to handle repairs and more complex maintenance, analyzers often operating on a closed-channel basis, and calibrators and reagents typically being purchased in a ready-to-use form, are also true for homocysteine immunoassays or enzymatic assays. In general, immunoanlyzers are more expensive than basic clinical chemistry analyzers that can conduct colorimetric tests.

Most research laboratories have access to an HPLC system and although a fluorescence detector is more expensive than a standard UVA detector, the cost is still much lower than for any mass spectrometer. An autosampler (preferably with a thermostat), column oven, computer, and software are part of standard HPLC packages. The protein precipitation step requires a centrifuge, whereas the derivatization reaction may require a heating block. Regardless of the method specifics, the laboratory needs to have access to a number of basic instruments, such as a precision balance, pH meter, various adjustable air displacement pipettes, vortex mixer, stirring plate, and ideally a barcode scanner. The use of a liquid handler to automate the pipetting steps can greatly increase the throughput of the method; however, some steps still have to be handled manually by the operator (e.g., centrifugation step, derivatization step). The laboratory has to purchase chemicals and prepare calibrators, buffers, mobile phase, and other reagents on a regular basis. Most of this is true for LC-MS/MS and GC-MS/MS assays, with the additional need for staff with relevant technical expertise, a good understanding of instrument software and hardware, and much more frequent access to a service engineer for repairs and maintenance than for HPLC and GC instrumentation.

### General principles in quality assessment

Quality assessment (QA) ensures that the laboratory results are accurate and of highest quality and is designed to address the following:

- avoidance of mistakes;
- consistency of performance;
- data integrity; and
- full staff participation in opportunities for training, which is needed to achieve high-quality results.

The basic components of a QA system are listed in Table 24.

Before the quality and consistency of a laboratory method can be monitored, prospect methods must be validated (for accuracy, precision, sensitivity, and ruggedness) and verified periodically (verification of assay calibration, verification of accuracy of pipettes, instruments). For a more detailed description of each QA system component, an example of a minimum QA system for a low-resource setting, and instructions on how to prepare, characterize, and use quality-control (QC) materials, the reader is referred to the Survey Toolkit for Nutritional Assessment, Laboratory and Field section, Quality Control and Quality Assurance subsection, developed by the CDC and hosted by the Micronutrient Initiative (349).

For convenience, some users prefer to purchase commercial QC materials. Unless one obtains the same batch of material, this practice may not be advisable for use over longer periods of time because frequent lot changes may prevent an assessment of assay shifts. In-house preparation of large batches of QC pools has the advantages of being more cost-efficient and being able to closely monitor assay performance. It is advisable to prepare 2 (normal and abnormal) or 3 (low, medium, and high) levels of QC pools, characterize them over the course of 20 individual analytical runs to establish target values and assay-associated variability, and then include them in every analytical run together with the unknown samples to judge whether the run is in control.

Although participation in proficiency testing programs is required to comply with certain laboratory certifications as well as recommended for good laboratory practice to allow external verification of results, the limitations of proficiency testing programs should be recognized and include the following:

- Most proficiency testing programs use method means (so-called peer-group means) to evaluate laboratories, making it difficult to identify methods with unsatisfactory performance or even monitor method shifts over time due to the lack of a stable reference point.
TABLE 20  Requirements for laboratory analysis of serum/RBC folate

<table>
<thead>
<tr>
<th>Method</th>
<th>Requirements</th>
</tr>
</thead>
</table>
| Serum or RBC folate (general) | ● A midlevel laboratory infrastructure that guarantees uninterrupted electrical power supply for freezers, refrigerators, and the operation of analytical instrumentation.  
● A water purification system that provides deionized water.  
● Protection of samples and particularly folate calibrators from direct sunlight and artificial light is highly recommended.  
| PBA methods            | ● A suitable immunanalyzer to measure folate with commercial kit assays; however, the cost for such an instrument is relatively expensive and most analyzers operate on a closed-channel basis allowing only reagents from 1 particular manufacturer to be used.  
● Calibrators and reagents are typically purchased from the manufacturer in a ready-to-use form or they require minimal handling.  
| MBA                    | ● Several, albeit comparatively less expensive, pieces of instrumentation, including the following:  
  o microplate reader;  
  o 37°C incubator;  
  o stirring hotplate;  
  o vortex mixer; balance accurate to at least 2, preferably 3, decimal points (0.001 g);  
  o UV/Vis spectrophotometer to determine the concentration of the folate calibrator; and  
  o various adjustable air displacement pipettes including an 8-channel pipettor and a repeater pipettor.  
● Specific chemicals, calibrator preparation, and reagents such as the growth medium.  
● A plate rotor can help to carefully mix the whole-blood hemolysates without causing foaming of the sample.  
● Throughout this method can be increased by use of a liquid handler to automate the various pipetting steps including the dilution of serum and whole-blood hemolysates, which is fairly laborious and can take several hours if conducted manually.  
● A computer-based sample tracking system can speed up sample log-in and avoid transcription errors by using a barcode scanner.  
| Chromatography-based    | ● Highly specialized instrumentation.  
● Staff with technical expertise in analytical chemistry and a good understanding of instrument software and hardware, regular access to a service engineer who performs repairs and more complex maintenance, generally as part of an annual service agreement.  
● LC-MS/MS instrumentation is very expensive and considerably more maintenance-intensive than HPLC coupled to other forms of detection such as UV, fluorescence, or electrochemical.  
● Because most methods rely on some form of solid-phase extraction for sample extraction and cleanup, at least a manual vacuum manifold is needed.  
● Automated solid-phase extraction and automated sample pipetting using a liquid handler are required to achieve high throughput/volume.  
● Depending on the method, other instrumentation may be needed, such as a sample evaporator (either through centrifugation in the presence of vacuum or through application of heat and/or the flow of an inert gas).  
● Regardless of the method specifics, the laboratory requires access to a number of basic instruments such as precision balance, UV/Vis spectrophotometer, pH meter, various adjustable air displacement pipettes, vortex mixer, stirring plate, and ideally a barcode scanner.  
● Chromatography-based assays produce a large amount of data that cannot be easily handled without an appropriate laboratory information management system; consideration has to be given to the time needed for data review and how the data will be stored so that it can be retrieved later; good access to IT services is essential.  
● The laboratory has to purchase numerous chemicals and prepare calibrators, buffers, mobile phase, and other reagents on a regular basis.  
● LC-MS/MS methods require stable-isotope-labeled internal standards, which are comparatively more expensive than unlabeled folate calibrators and only available from limited commercial sources (8); although certain folate polyglutamates (folic acid, 5-methyl-THF, and 5-formyl-THF) are commercially available, other reduced folate polyglutamates need to be custom synthesized (9).  

1  IT, information technology; LC-MS/MS, liquid chromatography–tandem mass spectrometry; MBA, microbiological assay; PBA, protein-binding assay; THF, tetrahydrofolate; UV/Vis, ultraviolet/visible.

- Proficiency testing samples are often modified (e.g., adding preservatives or other additives, supplementing materials with nonnative forms of analyte, using animal plasma or outdated human plasma from blood banks), potentially changing their behavior in the assay compared with fresh-frozen samples. This may lead to commutability problems with proficiency testing materials (350).
- As a result, information gained from the proficiency testing program may not be used to adjust assays.

Serum and RBC folate. To date, no formal standardization program exists for folate measurements, which may explain why considerable differences exist among laboratories and methods, particularly for RBC folate (9). A 2010 expert roundtable advising on folate biomarkers and methods for future NHANES surveys came to the conclusion that the close agreement obtained for serum folate results between the MBA and LC-MS/MS supported the introduction of the LC-MS/MS procedure for future NHANES (4). This allows for the measurement of individual folate vitamers, including unmetabolized folic acid, and calculation of total folate by summation of the individual vitamers. However, because the MBA gave ~25% higher concentrations than the LC-MS/MS procedure for RBC folate, NHANES retained the MBA for the measurement of RBC folate (4).

NIST has developed higher-order reference measurement procedures mainly for the measurement of serum 5-methyl-THF; these methods compared well with the CDC’s LC-MS/MS method (351). Serum-based international reference materials produced by NIST (351) and the UK National Institute for Biological Standards and Control (352) have been available for several years; unfortunately, certified concentrations are provided for 5-methyl-THF only. No whole-blood reference materials are currently available with certified concentrations for any folate form or total folate. Table 25 provides additional information on currently available reference materials and gives a selected list of proficiency testing programs for folate. Although there are no accuracy-based proficiency testing
programs available for folate, the UK National External Quality Assessment Service Haematinsics Survey recently showed that the all-laboratory consensus mean (instead of the method mean) proved to be sufficiently accurate (compared with LC-MS/MS assigned values) and stable to be used as the target for monitoring laboratory performance for serum folate (355).

**Plasma total homocysteine.** Although no formal standardization program exists for plasma homocysteine measurements, results obtained with common methods generally compare well (356–358) and the assays display good performance, such as accuracy, precision, and linearity (356). Several proficiency testing programs are available for homocysteine and NIST has developed higher-order reference measurement procedures for the measurement of homocysteine (359, 360) and assigned certified concentrations for homocysteine to 2 serum-based international SRMs: SRM 1955 (351) and SRM 1950 (Table 25). NIST has also conducted a commutability study for SRM 1955, which showed that this material was commutable for the majority of immunoassays available at the time (361). As part of the 2009 National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines on “Emerging Biomarkers of Cardiovascular Disease and Stroke,” analytical performance goals for the clinical usefulness of homocysteine measurements have been set to <10% for bias, <5% for precision, and <18% for total error (348). The guidelines also recommended that manufacturers of diagnostic assays for homocysteine should follow approved value transfer protocols to ensure that standardized assays are used for vascular risk assessment.

### TABLE 22 Main analytical method types used for the measurement of plasma total homocysteine

<table>
<thead>
<tr>
<th>Method</th>
<th>Advantages</th>
<th>Disadvantages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Immunoassay (FPIA, ICL, EIA)</td>
<td>High sample throughput, Quick turnaround time to first result, Available in commercial kit form, Minimum operator involvement, Good precision</td>
<td>Limited linear range (up to 50 μmol/L), Relatively high reagent cost, No control over lot-to-lot variability or assay recalibration/ref ormulation, Requires patented antibody</td>
</tr>
<tr>
<td>Enzymatic assay</td>
<td>Very small sample volume needed (≤50 μL), Can be performed on basic clinical chemistry analyzer or manually on a microplate reader</td>
<td>Manual pretreatment of samples needed, Background determination of α-amino acids needed</td>
</tr>
<tr>
<td>Chromatography-based assay (HPLC-FD, LC-MS/MS, GC-MS)</td>
<td>Can provide information on other thiols, GC-MS methods can simultaneously determine methylmalonic acid, methionine, and other compounds of the transulfuration pathway, HPLC-FD instrumentation commonly available, Use of internal standard (stable-isotope labeled for MS-based methods; other compounds for non-MS methods) compensates for procedural losses, Highly selective and specific, Good precision, in particular GC-MS, In-house control of performance</td>
<td>GC-MS and LC-MS/MS methods require expensive instrumentation, experienced operator, and frequent technical service and are therefore limited to specialized laboratories, Manual assay; several pipetting steps unless automated liquid handling is introduced, Complex sample extraction for most GC-MS methods because they require ion exchange chromatography step to separate amino acids, Derivatization is needed for all methods but LC-MS/MS, making full automation difficult</td>
</tr>
<tr>
<td>Capillary electrophoresis (with laser-induced fluorescence)</td>
<td>Good peak resolution, Short analysis time, No use of organic solvents, Ease of automation</td>
<td>Requires specialized expensive instrumentation not commonly available and experienced operator, Manual assay, complex sample extraction, derivatization needed</td>
</tr>
</tbody>
</table>

---

1 EIA, enzyme immunoassay; FPIA, fluorescence polarization immunoassay; GC-MS, gas chromatography–mass spectrometry; HPLC-FD, HPLC with fluorescence detection; ICL, immunochemiluminescence; LC-MS/MS, liquid chromatography–tandem mass spectrometry.
TABLE 23 Characteristics of methodologies used for homocysteine assessment

<table>
<thead>
<tr>
<th>Method</th>
<th>Characteristics</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Imмуnoassays</strong></td>
<td>• Rapid, fully automated immunoassay methods providing high sample throughput were developed in the 1990s due to the increasing clinical interest in Hcy as a potential risk factor for cardiovascular disease.</td>
</tr>
<tr>
<td></td>
<td>• They were adapted for various clinical analyzer platforms and the majority of clinical laboratories still use this approach. The common principle of all assays is the enzymatic conversion of free Hcy to S-adenosyl-L-homocysteine by the action of S-adenosyl-L-homocysteine hydrolase (333).</td>
</tr>
<tr>
<td></td>
<td>• The distinguishing feature of the assays is the detection mode, mainly including FPIA, ICL, and EIA.</td>
</tr>
<tr>
<td></td>
<td>• The FPIA assay has been used in the continuous NHANES survey from 1999 to 2006 (334) and compares well with a rapid and simple HPLC assay with fluorescence detection (335).</td>
</tr>
<tr>
<td></td>
<td>• The EIA assay, carried out on microplate plates with a microplate reader,</td>
</tr>
<tr>
<td></td>
<td>o has the potential for high throughput without the need for an expensive clinical analyzer;</td>
</tr>
<tr>
<td></td>
<td>o however, the imprecision of this assay is somewhat higher than that of fully automated immunoassays (243) and</td>
</tr>
<tr>
<td></td>
<td>o is not commonly used by laboratories participating currently in proficiency testing programs.</td>
</tr>
<tr>
<td><strong>Enzymatic assays</strong></td>
<td>• Enzymatic colorimetric assays do not require an immunoanalyzer; they can be performed on simpler clinical chemistry analyzers or manually using a microplate reader to record the colorimetric reaction.</td>
</tr>
<tr>
<td></td>
<td>• Various commercial assays have been developed:</td>
</tr>
<tr>
<td></td>
<td>o the A/C Diagnostics (San Diego, California) single-enzyme assay using homocysteine α,γ-lyase (336), which can now also be performed on a small portable fluorescence reader (337):</td>
</tr>
<tr>
<td></td>
<td>o the Catch (Bio-Pac Diagnostics, Inc; Bellevue, Washington) homogeneous enzymic assay based on pyruvate detection (338); and</td>
</tr>
<tr>
<td></td>
<td>o the Diazyme (Diazyme Laboratories, Poway, California) enzymic cycling assay based on ammonia detection (339).</td>
</tr>
<tr>
<td><strong>Capillary electrophoresis assays</strong></td>
<td>• This analytical approach seemed once an interesting alternative to HPLC methods; however, the emergence of simpler and more powerful LC-MS/MS methods has made this approach less attractive.</td>
</tr>
<tr>
<td><strong>Chromatography-based assays</strong></td>
<td>• This method type comprises a wide spectrum from the less expensive HPLC assays using mostly fluorescence detection (some methods use electrochemical or photometric detection) to the more cumbersome and less used GC-MS methods and to the newer and simpler LC-MS/MS methods that no longer require derivatization but rely on expensive tandem mass spectrometer instrumentation.</td>
</tr>
<tr>
<td></td>
<td>• Main advantages are as follows:</td>
</tr>
<tr>
<td></td>
<td>o they allow simultaneous measurement of other thiols in the same sample and</td>
</tr>
<tr>
<td></td>
<td>o the laboratory has in-house control of the assay performance and is not faced with unpredictable assay recalibration or reformulation by the manufacturer.</td>
</tr>
<tr>
<td></td>
<td>• All of these methods require the same first 2 steps:</td>
</tr>
<tr>
<td></td>
<td>o the conversion of the disulfide forms to reduced Hcy and</td>
</tr>
<tr>
<td></td>
<td>o the precipitation of proteins.</td>
</tr>
<tr>
<td></td>
<td>• A number of reducing reagents have been used (332): sulfhydryl agents such as dithiothreitol, dithioerythritol, or 2-mercaptoethanol; sodium or potassium borohydride; phosphine agents such as TBP and TCEP.</td>
</tr>
<tr>
<td></td>
<td>o TCEP has emerged as the reducing reagent with most advantages:</td>
</tr>
<tr>
<td></td>
<td>■ it is nonvolatile,</td>
</tr>
<tr>
<td></td>
<td>■ stable, and</td>
</tr>
<tr>
<td></td>
<td>■ soluble in aqueous solutions (335).</td>
</tr>
<tr>
<td><strong>Subtype HPLC</strong></td>
<td>• Less expensive.</td>
</tr>
<tr>
<td></td>
<td>• Uses mostly fluorescence detection (some methods use electrochemical or photometric detection).</td>
</tr>
<tr>
<td></td>
<td>• HPLC methods with fluorescence detection require a derivatization step; a number of reagents have been used: monobromobimane; halogenosulfonylbenzofurazans (SBD-F and AB-F; 3,6-Dphthalaldehyde) (332).</td>
</tr>
<tr>
<td></td>
<td>o SBD-F and AB-F seem to have some important practical advantages:</td>
</tr>
<tr>
<td></td>
<td>■ they are not fluorescent;</td>
</tr>
<tr>
<td></td>
<td>■ their thiol adducts are stable (no fluorescence degradation products), allowing the application of a simple isocratic chromatography (with shorter retention times for SBD-F compared with AB-F);</td>
</tr>
<tr>
<td></td>
<td>■ they are thiol-specific;</td>
</tr>
<tr>
<td></td>
<td>■ however, the derivatization needs to be performed at elevated temperature.</td>
</tr>
<tr>
<td><strong>Subtype GC-MS</strong></td>
<td>• More cumbersome and less commonly used than other methods in this class. Generally better precision than LC-MS/MS.</td>
</tr>
<tr>
<td><strong>Subtype LC-MS/MS</strong></td>
<td>• Superior analytical specificity and sensitivity.</td>
</tr>
<tr>
<td></td>
<td>• Expensive tandem mass spectrometer instrumentation.</td>
</tr>
<tr>
<td></td>
<td>• No longer require a derivatization step.</td>
</tr>
<tr>
<td></td>
<td>• Has also been adapted for dried blood spots (340, 341).</td>
</tr>
<tr>
<td></td>
<td>• A commercial kit specifically designed for LC-MS/MS has also been recently reported (342).</td>
</tr>
<tr>
<td></td>
<td>• Can incorporate the inexpensive deuterium-labeled Hcy as an internal standard to control for procedural losses and are considered higher-order reference methods.</td>
</tr>
<tr>
<td></td>
<td>• If only Hcy is of interest, the chromatographic run can be very short (≤2 min) and the data processing can be quick and easy.</td>
</tr>
</tbody>
</table>

1 ABD-F, 4-Iaminosulfonyl-7-fluoro-2,1,3-benzoxadiazole; EIA, enzyme immunoassay; FPIA, fluorescence polarization immunoassay; GC-MS, gas chromatography-mass spectrometry; Hcy, homocysteine; ICL, immunochemiluminescence; LC-MS/MS, liquid chromatography–tandem mass spectrometry; SBD-F, 7-Fluorobenzofurazan sulfonic acid; TBP, tri-n-butylphosphine; TCEP, tris(2-carboxyethyl)phosphine.
TABLE 24  Basic components of QA\textsuperscript{1}

- Internal QC through the use of bench and blind QC samples
- External QA via participation in proficiency testing programs
- Equipment monitoring and maintenance
- Documentation of policies and procedures
- Proper staff training
- Laboratory audits

\textsuperscript{1} QA, quality assessment; QC, quality control.

Folate status, and the vehicle in which folate was administered. The within-person variability for serum folate (CV (CV\textsubscript{w}) = 21.5\%) is about twice that for RBC folate (9.1\%) (370). It has been recommended that the method imprecision should be less than one-half of the CV\textsubscript{w}. Although this can be achieved with most current serum folate methods, RBC folate methods are nowhere near to achieving the much tighter requirement.

- Variables related to the sample collection. Although most laboratories prefer serum over plasma, both matrices generally produce comparable results for serum total folate (300, 363, 364), as long as the sample processing is not delayed (367).

- Variables related to the sample processing. Blood should be processed and frozen promptly. If delays in processing are unavoidable, the sample should be protected from light and kept cool; it should be processed no later than a few days after collection. Intact whole blood shows better folate stability than hemolysate (313, 364).

- Variables related to the sample storage. Generally, the lower the storage temperature, the better the folate stability. Folate in serum and hemolysates (but not in whole blood) can withstand a few short freeze/thawing cycles, particularly if the vials are closed most of the time to minimize the exposure of the sample to air (313, 366, 369). Folate in serum/plasma degrades rapidly at room temperature, particularly in the presence of EDTA (300, 367, 371). When Hannisdal et al. (367) kept unmatched serum and plasma samples at room temperature in the dark for up to 192 h, they did not find sample type differences at baseline (blood processed within <1 h and frozen immediately at −80°C) and 5-methyl-THF concentrations were essentially stable for 48 h in serum. However, in EDTA plasma, 5-methyl-THF decreased and MeFox (tentatively termed hmTHF in earlier publications) increased at a rate of 1.92%/h and 25.7%/h, respectively, during the first phase of rapid change. In serum, the reduction in 5-methyl-THF was totally recovered as MeFox after 96 h, whereas in EDTA plasma a smaller percentage of 5-methyl-THF was recovered as MeFox. Therefore, moderately degraded folate can be quantitatively recovered as MeFox. However, in serum samples stored for decades in biobanks, folate is degraded beyond MeFox but can be recovered as pABG equivalents after oxidation and mild acid hydrolysis of the folate species (372). These recovery strategies are useful for the assessment of folate status in epidemiologic studies, in which serum/plasma was processed, transported, and stored in biobanks under conditions that did not stabilize folate (i.e., in the absence of ascorbic acid).

**Plasma total homocysteine.** Plasma homocysteine is a very stable analyte as long as the plasma is separated from the RBCs within 1 h of blood collection (or within <8 h if the whole blood is kept on ice) (179) (Table 26). The within-person variability CV\textsubscript{w} for plasma homocysteine is 12.2\% (370). Most current homocysteine methods have an imprecision of between 5% and 10% and therefore could likely achieve a method imprecision of less than one-half of the CV\textsubscript{w}.

**Other biomarker methods.**

**Urinary folate/folic acid.** Although urine contains some folate derivatives, the bulk of the excretion products in humans are folate cleavage products. A small and variable amount of a folate dose is recovered as intact folate derivatives in urine in the first 24 h after the dose. Folate is freely filtered at the glomerulus and is reabsorbed in the proximal renal tubule. The net effect is that most of the secreted folate is reabsorbed (292). When large folate doses are given, more of the folate is excreted in the urine (373, 374) and the amount excreted depends on the type of

---

TABLE 25  Available reference materials and proficiency testing programs for folate status biomarkers\textsuperscript{1}

<table>
<thead>
<tr>
<th>Biomarker</th>
<th>Reference materials</th>
<th>Selected list of proficiency testing programs</th>
</tr>
</thead>
<tbody>
<tr>
<td>Serum folate</td>
<td>NIST SRM 1955 (human serum, frozen; 3 levels; certified values for 5-methyl-THF, reference values for FA, information values for total folate and 5-formyl-THF) (353)</td>
<td>CAP Ligand Assay General Survey</td>
</tr>
<tr>
<td></td>
<td>NIST SRM 1950 (human plasma, frozen; 1 level; certified value for 5-methyl-THF, reference value for FA) (353)</td>
<td>CAP Cal V/L Survey</td>
</tr>
<tr>
<td></td>
<td>NIBSC RM 03/178 (human serum, freeze-dried; 1 level; LC-MS/MS values for 5-methyl-THF, FA, 5-formyl-THF, and total folate) 354</td>
<td>UK NIBSC Haematinics Survey</td>
</tr>
<tr>
<td>Whole-blood folate</td>
<td>NIBSC RM 95/528 (human whole-blood hemolysate, freeze-dried; 1 level; consensus value) (354)</td>
<td>CAP Ligand Assay General Survey</td>
</tr>
<tr>
<td></td>
<td></td>
<td>CAP Cal V/L Survey</td>
</tr>
<tr>
<td></td>
<td></td>
<td>UK NIBSC Haematinics Survey</td>
</tr>
<tr>
<td>Plasma Hcy</td>
<td>NIST SRM 1955 (human serum, frozen; 3 levels; certified values) (353)</td>
<td>CAP Homocysteine Survey</td>
</tr>
<tr>
<td></td>
<td>NIST SRM 1950 (human plasma, frozen; 1 level; certified value) (353)</td>
<td>CAP Cal V/L Survey</td>
</tr>
<tr>
<td></td>
<td></td>
<td>NY State Department of Health Wadsworth Center General Clinical Chemistry</td>
</tr>
<tr>
<td></td>
<td></td>
<td>DEKS</td>
</tr>
</tbody>
</table>

\textsuperscript{1} Cal V/L, Calibration Verification and Linearity Survey; CAP, College of American Pathologists; DEKS, Danish External Quality Assessment Program; FA, folic acid; Hcy, total homocysteine; NEQAS, National External Quality Assessment Scheme; NIBSC, National Institute for Biological Standards and Control; NIST, National Institute of Standards and Technology; SRM, standard reference material; THF, tetrahydrofolate; UK, United Kingdom.
folate given as well as the dose. Humans have limited ability to reduce large doses of folic acid (221, 375, 376). More folic acid is excreted than 5-methyl-THF when large doses are given. Urinary folates can be measured by chromatography-based methods, which were discussed previously in the section on analytical methods under measurement of serum and RBC folate. Because folates occur as monoglutamates in urine, no deconjugation is necessary and the sample can be cleaned up by affinity chromatography, which requires no additional extraction step (377).

**Serum folic acid.** The main circulating folate vitamer is 5-methyl-THF (292), but unmetabolized folic acid can be present in varying concentrations (7, 294). This vitamer is measured by chromatography-based methods that provide information on individual folate forms and that were discussed previously in the section on analytical methods under measurement of serum and RBC folate. More recent methods have used tandem MS as the detector (300), but electrochemical detection (378) and MBA of folic acid–containing HPLC fractions (379, 380) have been used as well. It is important to note that under heat and/or low-pH conditions, THF can oxidize to folic acid via the highly unstable DHF intermediate. Assays measuring unmetabolized folic acid in serum should therefore verify that this compound is not an artifactual result of THF oxidation due to analytical steps.

**Urinary and serum pABG and apABG.** The oxidative folate catabolites pABG and apABG, biomarkers of folate status and turnover, are found in both urine and blood. Urinary pABG and apABG, which reflect turnover in endogenous folate pools, are frequently measured by chromatography-based methods (HPLC, GC-MS) after preanalytical passage through immobilized FBP affinity columns to remove potential interference from intact folate (258, 381). More recent studies reported the development of faster and highly sensitive LC-MS/MS procedures for the quantification of pABG and apABG in urine (382, 383) and the use of this procedure for quantifying these catabolites in fasted spot urine as a noninvasive alternative to 24-h urine analysis (384). pABG and apABG in serum can also be measured by LC-MS/MS by using procedures developed for the selective and simultaneous quantification of pABG and apABG and other folate species (5-methyl-THF, 5-formyl-THF, hmTHF, folic acid) (367). In serum samples stored for decades in biobanks, degraded folate can be recovered as pABG equivalents after oxidation and mild acid hydrolysis of the folate species (372). As indicated earlier, this recovery strategy can be useful for the assessment of folate status in epidemiologic studies in which serum/plasma was processed, transported, and stored in biobanks under conditions that did not stabilize folate (i.e., in the absence of ascorbic acid).

**Genetic markers.**

**DNA methylation.** One can examine cytosine methylation across all cytosines in the genome or in specific regions of the genome such as long interspersed nucleotide elements-1 (LINE-1) repetitive sequences or promoter sequences of single genes. The most commonly used methods require that DNA is isolated from cells to perform DNA methylation analysis (264, 385); however, it is possible to visualize methylated cytosine in the nuclei or chromosomes by using labeled antibodies (386). DNA methylation in human epidemiologic studies is usually measured in DNA from isolated lymphocytes or in DNA from whole blood. The preferred approach is to use DNA from isolated lymphocytes because DNA methylation status may vary between leukocyte subsets (387, 388) and leukocyte subset ratios may differ significantly between individuals depending on their age, sex, health, level of physical exercise, and lifestyle or nutritional status (389–391), which may then make interpretation of data difficult.

One of the earlier most utilized techniques in folate-related DNA methylation research is the CpG methyl transferase SssI (from Spiroplasma sp. strain) methyl acceptance assay in which DNA is incubated with the SssI enzyme with SAM containing a tritiated methyl group (392). The capacity of the DNA to accept tritiated methyl groups from SAM is then calculated from the degree of its radioactivity after isolation from the reaction mixture. A higher degree of radioactivity reflects a higher capacity to accept methyl groups and therefore indicates the extent to which the DNA’s cytosines at CpG sites were initially hypomethylated. Another method that has been used successfully is based on the initial digestion of isolated DNA to single bases and subsequent measurement of the abundance of cytosine and 5-methylcytosine by LC in combination with UVA detection (393) or MS (139). The 5-methylcytosine/(cytosine + 5-methylcytosine) ratio provides a measure of global cytosine methylation.

The LINE-1 retrotransposon is a mobile parasite genetic element that is abundant in the human genome, representing ~17% of the total human DNA (394). Methylation of LINE-1 sequences is essential for suppressing its expression, which if left unchecked, can multiply rapidly and insert itself randomly into the human genome, disrupting normal gene expression and causing chromosomal instability (264, 394). Several investigators are now measuring LINE-1 methylation in relation to folate status and folate metabolism gene polymorphisms by pyrosequencing of bisulfited DNA (395, 396). The DNA of interest is extracted and treated with bisulfite to convert unmethylated cytosines into uracils. After PCR amplification, by which all uracils result in thymidine, the sample is denatured to form single-stranded DNA. The single-stranded DNA is then sequenced and the degree of methylation at each CpG position in a sequence is determined from the ratio of T and C at that position.

**Uracil misincorporation.** Initially indirect methods were used to measure folate status of cells by determining either their resistance to incorporate tritiated thymidine when supplied with deoxouridine (deoxouridine suppression test) (397) or their uptake and metabolism of tritiated deoxouridine by measuring radiolabeled uracil or thymidine in DNA, which reflected the cells’ capacity to synthesize dTTP (398).

Other indirect methods involve the treatment of either nuclei or isolated DNA with uracil glycosylase (UDG), which converts uracil in DNA into an abasic site. In the former case, it is possible to use the comet assay under alkaline conditions (pH 13) to measure double-strand breaks in nuclei resulting from abasic sites that are either occurring spontaneously or are induced by UDG (399). The difference between the 2 measures then provides an estimate of the presence of uracil in DNA. In the case of isolated DNA, one can measure spontaneous and UDG-induced abasic sites by using labeled aldehyde reactive probe and ELISA detection (400); similarly, the difference between these 2 parameters provides a measure of uracil in DNA. More direct and quantitative measurement of uracil in DNA can be achieved by HPLC (401) or GC-MS analysis (402) of abundance of each base in hydrolyzed DNA. An alternative approach is to specifically release the uracil in DNA by UDG digestion and then analyze uracil extracted from the reaction mixture by GC-MS (403, 404).

**Micronuclei.** Micronuclei are best scored in once-divided cells because only cells that complete nuclear division can efficiently express micronuclei. Usually, micronuclei in humans are measured in mitogen-stimulated lymphocytes cultured ex
TABLE 26  Preanalytical factors influencing biochemical indicators of folate status\(^1\)

<table>
<thead>
<tr>
<th>Variables</th>
<th>Serum folate</th>
<th>RBC folate</th>
<th>Plasma Hcy</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subject</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fasting</td>
<td>Essential for individual but probably not for population ((-10%) average difference between overnight fasted and (&lt;3\ h) fasted) (362)</td>
<td>Not required (362)</td>
<td>Generally not required (179); variations in Hcy in response to a high-protein meal (332)</td>
</tr>
<tr>
<td>Biological variation, (^2) %</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Within-person</td>
<td>21.5</td>
<td>9.1</td>
<td>122</td>
</tr>
<tr>
<td>Between-person</td>
<td>48.7</td>
<td>35.8</td>
<td>37.1</td>
</tr>
<tr>
<td>Sample collection</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Venous vs. capillary blood</td>
<td>No data</td>
<td></td>
<td>No data</td>
</tr>
<tr>
<td>Influence of anticoagulants</td>
<td>Serum preferred over plasma (might contain fibrinogen clots); generally both matrices provide similar results (300, 363, 364)</td>
<td>EDTA whole blood is used; other anticoagulants are not customary</td>
<td>EDTA plasma preferred over serum because the evacuated tubes can be immediately centrifuged.</td>
</tr>
<tr>
<td>Sample processing</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>General requirements</td>
<td>Protect evacuated tubes with whole blood from light and keep cool (avoid freezing to keep RBCs intact); prompt processing and freezing of serum recommended</td>
<td>Protect evacuated tubes with anticoagulated EDTA whole blood from light and keep cool (avoid freezing to keep RBC intact); prompt processing and freezing of hemolysate recommended; Measure hematocrit to correct for packed cells; prepare hemolysate with ascorbic acid (1% wt:vol) by using accurate pipetting; use of serum folate concentration in calculation of RBC folate concentration preferred</td>
<td>It has been recommended that Hcy be measured in plasma because the sample can be processed immediately; to obtain serum, on the other hand, a blood sample has to be left at room temperature for 30–60 min to allow coagulation, which leads to an artificial increase in Hcy due to an ongoing release of Hcy from RBCs. Serum concentrations will therefore be (~5–10%) higher than those obtained in optimally prepared plasma. Separate plasma from RBC within 1 h of collection to avoid artificial increase in Hcy (ongoing release of Hcy from RBCs: (\sim1\ \mu\text{mol}/(L\times h)) at room temperature) (179).</td>
</tr>
<tr>
<td>Delayed processing</td>
<td>Prepare serum within 1 d, but no later than within 2–3 d of blood collection</td>
<td>Prepare hemolysate with ascorbic acid (1% wt:vol) within 1 d, but no later than within 4 d of blood collection (folate recovery is (&gt;90%) at 4°C (313, 364))</td>
<td>Alternately, keep evacuated tubes with anticoagulated EDTA whole blood on ice for (&lt;8\ h) before preparation of plasma (179). Adenosine analogs (e.g., 3-deazaadenosine) prevent formation or release of Hcy from RBCs but are not compatible with immunoassays based on S-adenosylhomocysteine hydrolase (179).</td>
</tr>
<tr>
<td>Sample storage</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Storage stability</td>
<td>Stable for 1–2 d at room temperature in serum, but not in EDTA plasma; EDTA accelerates folate degradation (2%/h) (367)</td>
<td>Hemolysate with ascorbic acid (1% wt:vol) stable for several weeks at (\sim20%) if stored at (\sim70\°C) (179, 363, 364)</td>
<td>Stable for days at RT; stable for weeks refrigerated; stable for years frozen (179, 332)</td>
</tr>
<tr>
<td>stable for 1 wk refrigerated ((&lt;10%) loss) (366, 368)</td>
<td>Stable for several weeks at (\sim20%) (313) and a few years at (\sim70\°C) (9)</td>
<td>Moderate folate losses can occur if whole blood is stored frozen (\sim20%) loss after 2 y at (\sim70\°C) (369)</td>
<td></td>
</tr>
<tr>
<td>stable for a few years at (\sim70\°C) (2)</td>
<td>Moderate folate losses can occur if whole blood is stored frozen (\sim20%) loss after 2 y at (\sim70\°C) (369)</td>
<td>Stable for days at RT; stable for weeks refrigerated; stable for years frozen (179, 332)</td>
<td></td>
</tr>
<tr>
<td>Ascorbic acid can be added (0.5% wt:vol) before storage to improve stability</td>
<td>Stable for several weeks at (\sim20%) (313) and a few years at (\sim70\°C) (9)</td>
<td>Moderate folate losses can occur if whole blood is stored frozen (\sim20%) loss after 2 y at (\sim70\°C) (369)</td>
<td></td>
</tr>
<tr>
<td>Freeze/thaw stability</td>
<td>Little deterioration for at least 3 cycles (366)</td>
<td>Little deterioration in hemolysates for at least 3 cycles (369); significant folate loss in whole blood already at 2 cycles (369)</td>
<td>Excellent stability; however, thorough mixing of samples required after thawing (179)</td>
</tr>
</tbody>
</table>

\(^1\) Hcy, homocysteine; RT, room temperature.

\(^2\) Data from reference 263.
vivo and blocked at the binucleate stage of mitosis by using cytochalasin B, a cytokinesis inhibitor, to identify once-divided cells (405). Micronuclei may also be measured in erythrocytes due to micronuclei formation in vivo in bone marrow normoblasts from which erythrocytes are derived after enucleation. Preferably, micronuclei are measured in very young erythrocytes known as reticulocytes, which can be identified by their larger size, higher RNA content, and by being positive for the transferrin receptor (131, 132, 406).

**New Directions and Technologies**

**Omnics (genome, epigenome, transcriptome, proteome, metabolome)**

A biomarker may not necessarily refer to a single metabolic or genomic indicator. Rather, it could represent a panel of markers (407, 408) that reflect physiologic patterns or disease states (407, 409). Genome-related markers have the potential to serve as functional biomarkers of folate-dependent nucleotide biosynthesis and/or homocysteine remethylation, including the cellular methylation potential. Potential genomic biomarkers of folate status and function include alterations in chromatin methylation (410, 411), gene expression (412, 413), nuclear genome stability, and uracil content in nuclear DNA (29, 131, 414). Uracil misincorporation into nuclear DNA increases during folate deficiency, leading to increased levels of uracil content in DNA and DNA instability, but uracil accumulation in DNA is not specific to folate deficiency because vitamin B-12 and B-6 deficiency can impair folate utilization, leading to elevated uracil in DNA. Uracil in DNA also exhibits cell and tissue-type variations and has not been shown to be dose responsive to folate supplementation, limiting its role as a biomarker. Disruption of de novo dTMP synthesis in mitochondria results in elevated uracil levels in mitochondrial DNA (146), but the utility of uracil in mitochondrial DNA as a robust biomarker of folate nutritional status or de novo dTMP synthesis has yet to be established. Functional variation in folate-dependent homocysteine remethylation, which generates the cofactor SAM, includes Cpg DNA methylation levels and protein methylation (including histones), which affect gene expression and DNA stability (138–141). However, methylation patterns are affected by not only folate but also by vitamin B-12, choline, threonine, and other one-carbon donors (415, 416). Changes in the DNA and histone methylene can be either global or specific to one or more genetic loci.

**New technologies as research tools**

**High-throughput omics platforms for data collection.** Biomarker discovery and validation, and determination of interindividual variation in biomarker responses to dietary exposures, increasingly require profiling of the metabolome, transcriptome, genetic variation, and the epigenome, including for quantitative profiling of biomarkers of one-carbon metabolism (417, 418). Rates and costs of data collection are limiting factors in biomarker discovery, validation, and use. Untargeted metabolomic approaches have the potential to reveal unexpected and new associations among metabolites and disease risks but are limited by the ability to detect low-abundance compounds beyond what current MS technologies can provide (419, 420). This approach is vulnerable to false discovery, as shown by the reported association between prostate cancer and urinary sarcosine (421), which could not be confirmed, probably because of interference from alanine (422). The risk of false discovery can be addressed by large sample size, data splitting, and validation cohorts (423). Therefore, candidate biomarkers identified through untargeted approaches must be validated and their biological plausibility established to become true targets.

Targeted metabolic profiling may be hypothesis driven, and it may be difficult to formulate adequate hypotheses within a system composed of complex interactive metabolic networks. However, methods can be developed and optimized to quantitatively determine a panel of low- and high-abundance metabolites within a defined metabolic pathway and the statistical problem of false discovery rate is mitigated. Last, the development and implementation of appropriate QC systems is currently a limiting factor in all “omics” research (424). Looking forward, the greatest need and opportunity in biomarker research and development is to exploit new or existing technologies to serve as platforms for simultaneous measurement of multiple biomarkers, particularly in field settings. Such methods are under development and offer the potential to access comprehensively the nutritional status of individuals and populations.

**Mathematical models to predict, identify, and integrate biomarkers of impaired folate metabolism.** Deterministic mathematical models of one-carbon metabolism have been reported that describe the network including the effect of genetic variation and nutritional status on network outputs (158, 425). These deterministic modeling approaches use ordinary differential equations and represent metabolites as continuous variables (426) and serve to model system behavior from reaction velocities, usually described in terms of Michaelis-Menten kinetic parameters. Deterministic models have several limitations, the most important being that the combinatorial complexity of the system, when including all reactions, interactions, and gene expression data, can become a limiting factor (427). Thus, other approaches are needed to model folate metabolism and all of its interactions and regulation in the context of whole-body physiology.

Computational models can be generated for integrating and interpreting large-scale omics data (428), including transcriptomic (429–431), proteomic, and metabolomic data (432, 433). These reconstructions can be incorporated into in silico models for mathematical modeling to study network properties, structure, and dynamics. Mathematical modeling enables simulations and predictions of network responses to genetic and environmental perturbations, including drug treatments and nutritional interventions, and can assist in the discovery and validation of biomarkers that inform preventative or management treatments (159, 425). They have the potential to inform DRIs for essential nutrients (434). As an example, Recon 1, a global reconstruction of the human metabolic network (430), was built from a human genome sequence and the accumulated knowledge of human metabolism, encompassing 1496 genes, 2004 proteins, 2712 metabolites, and 3311 metabolic reactions. Although still in development, Recon 1 has been used to stimulate hypothesis-driven studies of human metabolism (435, 436), for computational simulation to identify biomarkers for disease management strategies (428, 430), and to investigate the effect of dietary interventions on transcriptome profiles at different stages of the intervention (429), which revealed interactions between metabolic and inflammatory pathways on insulin sensitivity. Computer simulations have also led to the systematic effort to predict biomarkers for >300 metabolic disorders (437), which were 10 times higher than random chance (438). The prediction of extracellular biomarkers in folate metabolism will benefit from a whole-body network model that incorporates different cells and tissues (438).
Research Gaps and Needs
Lacking are functional biomarkers that report on individual pathways within the folate-mediated one-carbon metabolic network as well as validated biomarkers of risk of folate-associated pathologies including developmental anomalies, neurodegeneration, cancers, and other diseases of aging. There are no established blood metabolite biomarkers that are specific to impaired de novo purine or thymidylate biosynthesis. There are several robust biomarkers of homocysteine remethylation function, including plasma concentrations of SAM, homocysteine, and SAH. However, apart from folate, these biomarkers are sensitive to choline and vitamin B-12 status, as well as genetic variation. Blood biomarkers that report on the activity of mitochondrial one-carbon metabolism are also lacking. Plasma formate concentrations may report on mitochondrial formate production (439) but its use as a functional biomarker has not been extensively investigated. Nonketotic hyperglycinemia, an inborn error of metabolism resulting in compromised folate-dependent glycine cleavage in mitochondria, results in elevated glycine concentrations in cerebral spinal fluid, but this biomarker is not relevant for healthy populations (440).

Recent evidence suggests that alterations in gene expression specific to folate deficiency (441, 442) and proteomic changes in response to folic acid supplementation (443) can be identified, which potentially could be used to supplement interpretation of established biomarkers. Furthermore, gene expression network analysis was used to identify gene expression patterns associated with micronuclei formation under different environmental exposure conditions such as acrylamide or nitrosamine exposure (444, 445). A similar approach could be developed to identify gene expression networks that relate to folate deficiency–induced uracil misincorporation, DNA hypomethylation, and micronuclei and possibly also include folate deficiency–specific microRNAs (e.g., miR-222) in the diagnostics (446).

Future research can address all of the above but should also seek to consider the following:

- studies in better defined leukocyte subpopulations rather than total leukocytes;
- studies in easily accessible epithelial tissues, such as buccal cells and skin;
- larger studies to be able to determine the impact of genoytype;
- replication studies within the same population and across populations;
- harmonization of assay protocols across laboratories;
- continuing and sustained efforts to improve assay robustness, cost-effectiveness, and transportability to low-resource settings;
- simultaneous measurement of different but complementary biomarkers (i.e., DNA methylation, uracil in DNA, and DNA or chromosomal breaks; gene expression patterns) associated with folate deficiency or excess;
- harmonization of robust study designs to determine the genomic effects of depletion and repletion of folate; and
- inclusion of gene expression network analysis to verify mechanisms underlying observed genomic effects.

Acknowledgments
This review is the result of deliberations and contributions of the Folate Expert Panel [LBB (Chair), PJS, HM, MFP, JFG, and JLM] and scientific consultants (CMP, ZF, MZ, PMU, AMM, MAC, BS, RJB, and RLB). Allyson West’s contribution to the content of the choline section is acknowledged.

RR summarized the deliberations of the Folate Panel and scientific consultants and coordinated preparation of the manuscript draft; LBB was responsible for assignment of Folate Panel members and consultants as authors of specific sections of the review and oversight of scientific content; DBH assisted with manuscript revisions and screened final content. DJR provided oversight to the overall BOND process. All authors read and approved the final version of the manuscript.

References

1670S Supplement


Biomarkers of nutrition for development—folate review 1617S


Fox JT; Stover PJ. Folate-mediated one-carbon metabolism. Vitam Horm 2008;79:1–44.


Fenech M. Folate (vitamin B9) and vitamin B12 and their function in the maintenance of nuclear and mitochondrial genome integrity. Mutat Res 2012;733:21–33.


Bogenhagen D, Clayton DA. Mouse L cell mitochondrial DNA molecules are selected randomly for replication throughout the cell cycle. Cell 1977;11:719–27.


Biomarkers of nutrition for development—folate review 1673S


279. Fench M, Baghurst P, Luderer W, Turner J, Record S, Ceppi M, Bonassi S. Low intake of calcium, folate, nictinic acid, vitamin E, retinol, beta-carotene and high intake of pantothenic acid, biotin and riboflavin are significantly associated with increased genome instability—results from genome damage and micronucleus index survey in South Australia. Carcinogenesis 2005;26:991–9.


407. Kouskoumvekaki I, Panagiotou G. Navigating the human metabo-
lome for biomarker identification and design of pharmaceutical

408. Weljie AM, Dowlatbadi R, Miller BJ, Vogel HJ, Jirk FR. An
inflammatory arthritis-associated metabolite biomarker pattern

409. Mamas M, Dunn WB, Neyses L, Goodacre R. The role of metabolites
and metabolomics in clinically applicable biomarkers of disease. Arch

410. LaSalle JM. A genomic point-of-view on environmental factors

411. Parle-McDermott A, Ozaki M. The impact of nutrition on differential

412. Caldwell PT, Manziello A, Howard J, Palbykin B, Runyan RB, Selmin
O. Gene expression profiling in the fetal cardiac tissue after folate and

413. van Oostrom O, de Klein DPV, Flederus JOS, Pescatori M, Stubbs A,
Tienenburg A, Lim SK, Verhaar MC. Folic acid supplementation
normalizes the endothelial progenitor cell transcriptome of patients
with type 1 diabetes: a case-control pilot study. Cardiovasc Diabetol
2009;8:47.

414. Dhillon VS, Thomas P, Iarmarcovai G, Kirsch-Volders M, Bonassi S,
Fenech M. Genetic polymorphisms of genes involved in DNA repair
and metabolism influence micronuclear frequencies in human periph-
eral blood lymphocytes. Mutagenesis 2011;26:33–42.

415. Bluszczyn J, Mellott TJ. Choline nutrition programs brain develop-
ment via DNA and histone methylation. Cent Nerv Syst Agents Med

416. Shyb-Chang N, Locasale JW, Lyssiotis CA, Zheng YX, Teo RY,
Ratansintraavoowat S, Zhang J, Onder T, Unternehmer JJ, Zhu H,
et al. Influence of threonine metabolism on S-adenosylmethionine

417. Fredriksen A, Meyer K, Ueland PM, Vollset SE, Grotmol T, Schnede
J. Large-scale population-based metabolic phenotyping of thirteen
 genetic polymorphisms related to one-carbon metabolism. Hum

418. Midtun O, Hustad S, Ueland PM. Quantitative profiling of bio-
markers related to B-vitamin status, tryptophan metabolism and
inflammation in human plasma by liquid chromatography/tandem

419. Gibney MJ, Walsh M, Brennan L, Roche HM, German B, van Ommen
B. Metabolomics in human nutrition: opportunities and challenges.

420. Rezzi S, Ramadan Z, Fay LB, Kochhar S. Nutritional metabolomics:

421. Sreekumar A, Poisson LM, Rajendran TM, Khan AP, Cao Q, Yu JD,
delineate potential role for sarcosine in prostate cancer progression.

422. Meyer TE, Fox SD, Issaq HJ, Xu X, Chiu LW, Veenstra TD, Hsing AW.
A reproducible and high-throughput HPLC/MS method to separate
sarcosine from alpha- and beta-alanine and to quantify sarcosine in

423. Dahl FA, Grotel M, Benth JS, Natvig B. Data splitting as a
countermeasure against hypothesis fishing: with a case study of

424. Gika HG, Theodoridis GA, Earl M, Wilson ID. A QC approach to the
determination of day-to-day reproducibility and robustness of LC-MS
methods for global metabolite profiling in metabolomics/metabolom-

425. Reed MC, Thomas RL, Pavsic J, James SJ, Ulrich CM, Nijhout HF. A
mathematical model of glutathione metabolism. Theor Biol Med
Model 2008;5:8.

426. Ullah M, Schmidt H, Cho KH, Wolkenhauer O. Deterministic
modelling and stochastic simulation of biochemical pathways using

427. Bachman JA, Sorger P. New approaches to modeling complex

428. Bordbar A, Palsson BO. Using the reconstructed genome-scale human
metabolic network to study physiology and pathology. J Intern Med

429. Capel F, Klimekova E, Viguerie N, Roussel B, Vitekova M,
Macrophages and adipocytes in human obesity: adipose tissue gene
expression and insulin sensitivity during calorie restriction and weight

430. Duarte NC, Becker SA, Jamshidi N, Thiele I, Mo ML, Yo TD, Srinivas
R, Palsson BO. Global reconstruction of the human metabolic
network based on genomic and bibliometric data. Proc Natl Acad Sci
USA 2007;104:1777–82.

network topology reveals transcriptional regulatory signatures of type

432. Deo RC, Hunter L, Lewis GD, Pare G, Vasan RS, Chasman D, Wang
TJ, Gersten RE, Roth FP. Interpreting metabolomic profiles using

433. Vo TD, Paul Lee WN, Palsson BO. Systems analysis of energy
metabolism elucidates the affected respiratory chain complex in


436. Orth JD, Palsson BO. Systematizing the generation of missing

437. Shlomi T, Benyamini T, Gottlieb E, Sharon R, Ruppin E. Genome-scale
metabolic modeling elucidates the role of proliferative adaptation in

438. Shlomi T, Cabili MN, Ruppin E. Predicting metabolic biomarkers of

439. Lamare SG, Molloy AM, Reinke SN, Sykes BD, Brossmann ME,
Brosnan JT. Formate can differentiate between hyperhomocysteinemia
due to impaired remethylation and impaired transsulfuration. Am J

HC, Gray L, Jaeken J, Kahler SG. One-methyl group metabolism in
non-ketotic hyperglycinaemia: mildly elevated cerebrospinal fluid

Moderate folate depletion modulates the expression of selected genes
involved in cell cycle, intracellular signaling and folate uptake in

442. Chango A, Nour AA, Bousseroul E, Eveillard D, Anton PM, Guentz
JL. Time course gene expression in the one-carbon metabolism
network using HepG2 cell line grown in folate-deficient medium.

443. Duthie SJ, Horgan G, de Roos B, Rucklidge G, Reid M, Duncan G,
Pirie L, Basten GP, Powers HJ. Blood folate status and expression of
proteins involved in immune function, inflammation, and coagulation:
biochemical and proteomic changes in the plasma of humans in
response to long-term synthetic folic acid supplementation. J Proteome

444. Hebels DGJ, Jennen DGG, van Herwijnen MMH, Moonen EJC,
Pedersen M, Knudsen LE, Kleijmans JCS, de Kok TMC. Whole-
genome gene expression modifications associated with nitisomine
in exposure and microsomal frequency in human blood cells. Muta-
genesis 2011;26:753–61.

445. Hochstenbach K, van Leeuwen DM, Gmuender H, Gottschalk RW,
Lovik M, Granum B, Nygaard U, Namork E, Kirsch-Volders M,
Decordier I, et al. Global gene expression analysis in cord blood
reveals gender-specific differences in response to carcinogenic expo-

### Supplemental Table 1 Biomarker Specific Characteristics

#### Serum Folate: General Characteristics

<table>
<thead>
<tr>
<th>Question</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Humans versus animal models versus cell/molecular studies?</td>
<td>Model systems, including animals and cell cultures, are often used for preclinical and mechanistic studies of biological systems. For folate biomarker research, they can be used effectively to model gene-nutrient interactions, discover new folate-dependent enzymes and genes, understand metabolic pathways, investigate the responsiveness of biomarkers to dietary challenges and identify genes involved in folate-responsive NTDs (1). No model system faithfully recapitulates human physiology. Although the pathways in one-carbon metabolism are highly conserved between mice and humans, the regulation of the pathways can differ substantially (2). Serum/plasma folate concentrations are about 10-fold higher in mice than in humans (3). The limitations inherent with the model system must be understood and accounted for in the experimental design and interpretation of results.</td>
</tr>
<tr>
<td>Exposure (short-/long-term?)</td>
<td>The measurement of serum folate provides information on the short-term folate status of the individual. Serum folate is the earliest indicator of altered folate exposure and will reflect recent dietary intake (4). Repeated measures over time in the same individual may reflect chronic folate deficiency.</td>
</tr>
<tr>
<td>Status: are there validated norms to define deficiency/adequacy?</td>
<td>During the late 1960s, biological cut-off points for sequential stages of folate deficiency were established through depletion/repletion experiments. A serum folate concentration &lt;7 nmol/L (3 ng/mL) indicated negative folate balance at the time the blood sample was drawn (5). More recently, cut-off points for folate deficiency (serum folate &lt;10 nmol/L) were defined based on a metabolic indicator (increased plasma total homocysteine [Hcy]) (6). These cut-off points have been recommended by the 2005 WHO Technical Consultation on Folate and Vitamin B12 Deficiencies for the assessment of folate status of populations (7, 8). The measurement of serum folate may further elucidate the role of folate in relation to various health outcomes, however, no cut-off points indicative of low or high serum folate concentrations or desirable ranges have been identified in this context to date.</td>
</tr>
</tbody>
</table>


<table>
<thead>
<tr>
<th>Function: does biomarker reflect direct function, (e.g., enzyme stimulation assays) or indirectly reflect function of biological systems, (e.g. growth)</th>
<th>Serum folate reflects recent folate intake and indicates short-term status, whereas RBC folate represents the amount of folate that accumulates in blood cells during erythropoiesis and is a long-term indicator of folate status. Recurrent measures of serum folate on the same individual overtime can reveal chronic folate deficiency. Thus serum folate reflects a different folate pool than RBC folate, and shows a moderate but variable correlation with RBC folate ($r$ in the range $0.41$ to $0.63$) in different populations (9).</th>
</tr>
</thead>
<tbody>
<tr>
<td>Effect: does the biomarker directly reflect a response to an intervention either positive or negative?</td>
<td>Serum folate is highly responsive to intervention with folic acid, with natural food folates typically resulting in a poorer serum folate response compared to folic acid at similar intervention levels. Likewise, population data show that serum folate concentrations are highly reflective of exposure to folic acid, with the highest concentrations observed in people who consume folic acid in both supplements and fortified foods, both in regions with mandatory fortification and voluntary-only fortification (10-12). Serum folate increased in a linear, dose-dependent manner in response to intervention with folic acid at doses of 200, 400 and 800 $\mu$g/d for 6 months (13).</td>
</tr>
<tr>
<td><strong>User groups considerations for biomarker with regard to serum folate:</strong></td>
<td>Although serum folate is a marker for short term folate exposure, it is the most practical marker for large scale studies in populations. As noted in section 5, stable assays which can be verified and controlled in-house are preferable for population assessments. Due to manufacture recalibration or reformulation, assay kit assays can change over time and thus may not be a good choice for a public health laboratory that needs to monitor trends in folate concentration distributions in a population over time and compare folate status between population groups in different countries (14). For low-resource settings, the microbiologic assay (MBA) is the method of choice because it is the least expensive assay, its calibration and long-term performance can be controlled in-house, and it generates results that are generally in good agreement with higher-order LC-MS/MS methods. The CDC has developed a Nutrition Survey Toolkit that describes in detail how specimens can be collected, handled and assayed by the MBA (15). The use of blood spots collected on filter paper is being explored for use in developing countries where obtaining and managing serum samples may be difficult.</td>
</tr>
</tbody>
</table>

**Population**  
(e.g. policy makers assessing status of population; agencies conducting national surveys; agencies responsible for development, implementation, and evaluation of food/nutrient based programs)  
Different environment and resources:  
- developed countries  
- developing-low resource countries
**Research settings** (e.g. researchers and educators involved in studies of nutrition/health including development and utilization of biomarkers and training students and research staff)

In research, serum folate is measured in human participants and animal models to investigate the effects of genetics on folate status and requirements, the effects of other nutrients and diets on folate status, and to study folate bioavailability. Serum folate reflects short-term status (*exposure*), is very responsive to folate intake (*effect*), and has wide utility in the research setting because there are established reference values and cut-offs (*status*) based on haematological indices (*function*) published in the folate DRI (16). Additional cut-offs indicating high or "supranutritional" status (17, 18). As it best reflects short-term status, serum folate is often considered in concert with RBC folate, a folate biomarker indicating long-term status. However, in populations with invariant folate intakes (19) and when measured repeatedly on the same individual over time, serum folate can also reflect long-term status. Serum folate (versus RBC folate) is the preferred status marker in dose-response studies where repeated measures of serum folate are obtained within the same individual to assess response to a known folate intake. It is important that interpretation of serum folate values in research settings fully consider the variety of biological and contextual factors (covered in detail below) that can impact circulating concentrations. Serum total folate is the most widely utilized folate biomarker; however, serum folate vitamers, including 5-methyltetrahydrofolate (20), formyl folate (20, 21), and folic acid (17, 22-25) are also important folate biomarkers in the research setting.

**Clinical settings**

Folate biomarkers used within the clinical context have more validity than when used in the absence of clinical information. Folate status is often altered during a number of pathological conditions, including cancer, psoriasis, inflammatory bowel disease, hemolytic anaemia, HIV infection and kidney failure (see below). The primary aim of folate testing in clinical laboratories is to determine whether a patient is folate deficient. Serum folate is a useful marker of folate status in the clinical setting, although it is somewhat labile with levels influenced by recent consumption of a high folate meal, folic acid supplement or alcohol. It has been shown that serum folate levels may be in the normal range in patients who have clear clinical evidence of folate deficiency and may be low in patients without clinical abnormalities. Repeated measures over time can make serum folate testing more informative. Confirmatory testing using a second marker such as Hcy is helpful.
Clinical laboratories require inexpensive, automated, and high throughput assays to be able to report results within a day or less of receiving a sample. Protein-binding assays have been developed with the clinical laboratory in mind, to enable the diagnosis of folate deficiency. Most are fully automated for clinical analyzers to provide high throughput measurements with turnaround times of less than 1 h. Further, unlike the microbiologic assay they are not influenced by the presence of antibiotics or antifolates which may inhibit bacterial growth and could be an issue when working in the clinical setting.

### Biological Factors; impact of the following on interpretation of each biomarker:

<table>
<thead>
<tr>
<th>Factor</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Race/ethnicity</td>
<td>Folic acid fortification in the US, enacted in 1998, has markedly improved all markers of folate status across all ethnicities. Comparing data from NHANES III 1988—1994 with NHANES 1999-2000, NHANES 2001-2002 and NHANES 2003-2006, shows an approximate 130% and 60% increase in serum folate and RBC folate, respectively, and a moderate decline in plasma Hcy of 20% (26, 27). Notably, both before and after fortification, non-Hispanic whites (NHW) have higher serum and RBC folate than Mexican Americans (MA). Non-Hispanic blacks (NHB) have the lowest level of serum and RBC folate (26, 27). The differences in folate status according to ethnicity may be due to higher folate requirements in NHB (28) and/or higher intake of folate in NHW (11). In a recent analysis of NHANES 2003-2006 data, race-ethnic differentials in serum and RBC folate concentrations remained significant after adjustment for sociodemographic and lifestyle variables (29).</td>
</tr>
<tr>
<td>Age-life stage/ endocrinology (infants/children; adolescents; women of reproductive age; pregnancy; elderly)</td>
<td><strong>Age and gender:</strong> Folate biomarkers and their interrelations change markedly from birth to senescence. Infants (&lt; 1 year of age) have a biochemical profile characterized by relatively high serum folate (~ 30 nmol/L), relatively high Hcy (~ 7 µmol/L) and low serum cobalamin. RBC folate is high at birth (~ 550 nmol/L) but declines abruptly by nearly 50% within 6 weeks (30). No difference in folate biomarkers according to gender were reported in several studies (30, 31). In contrast, higher serum and RBC folate levels were recently reported for adult (aged ≥ 20 y) women as compared to men from NHANES 2003-2006 (29). This difference remained after adjustment for sociodemographic and lifestyle variables. After one year of age, serum folate declined markedly and RBC folate declined moderately. No differences in folate</td>
</tr>
</tbody>
</table>
Online Supporting Material

Biomarkers were observed between girls and boys aged < 15 years (30-33), but in older age groups (32, 33) males attained lower serum folate and slightly lower RBC folate than females (26).

The lowest values for serum folate (~10 nmol/L) and RBC folate (~230 nmol/L) were observed in age ranges of 10 - 40 (26, 30). Thereafter, all three biomarkers increased in both genders (26).

Notably, in infants high serum folate is attributed to methyl folate trapping as demonstrated by reduction of both Hcy and serum folate following cobalamin supplementation (34).

**Pregnancy:** There are substantial changes in folate biomarkers throughout pregnancy. Many studies do not allow quantification of such changes because of lack of preconception levels (35), and comparison of folate concentrations between studies is difficult due to different and non-standardized analytical methodology.

A decrease in serum folate during pregnancy is a common observation whereas the change in RBC folate varies (36). In most (35-38) but not all (39) longitudinal studies, serum folate declines throughout pregnancy, in particular in women carrying the MTHFR 677-T allele (40, 41). RBC folate has been reported to show smaller changes with a moderate increase during mid pregnancy (38), or a decrease during the last 2 (37) or 5 months (35, 42). These changes in serum and RBC folate are modified by onset of folic acid intake (43). Plasma folate and RBC folate concentrations are correlated and both are inversely associated with Hcy in pregnant women (35, 42). In a recent analysis of NHANES 2003-2006 data, pregnant compared to non-pregnant women aged 20-49 y had 18% and 26% higher serum and RBC folate concentrations, respectively after adjusting for demographic variables, smoking, use of dietary supplements, fasting, inflammation, and renal function, but without adjusting for total folate intake from foods and supplements (44).

Several mechanisms for the change in folate status during pregnancy have been proposed, including increased folate or methionine demand, increased folate catabolism, increased clearance and excretion of folate, decreased folate absorption, hormonal effects, hemodilution due to plasma volume expansion, increased renal Hcy clearance and decreased Hcy binding to albumin (36).
**Oral contraceptives:** Early studies on the effect of oral contraceptives (OCs) suggest a negative effect on folate status (45). OCs with low estrogen content have no non-equivocal effect on serum or RBC folate in recent studies controlling for potential confounders, and no conclusion on the effect from OCs on folate status can be made (46).

**Male sex hormones** affect the activities of folate metabolizing enzymes in the rat (47), but there is no data showing effects of male sex hormones on folate status in humans.

---

**Genetics**

The (single nucleotide) polymorphisms most commonly investigated in relation to folate status are located on genes encoding for enzymes involved in folate-dependent one-carbon metabolism and Hcy metabolism. These include methylenetetrahydrofolate reductase (*MTHFR*) c.665C>T (known as 677C>T; p.Ala222Val) and c.1286A4C (known as 1298A>C; p.Glu429Ala), methionine synthase (*MTR*) c.2756A>G (p.Asp919Gly), methionine synthase reductase (*MTRR*) c.66A>G (p.Ile22Met), methylenetetrahydrofolate dehydrogenase (*MTHFD1*) c.1958G>A (p.Arg653Gln), p.Arg239Gln), reduced folate carrier-1 (*SLC19A1*) c.80G>A (p.Arg27His) (48), cystathionine beta-synthase (*CBS*) c.844_845ins68 and *CBS* c.699C>T (p.Tyr233Tyr) (49). The strongest and most consistent effects have been observed for *MTHFR* 677C>T (50). The *MTHFR* 1298 A>C variant is also worth mentioning as it is in linkage disequilibrium with *MTHFR* 677C>T, which has caused considerable confusion in the literature. When the effects of the two variants have been dissected out, it has been shown that 1298 does not significantly affect folate levels. For the other polymorphisms, the associations with folate biomarkers are weak and somewhat inconsistent across different studies, some of which are small and lack power.

There are consistent results demonstrating that Hcy increases and serum folate decreases in a dose-response manner according to the number of *MTHFR* 677-T alleles. These effects are most pronounced in subjects/populations with low folate status, and the inverse association between Hcy and serum folate is strongest in subjects with the TT genotype (50). The *MTHFR* 677 C>T polymorphism also seems to alter the distribution of RBC folates by decreasing the relative amount of methylated tetrahydrofolate in subjects with the variant TT genotype (51, 52), but the magnitude of the overall effect on RBC folate is related to the specificity of the applied folate assay (53). These effects on folate in serum and RBC are explained by reduced catalytic activity of MTHFR.
encoded by the 677 variant T-allele (so-called thermolabile enzyme), which has lower affinity for methylenetetrahydrofolate (and FAD), leading to impaired formation of 5-methyltetrahydrofolate and its polyglutamated derivatives (in RBC) (50).

The *MTHFR* 677C>T distribution is different across geographic regions and ethnic groups. The T-allele frequency is 0.15 – 0.17 in south Asia, 0.30 – 0.35 in northern Europe, 0.39 or higher in Japan and 0.45 in Italy (54), 0.33 among US NHW, 0.11 among US NHB and 0.45 among US MA (55). The prevalences of the variant alleles of *MTHFR* 1298 A>C and *MTRR* 66A>G are also significantly higher among NHW than among NHB or MA (55).

In the prefortification US population (NHANES III), persons with the *MTHFR* 677 TT genotype had a 22.1% (95% CI: 14.6%, 28.9%) lower serum folate and a 25.7% (95% CI: 18.6%, 33.2%) higher Hcy concentration than did persons with the CC genotype (55). The difference in serum folate becomes abolished in subjects taking > 400 μg/d of folic acid whereas the Hcy difference is only moderately reduced by supplementation or moderate intake of folic acid (56), but higher in Asia and Europe as compared to the US and ANZ (54).

The serum folate response to intervention with folic acid (irrespective of dose) is however strongly affected by the common 677 C>T polymorphism in *MTHFR*. One large randomized controlled trial (RCT) in China showed that despite 6 months of supplementation with 4000 μg/d folic acid, women with the *MTHFR* 677 TT genotype achieved lower serum folate and higher plasma Hcy concentrations than did those with the CC genotype (56).

In the prefortification US population, differences in serum folate by *MTHFR* 677C>T genotype were noted for all race-ethnicity groups, with serum folate values lower among NHB (34 %), NHW (20%) and MA (21%) of the TT as compared with the CT genotype (55).

See Table 12 for a description of the impact of poor riboflavin status on serum folate concentrations in individuals with the *MTHFR* 677 TT genotype.

| Body mass index | There are several reports on an inverse relation between serum folate and BMI in both genders and in different age groups (29, 57-63). Studies on RBC folate and BMI are less consistent, demonstrating either a positive (29, 63) or no (58, 62, 64) association. |
The link between obesity and low folate status is potentially important in women of childbearing age, since both are risk factors for birth defects, including NTD (64). BMI was associated with low serum folate in US women aged 17 – 49 years both before (NHANES III) and after (NHANES 1999 - 2000) folic acid fortification, and the association was strongest in women aged > 20 years. Women with high BMI used less supplements and had lower folate intake from food, but the inverse association between BMI and serum folate persisted after adjustment for these factors and after adjustment for insulin levels and glucose. The latter observation indicates that insulin resistance does not fully explain the BMI-serum folate association (64). A recent study analyzing postfortification data from the NHANES 2003–2004, 2005–2006, and 2007–2008 cycles demonstrated that RBC folate increases with increasing BMI both in supplement users and non-users (63). This suggests the BMI affects cellular uptake and tissue distribution of folate. Furthermore, an inverse association between serum folate and BMI was only observed among supplement non-users suggesting that high intake of folic acid may compensate for altered folate distribution in obese women (63). Experimental evidence of differences in the pharmacokinetic response to the current recommended dose of folic acid between obese and normal weight women of childbearing age was provided by a recent study by da Silva et al. (65).

### Endemic disease (e.g. malaria; HIV)

**Malaria:** There is some evidence that malarial infection may induce folate deficiency in adults (66). The causes include inadequate intake, malabsorption, hemolysis and antimalarial drugs. Notably, there are consistent reports of increased RBC folate in malarial infection (67, 68), which has been attributed to de novo parasite folate synthesis or predisposition of malaria in subjects with high RBC folate. Malaria may also induce increased hemolysis of folate-rich cells that can lead to an increase in serum folate. The levels of folate biomarkers in malaria seems to be influenced by the infection itself and their usefulness to assess folate status is uncertain.

**HIV/AIDS:** Micronutrient deficiencies are common in subjects with HIV/AIDS (69). Low serum folate or RBC folate (70) has been reported in HIV-infected pregnant women (71), children (72) and adults (73) in developing countries, but folate status was normal in a study of HIV infected children in New York (74).
### Inflammation

It is difficult to conclude from published data whether folate biomarkers are related to inflammation, because the data are inconsistent, and the underlying condition leading to inflammation may itself affect folate status. It has been stated that serum folate and to a lesser extent RBC folate are low during acute inflammation (75), but the supportive data are not convincing.

Plasma/serum folate and Hcy are not related to C-reactive protein (CRP) and other inflammatory markers in healthy middle aged subjects in the Atherosclerosis Risk in Communities (ARIC) study (76) or to inflammation (as assessed by CRP) in participants from the population-based Framingham Heart Study cohort (77). Supplementation with folic acid does not affect the level of inflammatory biomarkers in most studies (78, 79) but did so in one study (80). It is possible that folate status is related to expression of proteins involved in activation and regulation of immune function that are not captured by CRP (81).

### Disease

**Cancer:** Patients with established cancer, particularly at advanced stages may have low folate status, as measured by low circulating folate and high Hcy (82, 83). The mechanisms involved may include inadequate folate intake, increased folate requirements due to accelerated DNA synthesis, increased folate catabolism by cancer cells (45, 83) and antifolate chemotherapy (82, 84).

**Psoriasis:** Patients with psoriasis have lower folate levels and higher Hcy than healthy controls. Notably, blood levels of other B-vitamins are often normal (85). Concentrations of Hcy are related to disease severity but also to low folate levels in psoriatics (86). The most likely explanation is increased folate requirement due to increased keratinocyte turnover, but lifestyle factors, obesity (85) and methotrexate therapy (87) may contribute as well.

**Inflammatory bowel disease:** Blood levels of several micronutrients, including folate, are often low in patients with inflammatory bowel disease (IBD), in particular Crohn’s disease (CD). Most studies on folate status involve measurement of serum folate, which demonstrate a prevalence of deficiency of about 25%. A few studies based on RBC folate demonstrate a lower prevalence, and RBC folate may be a more accurate test since it reflects long term-status (88). Notably, it has been recommended that low circulating folate in IBD should be confirmed by Hcy measurement, regarded as a more sensitive test in these
Online Supporting Material

patients (88). The most important mechanisms behind impaired folate status are enteric loss, malabsorption, inadequate intake of folate, and treatment with folate antagonists like sulfasalazine (88).

**Sickle cell disease (SCD):** Low serum and RBC folate (89, 90) have been reported in SCD in most but not all studies (91-93). Low RBC folate has been detected even in subjects prescribed folic acid supplements (90). RBC folate, however, does not seem to be an adequate measure of folate status in SCD patients because RBC folate increases with decreasing RBC age; therefore serum folate and Hcy have been recommended for assessment of folate status in these patients (94). However, the accuracy of folate biomarkers to assess folate status in SCD may vary according to intake of folic acid supplements, age and renal function (93).

**Thyroid Disease:** Folate and Hcy status change according to thyroid state. Hypothyroid patients have low RBC and serum folate and elevated Hcy, whereas hyperthyroid patients have an opposite profile with elevated RBC and serum folate and low Hcy (95-97). These changes have been documented in longitudinal studies of patients during treatment, which normalizes thyroid state (95, 98-101). Altered folate status has been attributed to effects of thyroid hormones on folate metabolism including altered riboflavin status (100, 102) that in turn affects the FAD-dependent MTHFR.

**Diabetes:** Studies have demonstrated moderately elevated serum/plasma folate in type 1 and type 2 diabetic patients (103-105), adequate serum and RBC folate in type 1 and type 2 diabetic patients (106, 107), and lower serum folate in type 2 diabetics than in healthy controls (108). Thus, no equivocal conclusion can be made on the effect of the diabetic state itself on circulating folate.

**Renal failure:** Patients with renal failure have deficiencies of several water soluble micronutrients and B-vitamins, including folate (109). Serum and RBC folate are often below normal values in chronic renal impairment (110), and folate deficiency is more frequent in hemodialysis than peritoneal dialysis patients (111, 112). Treatment of renal patients with folic acid normalizes circulating folate. These observations suggest impaired folate function in renal patients, who might require larger folate intake than healthy subjects.

**Contextual Factors; impact of the following on performance of each biomarker:**
<table>
<thead>
<tr>
<th>Sample source</th>
<th>While most laboratories prefer serum over plasma, both matrices generally produce comparable results for serum total folate (113-115), as long as the sample processing is not delayed (116).</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bioavailability</td>
<td>Serum folate is often used in acute studies in research settings to reflect differences in folate bioavailability when provided as a bolus dose/meal.</td>
</tr>
<tr>
<td>Fasting; time of day; time of exposure/meal/intervention</td>
<td>Data from several thousand U.S. adults participating in NHANES 2003–2006 have shown that samples from fasted (≥8 h, no dietary supplement consumed during the fast) participants had on average significantly lower serum (10%) and RBC folate (5%) concentrations compared to samples from non-fasted (&lt;3 h) participants, but the difference was relatively small, indicating that fasting may not be essential when assessing the folate status of populations (44). However, in the individual, serum folate concentrations can increase drastically as a result of folate intake (either with food or as a dietary supplement), reaching a peak concentration ~1 h after the dose, with peak concentrations dependent on the size of the dose, the baseline folate status, and the vehicle in which folate was administered. The variability of biomarkers over time is critical for their use in epidemiological studies and for being able to judge if or to what extent a single measurement reflects long-term exposure. Reliability of plasma folate was determined in 40 Nurses’ Health Study (NHS) participants over 1-2 years and in 551 patients with stable angina pectoris from the WENBIT study over 3.5 years, and the results were good (ICCs of 0.61 and 0.50, respectively). Notably, in the WENBIT population reproducibility for plasma folate showed a stronger relation to time between measurements than for other nutritional biomarkers, and ICC decreased from 0.71 over 1 month to 0.61 over 1 year and 0.50 over 3.5 years (117). To our knowledge, no data on reliability of RBC folate measurement have been published. The reproducibility of serum/plasma folate over time allows one-time assessment of biomarker status.</td>
</tr>
<tr>
<td>Drug use (in context of acute or chronic treatment for disease; recreational)</td>
<td>Some drugs have a negative effect on folate status and thereby increase plasma Hcy, but many drugs affect plasma Hcy by mechanisms independent of folate. \textbf{Folate antagonists:} Methotrexate (MTX), the most widely known antifolate, has been used to combat cancer since the 1950s and has been especially effective in alleviating…</td>
</tr>
</tbody>
</table>
inflammation in patients with rheumatoid arthritis.

Structurally, MTX is an analog of folic acid with modifications that result in a higher affinity for the drug’s enzyme target, dihydrofolate reductase (DHFR) (118). Accordingly, methotrexate decreases circulating folate and increases Hcy. This response is observed at low doses used in patients with psoriasis (87) or rheumatoid arthritis (119, 120) to high doses given to cancer patients (82), and is explained by inhibition DHFR. The antibiotic, trimethoprim, is also a DHFR inhibitor, and has a similar effect on folate (121).

**Anticonvulsants:** Conventional antiepileptic drugs (AEDs) like carbamazepine, phenobarbital, primidone and phenytoin are associated with reduced plasma folate and markedly elevated Hcy (122, 123). This effect has been explained by increased degradation and elimination of folate, secondary to the marked induction of liver enzymes caused by these drugs (45). New AEDs such as levetiracetam and lamotrigine have no or less inductive potential and no effect on folate and Hcy status (122, 123).

**Antihypertensive drugs:** Therapy with diuretics including hydrochlorothiazid is associated with decreased circulating folate and elevated Hcy. The underlying mechanisms may involve folate depletion and impaired renal function (124).

**Warfarin:** RBC but not serum folate is decreased in patients after 6 months on warfarin therapy. Whether altered folate status is caused by warfarin itself, or is secondary to dietary advice in these patients, is uncertain. There is no increase in Hcy, which may reflect increased baseline Hcy after the acute event preceding therapy (125).

| Coffee Consumption | Coffee consumption is associated with a decrease in plasma folate (126, 127), vitamin B6 and riboflavin (but not vitamin B12) and parallel increase in Hcy (127). Thus, coffee drinkers have lower mean folate and higher mean Hcy than non-drinkers, but the differences are only observed at the higher end of the folate distribution (127, 128) and at the lower end of the Hcy distribution (129). Possible mechanisms involved are increased renal excretion of folate (at high plasma folate) mediated by caffeine (127). |
| Smoking tobacco | Smoking is associated with deficiencies of several micronutrients and B-vitamins, including folate. Smokers have lower RBC and plasma/serum folate and higher Hcy than non-smokers (29, 130, 131). Folate and Hcy status improve somewhat within days of smoking cessation, but |
### Online Supporting Material

<table>
<thead>
<tr>
<th>Category</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alcohol consumption</td>
<td>The associations between folate and Hcy status and alcohol intake are inconsistent and complex and related to type and amount of alcohol. Intake of beer and to a lesser extent wine may be positively associated with circulating folate and inversely related to Hcy, which may partly be related to vitamin content in beer (128). However, these associations could be confounded by nutrition and lifestyle factors. In a controlled intervention study, 2 weeks with red wine or vodka (24 g ethanol daily) decreased serum folate and increased Hcy (133). Excessive alcohol intake or alcoholism is associated with B-vitamin deficiencies including impaired folate status (45, 134). The ethanol related folate-deficiency has been explained by low intake, malabsorption, altered liver metabolism, increased catabolism and renal excretion of folate (45, 135).</td>
</tr>
<tr>
<td>Exercise</td>
<td>Data on associations between exercise in leisure time and folate are limited (136), but there are reports on higher levels of serum folate in physically active persons (137, 138). Physical activity is associated with several potential confounders, including nutritional and life-style factors and physiological and metabolic changes. Thus, from published results one cannot conclude that physical exercise has a direct effect on biomarkers of folate status. In a recent analysis of NHANES 2003-2006 data, US adults who expended 750 vs. 150 total metabolic equivalent tasks minutes/week from leisure-time physical activity had slightly higher serum (1.4%) and RBC folate (0.6%) concentrations after adjustment for sociodemographic and lifestyle variables (29).</td>
</tr>
<tr>
<td>Socioeconomic (e.g. education; income)</td>
<td>A recent report from NHANES 2003-2006 (31) indicated that the socioeconomic variables of education and family poverty-income ratio were significantly associated with serum and RBC folate, however they did not account for much of the variability in biomarker concentration.</td>
</tr>
</tbody>
</table>

There is a long-term effect in ex-smokers lasting for years with ex-smokers having lower folate and higher Hcy than never smokers (132). It has been suggested that the acute effect of smoking is related to increased folate breakdown or utilization caused by toxic (prooxidant) chemicals, which is in agreement with persistence of low folate after adjustment for dietary intake. The chronic effect may be explained by imprudent dietary habits of ex-smokers in combination with the time required to replenish folate stores (132).
### Seasonal variations

A cross-sectional study indicated seasonal variation in serum and RBC folate (139) whereas a longitudinal study on an Irish population demonstrated a moderate reduction in RBC folate in spring compared with autumn; no seasonal changes were observed for serum folate and Hcy (140). In a large epidemiological study from China, serum and RBC folate were lower in the spring than in the fall in the North and lower in the fall than in the spring in the South (141). Plasma Hcy was inversely associated with circulating folate across regions and seasons (142). Thus, the seasonal variations in folate biomarker seem to be moderate, might be concealed in a fortified population, are different between geographical regions, and probably reflect seasonal differences in the availability of fresh fruit and vegetables.

### Red Blood Cell Folate: General Characteristics

<table>
<thead>
<tr>
<th>Humans versus animal models versus cell/molecular studies?</th>
<th>See serum folate (humans versus animal models versus cell/molecular studies) for more information.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exposure (short-/long-term?)</td>
<td>RBC folate is a sensitive indicator of longterm folate status. RBC folate compared with serum folate will respond more slowly to changes in dietary folate intake and is a better indicator of folate intake over the previous 3-4 months when circulating folate is incorporated into the maturating red cells (143).</td>
</tr>
<tr>
<td>Status: are there validated norms to define deficiency/adequacy?</td>
<td>During the late 1960’s, biological cut-off points for sequential stages of folate deficiency were established through depletion/repletion experiments. A RBC folate concentration &lt;363 nmol/L (160 ng/mL) indicated the onset of folate depletion, concentrations &lt;272 nmol/L (120 ng/mL) marked the beginning of folate-deficient erythropoiesis, and concentrations &lt;227 nmol/L (100 ng/mL) marked folate-deficient anemia (5). It was more common though for investigators to use a single cutoff point for RBC folate to designate deficiency: &lt;317 nmol/L (140 ng/mL) (144). More recently, cut-off points for folate deficiency (RBC folate &lt;340 nmol/L) were defined based on a metabolic indicator (increased plasma total Hcy) (6). These cut-off points have been recommended by the 2005 WHO Technical Consultation on Folate and Vitamin B12 Deficiencies for the assessment of folate status of populations (7).</td>
</tr>
</tbody>
</table>
### Online Supporting Material

| Function: does biomarker reflect direct function, e.g., enzyme stimulation assays or indirectly reflect function of biological systems, e.g. growth | RBC folate parallels liver concentrations (accounting for about 50% of total body folate) and is thus considered to reflect tissue folate stores (145). RBC folate represents the amount of folate that accumulates in blood cells during erythropoiesis and reflects folate status during the preceding 120 days, i.e. the half-life of red cells (146, 147).

RBC folate and serum folate reflect different folate pools; RBC shows a moderate but variable correlation with serum folate (r in the range 0.41 to 0.63) in different populations (9). |
|---|---|
| Effect: does the biomarker directly reflect a response to an intervention either positive or negative? | RBC folate is highly responsive to intervention with folic acid, with natural food folates typically resulting in a poorer RBC folate response compared to folic acid at similar intervention levels. Likewise, population data show that RBC folate concentrations are highly reflective of exposure to folic acid, with the highest concentrations observed in people who consume folic acid in both supplements and fortified foods, both in regions with mandatory fortification and voluntary-only fortification (11, 12).

As circulating folate is incorporated into red cells during erythropoiesis and the average life-span of red cells is 120 days (143), intervention trial periods of 3-4 months are considered necessary in order to allow an optimal RBC folate response to an increase in folate intake to be observed. The RBC folate response to intervention with folic acid (irrespective of dose) is strongly affected by the common 677 C>T polymorphism in *MTHFR*. |

### User groups considerations for biomarker with regard to RBC folate:

| Population (e.g. policy makers assessing status of population; agencies conducting national surveys; agencies responsible for development, implementation, and evaluation of food/nutrient based programs) Different environment and resources: • developed countries • developing-low resource countries | Red cell folate is a marker for longer term (months) folate exposure. There are, however, obstacles to using it in population studies because the specimen preparation (generation of a whole blood hemolysate using accurate pipetting) is more difficult than for serum folate, and red cell folate assays are prone to more variability and less agreement across assay platforms. Kit assays can change over time as a result of manufacturer recalibration or reformulation, and may not be a good choice for a public health laboratory that needs to monitor trends in folate concentration distributions in a population over time and compare folate status between population groups in different countries (14). Detailed specimen processing protocols and thorough training of field staffs are essential if this marker is to be used successfully in large scale population studies, particularly those in low |
resource areas. Alternatively, the MBA for dried blood spots (DBS) developed by O’Broin et al. (148, 149) and implemented at the CDC (150) is a suitable tool to assess folate status in a population when no venous sample can be collected. The great sensitivity of the MBA is of particular benefit when only a small sample volume is available, such as for samples collected from a finger-stick or as a DBS. No other type of method has so far been applied successfully to DBS. Concentrations thought to be protective of neural tube birth defects (8, 151, 152) have also been published.

| Research settings | In research, RBC folate is measured in human participants and animal models to investigate the effects of genetics on folate status and requirements, the effects of other nutrients and diets on folate status, and to study folate bioavailability.

RBC folate reflects long-term status (exposure) and has wide utility in the research setting because there are established reference values and cut-offs (status) based on haematological indices (function) published in the folate DRI (16). RBC folate is responsive to folate intake (effect); as a long-term marker of folate status, it is often considered in concert with serum folate, a biomarker that reflects short-term folate status. It is important that interpretation of RBC folate values in research settings fully consider the variety of biological and contextual factors (covered in detail below) that can impact circulating concentrations. RBC total folate is the most widely utilized RBC folate biomarker; however, RBC folate vitamers, including 5-methyltetrahydrofolate and formyl folate (51, 153) are also important folate biomarkers in the research setting. |
| Clinical settings | Folate enters red blood cells as they form in the bone marrow. The concentration is determined by exposure before they are released into the circulation. When RBC folate is measured clinically, it reflects the availability of folate when the circulating red blood cells were developing. Because the life of these cells is approximately 90 to 120 days, measuring red cell folate provides a long term marker of folate status. Thus, it is useful in conjunction with serum folate, a short term marker of folate status. Because vitamin B12 is required for folate retention in developing red blood cells, RBC folate concentrations are dependent on vitamin B12 as well as folate availability and low levels may reflect vitamin B12 deficiency as well as folate deficiency. The same factors that influence serum folate (pregnancy, alcohol, anti-folate drugs, etc.) can influence RBC folate concentrations. |
### Biological Factors; impact of the following on interpretation of each biomarker:

<table>
<thead>
<tr>
<th>Factor</th>
<th>See above (serum folate)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Race/ethnicity</td>
<td></td>
</tr>
<tr>
<td>Gender</td>
<td></td>
</tr>
<tr>
<td>Age-life stage/endocrinology</td>
<td></td>
</tr>
<tr>
<td>Genetics</td>
<td></td>
</tr>
<tr>
<td>Body mass index</td>
<td></td>
</tr>
<tr>
<td>Endemic disease (e.g. malaria; HIV)</td>
<td></td>
</tr>
<tr>
<td>Inflammation</td>
<td></td>
</tr>
<tr>
<td>Non-communicable disease (e.g. cancer)</td>
<td></td>
</tr>
<tr>
<td>Pharmacology (treatment interactions including traditional therapies)</td>
<td>See above (serum folate)</td>
</tr>
<tr>
<td>Nutrient interactions</td>
<td>See Table 12</td>
</tr>
</tbody>
</table>

### Contextual Factors; impact of the following on performance of each biomarker:

<table>
<thead>
<tr>
<th>Factor</th>
<th>See above (serum folate)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sample source</td>
<td></td>
</tr>
<tr>
<td>Bioavailability</td>
<td>Red blood cell folate reflects bioavailability if measured longitudinally where long term changes are reflected over several months.</td>
</tr>
<tr>
<td>Fasting; time of day; time of exposure/meal/intervention</td>
<td>See above (serum folate)</td>
</tr>
<tr>
<td>Drug use (in context of acute or chronic treatment for disease; recreational)</td>
<td>See above (serum folate)</td>
</tr>
<tr>
<td>Coffee consumption</td>
<td>See above (serum folate)</td>
</tr>
<tr>
<td>Smoking tobacco</td>
<td>See above (serum folate)</td>
</tr>
<tr>
<td>Alcohol consumption</td>
<td>See above (serum folate)</td>
</tr>
<tr>
<td>Exercise</td>
<td>See above (serum folate)</td>
</tr>
<tr>
<td>Socioeconomic (e.g. education; income)</td>
<td>See above (serum folate)</td>
</tr>
</tbody>
</table>
**Plasma Homocysteine: General Characteristics**

It has been recommended that Hcy should be measured in plasma because the sample can be processed immediately. To obtain serum, on the other hand, a blood sample has to be left at room temperature for 30-60 min to allow coagulation, which leads to an artificial increase in Hcy due to an ongoing release of Hcy from RBCs. Serum concentrations will therefore be ~5-10% higher than those obtained in optimally prepared plasma (154).

<table>
<thead>
<tr>
<th>Humans versus animal models versus cell/molecular studies?</th>
<th>Functional biomarkers of folate metabolism, including Hcy concentrations, were shown to vary among 13 different mouse strains (155). See serum folate (humans versus animal models versus cell/molecular studies) for more information.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exposure (short-/long-term?)</td>
<td>Plasma Hcy decreases at a rapid rate of 0.08 h⁻¹ and reaches a plateau 24 hours after iv administration of high dose 5-formylTHF (156). This is explained by the role of 5-methyl-THF as a methyl donor in the remethylation of Hcy catalyzed by the enzyme methionine synthase (154). Plasma Hcy responds within 3-4 weeks of folate depletion (increases) and subsequent repletion (declines) in healthy subjects (157). The fast response probably reflects that methyl groups for Hcy remethylation are dependent on “shallow” folate pool(s) with a fast turnover rate (158).</td>
</tr>
<tr>
<td>Status: are there validated norms to define deficiency/adequacy?</td>
<td>A multitude of factors affecting Hcy concentrations complicate the establishment of reference ranges and cut-off levels. Traditionally, Hcy below 15 µmol/L was considered as normal, 15–30 µmol/L as moderate hyperhomocysteinemia and &gt;30 µmol/L as severe hyperhomocysteinemia (154, 159). Optimized Hcy in the range 5-10 µmol/L were reported in several studies (160-163). Apart from providing an indication of functional folate deficiency, elevated plasma Hcy concentrations are associated with an increased risk of cardiovascular diseases. The 2009 US National Academy of Clinical Biochemistry (NACB) Laboratory Medicine Practice Guidelines on “Emerging Biomarkers of Cardiovascular Disease and Stroke” categorized Hcy concentrations (µmol/L) derived from standardized assays as follows: desirable ≤10; intermediate (low to high) &gt;10 to &lt;15; high ≥15 to &lt;30; and very high ≥30 (164).</td>
</tr>
<tr>
<td>Function: does biomarker reflect direct function (e.g, enzyme stimulation assays)</td>
<td>The measurement of plasma Hcy provides a sensitive functional biomarker of folate status. When the status of folate is low or deficient, plasma Hcy is invariably found to be</td>
</tr>
</tbody>
</table>
Plasma Hcy is not however a specific marker of folate status, as it will also be elevated with other B-vitamin deficiencies, lifestyle factors, renal insufficiency and drug treatments (154, 157). Most importantly, Hcy is also an indicator of vitamin B12 status, which is explained by methylcobalamin serving as a co-factor in the methionine synthase reaction which remethylates Hcy to methionine. In population groups that consume folic acid fortified foods or folic acid supplements, Hcy is considered a more reliable biomarker of vitamin B12 status than of folate status (154).

Plasma Hcy is an indicator of overall methyl status in vivo and is influenced by several vitamins and methyl donors involved in one-carbon metabolism, including vitamins B2, B6, betaine (and choline), in addition to B12 (165). This is demonstrated by the inverse association between plasma Hcy and serum folate, which is strongest when the other nutrients are low (166, 167). The most important genetic determinant of elevated plasma Hcy in the general population is the 677C>T polymorphism in MTHFR; individuals with the homozygous mutant MTHFR 677TT genotype will typically have significantly higher plasma Hcy compared to those with the CC or CT genotypes.

Effect: does the biomarker directly reflect a response to an intervention either positive or negative?

Plasma Hcy decreases in response to intervention with folate, alone or in combination with the other methyl donors involved in one-carbon metabolism: vitamin B12, vitamin B6, vitamin B2 and betaine (or choline).

Plasma Hcy was previously reported to decrease in a dose-responsive manner with folic acid supplementation, reaching a maximum reduction of 23% at ≥800 µg/d, an effect that was most pronounced in subjects with high Hcy and/or low blood folate at baseline (168). More recent evidence however showed that a dose of folic acid as low as 200 µg/d can, if administered for a prolonged period of 6 months, effectively lower Hcy concentrations regardless of initial plasma Hcy or folate concentrations, suggesting that higher folic acid doses were not necessary (13). Several previous trials probably overestimated the folic acid dose required for maximal lowering of plasma Hcy because of treatment durations that were too short to allow the maximal plasma Hcy response to be observed (168).
Mandatory folic acid fortification implemented in North America in 1998 was associated with a reduction in Hcy of about 7-10% (169, 170). Additional supplementation with folic acid appears to result in a further lowering of Hcy by about 15%, as indicated by intervention trials conducted after the introduction of mandatory folic acid-fortification in North America (171).

The plasma Hcy response to folic acid (irrespective of dose or duration of intervention) is however strongly affected by the common 677C>T polymorphism in MTHFR.

<table>
<thead>
<tr>
<th>User groups considerations for homocysteine with regard to:</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Population</strong> (e.g. policy makers assessing status of population; agencies conducting national surveys; agencies responsible for development, implementation, and evaluation of food/nutrient based programs)</td>
</tr>
<tr>
<td>Different environment and resources:</td>
</tr>
<tr>
<td>• developed countries</td>
</tr>
<tr>
<td>• developing-low resource countries</td>
</tr>
</tbody>
</table>

Theoretically, Hcy is an attractive candidate for population use because it reflects suboptimal levels of one or more B vitamins (folate, B12, B6, or B2) and is considered a functional marker of folate status. If the primary goal is to investigate folate status, however, the effect of other vitamins on Hcy status would be confounding. Moreover, other factors such as renal status, age and sex affect Hcy status as well.

<table>
<thead>
<tr>
<th><strong>Research settings</strong> (e.g. researchers and educators involved in studies of nutrition/health including development and utilization of biomarkers and training students and research staff)</th>
</tr>
</thead>
</table>

In research, total plasma Hcy is measured in human participants and animal models as a functional marker of folate status, to investigate the effects of genetics on folate function and requirements, and the effects of other nutrients and diets on folate function.

Plasma Hcy is a functional biomarker as it is related to methionine cycle activity and methyl group availability (function). There is an inverse relationship between folate intake and plasma Hcy (effect); however, there is a point at which increased folate intake will not continue to lower plasma Hcy (16). Cut-offs indicating elevated plasma Hcy for various populations have been suggested (status) (16, 154). Plasma Hcy is an ancillary indicator of folate status and should be considered in concert with serum and/or RBC folate.
concentrations. Biological and contextual factors (covered in detail below) should always be considered in the interpretation of plasma Hcy concentrations.

| Clinical settings | Plasma Hcy is a valuable marker of folate status because 5-methylTHF is required to convert Hcy to methionine. It is important to recognize that vitamin B12 is required for this reaction as well; therefore, elevated Hcy concentrations may result from folate deficiency, B12 deficiency, or a combination of the two. It is also important to note that other factors including age, sex, renal function, genetic variants such as MTHFR 677C>T and other vitamin concentrations (B6 and B2) have to be taken into account in interpreting Hcy results. In clinical settings Hcy can be used to confirm a suspected diagnosis of folate deficiency based on low serum folate or red cell folate. Because Hcy may be elevated by either folate or B12 deficiency it is often advisable to include a measure of B12 status when measuring Hcy. MMA is useful because unlike Hcy, it reflects B12, but not folate, status.

In the clinical setting, patients with extremely high Hcy (50 - 200 µmol/L) but with normal B-vitamin status and renal function are occasionally encountered. High Hcy could be due to inborn error homocystinuria, which is more common than usually reported (172) and has variable phenotypic expression. Since mutation(s) in cystathionine β-synthase, the most common cause of homocystinuria, also causes a substantial increase in plasma methionine (often > 100 µmol/L (173), the combined measurement of plasma Hcy and methionine could be diagnostic (174). |

**Biological Factors; impact of the following on interpretation of each biomarker:**


| Age-life stage/endocrinology | **Age and gender:** Folate biomarkers, including Hcy, and their interrelations change markedly from birth to senescence. |
Infants (< 1 year of age) have a relatively high Hcy (~ 7 µmol/L) which declines markedly after one year of age. No differences in folate biomarkers were observed between girls and boys aged < 15 years, but in older age groups, males attained a higher Hcy than females. The lowest values for Hcy (~ 5.5 µmol/L) were observed in the age range of 1 - 10 years. Thereafter, the biomarker increased in both genders.

Notably, in infants cobalamin rather than folate status predicts Hcy, and high serum folate is attributed to methyl folate trapping as demonstrated by reduction of both Hcy and serum folate following cobalamin supplementation. In children and adolescents, folate becomes a stronger predictor of Hcy than cobalamin, whereas in the elderly (> 60 years) Hcy correlates more strongly with cobalamin than with folate, in particular when including subjects taking supplements.

Pregnancy: Plasma Hcy is relatively low in fertile women with mean preconceptional plasma levels of about 8.5 µmol/L. It declines within 8 weeks of pregnancy, reaches a nadir corresponding to about 30% decline during the second trimester and thereafter approaches preconceptional levels at labor. The decline is not offset by folic acid intake but is less pronounced in supplement users than non-users. A between-subject variability, however, is maintained throughout pregnancy with strong to moderate correlations of Hcy during pregnancy with preconceptional levels (r of 0.71 to 0.54).

Oral contraceptives: Relatively low Hcy has been consistently demonstrated in women on estrogen replacement therapy. It has been concluded that higher estrogen status is associated with decreased Hcy, independent of nutritional status and muscle mass, and probably reflects hormonal effects on Hcy metabolizing enzymes.

Male sex hormones: Plasma Hcy is higher in men than in women, and higher in women with polycystic ovary syndrome (characterized by androgen excess) than controls; however, Hcy shows no relation with circulating levels of testosterone or dehydroepiandrosterone in middle aged men in a study adjusting for potential confounders.

Genetics: There are consistent results demonstrating that Hcy increases and serum folate decreases in a dose-response manner according to the number of MTHFR 677-T alleles. These effects are most pronounced in subjects/populations with low
Online Supporting Material

Folate status, and the inverse association between Hcy and serum folate is strongest in subjects with the TT genotype (50). In the prefortification US population (NHANES III), plasma Hcy was about 25% higher (54) in subjects with the TT genotype compared with the CC genotype; the Hcy difference was only moderately reduced by supplementation with > 400 µg/d of folic acid or moderate intake of folic acid (55). Plasma Hcy is higher in Asia and Europe as compared to the US and ANZ (54).

In the prefortification US population, differences in Hcy by MTHFR 677C->T genotype were noted for all race-ethnicity groups, with Hcy values lower among NHB (40%), NHW (26%) and MA (21%) of the TT as compared with the CT genotype (55).

See Table 12 for a description of the impact of poor riboflavin status on plasma Hcy in individuals with the MTHFR 677 TT genotype.

<table>
<thead>
<tr>
<th>Body mass index</th>
<th>Hcy shows no relation with BMI in most (60, 62, 181, 182) but not all studies (59).</th>
</tr>
</thead>
</table>
| **Endemic disease (e.g. malaria; HIV)** | **Malaria:** Plasma Hcy has been reported to be normal in some studies on malarial infections (68, 183), but elevated in one study on acute malaria (184). In the latter study, hyperhomocysteinemia was associated with disease severity and attributed to oxidative stress (184).  
**HIV/AIDS:** There are several studies on Hcy in HIV-infected patients, but the results are inconsistent (185, 186). In a recent study (187) the authors conclude that HIV and combination antiretroviral therapy (cART) do not influence the levels of Hcy: main determinants of hyperhomocysteinemia are deficiencies of folate and/or cobalamin (186, 187), and elevated Hcy may be effectively treated by B-vitamins (70). |
| **Inflammation** | Plasma Hcy is not related to CRP and other inflammatory markers in healthy middle aged subjects in the ARIC study (76) or to inflammation (as assessed by CRP) in participants from the population-based Framingham Heart Study cohort (77). Cardiovascular patients with high Hcy have higher levels of some inflammatory markers than patients with low Hcy, but CRP did not differ between the groups (188).  
Plasma Hcy shows a moderate to strong positive association with markers of cellular Th1 immune activation, like neopterin and the kynurenine/tryptophan ratio. Such associations have been observed in the elderly (189), in patients with rheumatoid |
arthritis (190), cardiovascular disease (191) and cancer (192). But the associations may reflect development of hyperhomocysteinemia as a consequence of immune activation rather than impaired folate status (191).

### Disease

<table>
<thead>
<tr>
<th>Disease</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Cancer</td>
<td>Patients with established cancer, particularly at advanced stages may have high Hcy (82, 83). The mechanisms involved may include increased folate requirements due to accelerated DNA synthesis, increased folate catabolism by cancer cells (45, 83) and antifolate chemotherapy (82), (84).</td>
</tr>
<tr>
<td>Psoriasis</td>
<td>Patients with psoriasis have higher Hcy than healthy controls. Concentrations of Hcy are related to disease severity but also to low folate levels in psoriatics (86).</td>
</tr>
<tr>
<td>Inflammatory bowel disease</td>
<td>A recent metaanalysis demonstrated a substantially higher Hcy in patients with inflammatory bowel disease than controls, but with no differences between patients with ulcerative colitis versus Crohn’s disease (193). Hyperhomocysteinemia is associated with impaired folate and cobalamin status, erythrocyte sedimentation rate and disease severity (193). Notably, it has been recommended that low circulating folate in IBD should be confirmed by Hcy measurement, regarded as a more sensitive test in these patients (88).</td>
</tr>
<tr>
<td>Sickle cell disease (SCD)</td>
<td>Elevated Hcy (91, 92, 194, 195), (93) has been reported in SCD in most but not all studies (92). As RBC folate does not seem to be an adequate measure of folate status in SCD patients, serum folate and Hcy have been recommended for assessment of folate status in these patients (94). However, there have been uncertainties whether elevated Hcy reflects impaired folate status in SCD patients (93, 195). In a large study including 90 adult patients and 76 controls, creatinine rather than folate was a significant predictor of hyperhomocysteinemia (93).</td>
</tr>
<tr>
<td>Thyroid Disease</td>
<td>Hcy status changes according to thyroid state. Hypothyroid patients have elevated Hcy, whereas hyperthyroid patients have low Hcy (95-97). These changes have been documented in longitudinal studies of patients during treatment, which normalizes thyroid state (95, 98-100). Renal function and folate status are both determinants of plasma Hcy in studies of thyroid patients (99-101, 196), suggesting that changes in folate status cannot be followed by measuring Hcy.</td>
</tr>
<tr>
<td>Diabetes</td>
<td>In diabetics, serum or RBC folate and kidney function are determinants of Hcy (106, 197), but in some studies renal function is the strongest or sole determinant (198),</td>
</tr>
</tbody>
</table>
in particular when renal dysfunction evolves (103). In diabetics (type I and II) with no complications, Hcy is lower than in healthy controls, which has been explained by hyperfiltration and hormonal effects on Hcy metabolizing enzymes (197, 199, 200). Likewise, insulin and hyperinsulinism decrease whereas insulin resistance (in type II diabetes) increases plasma Hcy (201).

**Kidney Disease/ Renal failure:** Hyperhomocysteinemia is observed in patients with nephropathy (201), which can be explained by impaired Hcy metabolism in kidney and liver (200). Plasma Hcy is markedly elevated even in mild renal impairment (111, 112), and there is an inverse association between Hcy and glomerular filtration rate (GFR) across the whole range of GFR values from above normal (as in early diabetes with hyperfiltration) to low GFR (renal dysfunction) (197), (203). Treatment of renal patients with folic acid normalizes circulating folate and also lowers (by about 30%), but does not normalize, Hcy (204). Higher (≥ 2.5 mg/d) than the standard folic acid dose (0.4 mg/d) effective in healthy subjects are required (205, 206) to normalize Hcy in these patients. In renal patients Hcy shows a strong, inverse association with serum and RBC folate even in folate replete patients treated with folic acid (207, 208). These observations suggest impaired folate function in renal patients, who might require larger folate intake than healthy subjects. In addition to folate inadequacy, hyperhomocysteinemia may reflect reduced renal clearance of Hcy and impaired Hcy remethylation (209).

<table>
<thead>
<tr>
<th>Pharmacology (treatment interactions including traditional therapies)</th>
<th>Some drugs have a negative effect on folate status and thereby increase plasma Hcy, but other drugs affect plasma Hcy by mechanisms independent of folate. See: Drug Use – below.</th>
</tr>
</thead>
</table>

**Contextual Factors; impact of the following on performance of each biomarker:**

<table>
<thead>
<tr>
<th>Sample source</th>
<th>EDTA plasma is preferred over serum for Hcy analysis because the vacutainer can be immediately centrifuged.</th>
</tr>
</thead>
</table>

| Fasting; time of day; time of exposure/meal/intervention | Fasting is generally not required (154); however, variations in Hcy concentrations have been observed in response to a high protein meal (210). The variability of plasma Hcy in healthy subjects (n=96) aged 65-75 years over a 1 year period was investigated 15 years ago (210). The reliability was found to be excellent with an (adjusted) ICC of 0.88. Recent assessments of within-subject stability of plasma Hcy in 40 Nurses' Health Study (NHS) participants over 1 -2 years and in 551 patients with stable |
angina pectoris from the WENBIT study over 3.5 years demonstrated a somewhat lower but still good reproducibility (ICCs of 0.71 and 0.73, respectively) (117). The reproducibility of plasma Hcy over time allows one-exposure assessment of biomarker status.

<table>
<thead>
<tr>
<th>Drug use (in context of acute or chronic treatment for disease; recreational)</th>
<th>Lipid-lowering drugs: Marked elevations of Hcy by 20-50% are observed in patients treated with fibric acid derivatives, like fenofibrate and bezafibrate. Folate and vitamin B12 are not affected. Suggested mechanisms involve enhanced creatine synthesis, renal cyclooxygenase (COX-2) down-regulation and PPARα activation (124). There is some evidence that nicotinic acid (niacin) moderately increases Hcy, probably by enhanced S-adenosylhomocysteine production during methylation of nicotinamide. HMG-CoA reductase inhibitors have essentially no effect on plasma Hcy (124, 212).</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Antihypertensive drugs: Therapy with diuretics including hydrochlorothiazid is associated with decreased circulating folate and elevated Hcy. The underlying mechanisms may involve folate depletion and impaired renal function (124). In contrast, beta blockers seem to reduce Hcy in hypertensive patients by unknown mechanisms (124).</td>
</tr>
<tr>
<td></td>
<td>Vitamin B6 and cobalamin antagonists: Elevated levels of Hcy have been reported in subjects treated with azauridine, isoniazid and theophylline (213). These drugs are inhibitors of the enzyme pyridoxal kinase and thereby may interfere with vitamin B6 function.</td>
</tr>
<tr>
<td></td>
<td>Plasma Hcy increases within hours in patients exposed to the anaesthetic gas, nitrous oxide, which is explained by oxidation of cobalamin bound to methionine synthase. Inhibition of the enzyme leads to a 5-methyltetrahydrofolate trap and thereby a transient increase in serum folate (214). A slow increase in Hcy over months reflecting cobalamin deficiency is observed in patients treated with drugs interfering with cobalamin absorption, which include H2-receptor antagonists (215), proton-pump inhibitors (216) and metformin (201, 217, 218).</td>
</tr>
<tr>
<td></td>
<td>Others: Parkinson patients treated with levodopa are at increased risk of elevated Hcy as a consequence of levodopa methylation by catechol-O-methyltransferase (COMT). Accordingly, the ensuing hyperhomocysteinemia is prevented by peripherally acting COMT inhibitors (212, 219).</td>
</tr>
</tbody>
</table>
|  | The immunosuppressive drug cyclosporine A (CyA) seems to increase plasma Hcy (213, 220), probably by its adverse effect on renal function, which may be difficult to distinguish from renal impairment from other causes in (cardiac and renal) }
Coffee consumption is a strong determinant of plasma Hcy, which shows a dose-response relationship with coffee intake. This relationship is observed for filtered coffee, boiled coffee but not for decaffeinated coffee, in smokers and non-smokers, and is only slightly attenuated after adjustment for vitamin intake (129, 222). The increase in Hcy is paralleled by a decrease in plasma folate (126, 127), but also a decrease in vitamin B6 and riboflavin (but not vitamin B12) (127). Thus, coffee drinkers have higher mean Hcy and lower mean folate than non-drinkers, but the differences are only observed at the lower end of the Hcy distribution (129) and at the higher end of the folate distribution (127, 128). It seems that plasma folate (127) and caffeine (223) are main determinants of Hcy. Possible mechanisms involved are increased renal excretion of folate (at high plasma folate) mediated by caffeine (127) and metabolism of chlorogenic acid in coffee by methylation, leading to increased Hcy production (224).

Smoking tobacco

Smoking is associated with deficiencies of several micronutrients and B-vitamins, including folate. Smokers have lower RBC and plasma/serum folate and higher Hcy than non-smoker (130, 131), and Hcy shows a positive association with cotinine, a marker of tobacco exposure, in passive smokers (225). Folate and Hcy status improve somewhat within days of smoking cessation, but there is a long-term effect in ex-smokers lasting for years with ex-smokers having lower folate and higher Hcy than never smokers (132). It has been suggested that the acute effect of smoking is related to increased folate breakdown or utilization caused by toxic (prooxidant) chemicals, which is in agreement with persistence of low folate after adjustment for dietary intake. The chronic effect may be explained by imprudent dietary habits of ex-smokers in combination with the time required to replenish folate stores (132).

Alcohol consumption

The association between Hcy status and alcohol intake is inconsistent, complex and related to type and amount of alcohol. Intake of beer and to a lesser extent wine may be inversely related to Hcy, which may partly be related to vitamin content in beer (128). Intake of liquor shows a positive association with Hcy (222). However, these associations could be confounded by nutrition and lifestyle factors. In a controlled intervention study, 2 weeks with red wine or vodka (24 g ethanol daily) decreased serum folate and increased Hcy (133). Excessive alcohol intake or alcoholism
is associated with Hcy concentrations twice normal, which are normalized in abstinent alcoholics (135). Thus, a J-shaped association between alcohol intake and Hcy seems to exist. The ethanol related folate-deficiency has been explained by low intake, malabsorption, altered liver metabolism, increased catabolism and renal excretion of folate (45, 135).

### Exercise

More than 15 years ago, Nygard et al. (226) reported an overall inverse association between exercise in leisure time and plasma Hcy in a large epidemiological study of about 16000 men and women. Physical activity is associated with several potential confounders, including nutritional and lifestyle factors and physiological and metabolic changes, and cross sectional and intervention studies (137) on exercise and Hcy have provided inconsistent results (227). Thus, from published results one cannot conclude that physical exercise has a direct effect on biomarkers of folate status, including plasma Hcy.

### Socioeconomic (e.g. education; income)

In a recent analysis of data from NHANES 2003-2006, the socioeconomic variables of education and family poverty-income ratio were significantly associated with Hcy, however they did not account for much of the variability in biomarker concentration (29).

### Biomarker utility of serum folic acid concentration:

Depending on the research question, unmetabolized folic acid in serum or plasma may be considered an exposure, status, functional, and/or effect folate biomarker.

<table>
<thead>
<tr>
<th><strong>Exposure:</strong></th>
<th>The appearance and quantity of unmetabolized folic acid in circulation has been associated with folic acid exposure via fortified foods, dietary supplements, and a combination of both (22, 23, 228).</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Status:</strong></td>
<td>There are no concentration cut-offs for unmetabolized folic acid in blood; however, in the research setting, cases are often grouped and analyzed as those without detectable unmetabolized folic acid versus those with detectable folic acid in circulation. In addition, greater concentrations of unmetabolized folic acid are associated with higher serum folate concentrations (20, 23), suggesting that the amount of folic acid in blood is related to whole body folate status.</td>
</tr>
<tr>
<td><strong>Function:</strong></td>
<td>Dihydrofolate reductase enzyme activity is variable (25), thus unmetabolized folic acid in blood may also be considered a</td>
</tr>
</tbody>
</table>
**Online Supporting Material**

<table>
<thead>
<tr>
<th><strong>functional indicator of the body’s ability to metabolize folic acid to a coenzymatic form.</strong></th>
</tr>
</thead>
</table>

**Effect:**

With bolus doses above 200 µg, which appear to exceed the capacity of the dihydrofolate reductase enzyme to reduce FA during intestinal absorption to the bioactive folate vitamer THF, unmetabolized folic acid appears in post-prandial circulation (229). Ingestion of folic acid, either by consumption of fortified foods or dietary supplements, increases the prevalence of detectable unmetabolized folic acid in blood (22, 228). However, there is large variation in folic acid concentrations and the dose response relationship between folic acid exposure and unmetabolized folic acid in circulation is not entirely clear. Any effect of unmetabolized folic acid in blood on cellular function and/or health remains to be elucidated.

**Biological and contextual factors:**

<table>
<thead>
<tr>
<th><strong>Genetics</strong></th>
<th>Genetic variation in dihydrofolate reductase is a biological factor that may contribute to the variation in unmetabolized folic acid concentrations (24, 25).</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Fasted vs. non-fasted blood collection</strong></td>
<td>As with serum folate concentrations, fasted versus non-fasted blood collection is an important contextual factor in the interpretation of unmetabolized folic acid concentrations.</td>
</tr>
</tbody>
</table>

**Biomarker utility of urinary folate/folic acid concentration:**

Intact 24-hour urinary folate excretion is not a commonly utilized folate biomarker; however, in research settings it can provide unique information about folate status and metabolism when used in concert with serum and/or RBC folate levels.

<table>
<thead>
<tr>
<th><strong>Exposure:</strong></th>
<th>Twenty-four hour urinary folate excretion captures the rise and fall of circulating folate concentrations in response to feeding and fasting and thus may be considered an indicator of “average” folate exposure and status over that 24-hour period (18). This is in contrast to serum folate concentration which reflects a single time point on the 24-h kinetic curve.</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Status:</strong></td>
<td>There are not validated norms to define deficiency/adequacy; however, historical/pre-fortification levels published in the folate DRI (16) can be used for comparison in assessing exposure and bodily folate stores.</td>
</tr>
<tr>
<td><strong>Function:</strong></td>
<td>Folate is reabsorbed from the kidney filtrate; however, the process is saturable, thus, intact urinary folate excretion is a</td>
</tr>
</tbody>
</table>
functional indicator that the folate concentration of the filtrate exceeded this capacity (230). Similarly, excretion of unmetabolized folic acid may be a functional indicator that the capacity of DHFR to reduce folic acid to a physiologic form was exceeded.

**Effect:** Urinary folate excretion is responsive to folate intake (231, 232); however, intact urinary folate excretion exhibits a large degree of inter- and intra-individual variability (233).

**Biological factors** Although less explored, biological factors that impact serum folate likely affect urinary folate excretion as urinary folate is folate which is filtered from blood. Specifically, pregnancy (18, 234) and race/ethnicity (28) have been shown to affect urinary folate excretion.

**Contextual factors** Study design and methods as well as companion folate biomarkers (i.e. serum and RBC folate), are important in the interpretation of urinary folate. Urinary folate excretion as a folate biomarker is most useful when folate intake is known or controlled. Incomplete or improper 24-hour urine collection by study participants is of concern and can be corrected with measurements of urinary creatinine. In the quantification of urinary folate, the large variation in collection volumes and concentrations may present challenges for method development.

**Biomarker utility of urinary and serum pABG and apABG:** The oxidative folate catabolites \( p \)-aminobenzoylglutamate (pABG) and \( p \)-acetamidobenzoylglutamate (apABG) are biomarkers of folate status and turnover. While pABG and apABG are found in blood, urinary pABG and apABG are studied most often.

**Status:** Total urinary catabolite excretion (i.e. pABG plus apABG) is positively correlated with serum total folate and RBC folate and negatively correlated with plasma Hcy (235). Similarly, pABG and apABG in serum are positively correlated with serum total folate concentrations (21).

But these catabolites have high renal clearance, and their serum levels increase up to 30-fold in patients with impaired renal function (21). In contrast, urinary excretion of catabolites reflect net production rate, and are most likely not influenced by renal function, unless severely impaired.
### Exposure:
Urinary pABG and apABG reflect turnover in endogenous folate pools rather than excretion of ingested pABG (236).

### Function:
Folate catabolism and excretion represent an obligatory route of folate loss (237). Importantly, the quantity of urinary pABG and apABG are related to the size and turn-over rates of body folate pools which is unique among folate biomarkers (235, 238).

### Effect:
Urinary excretion of pABG and apABG is positively associated with folate intake (235); however, it is not as sensitive to folate intake as urinary folate excretion (239), serum folate (238), and plasma Hcy (238).

### Biological and contextual factors

<table>
<thead>
<tr>
<th>Biological and contextual factors</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Pregnancy</strong></td>
<td>Pregnancy is an important biological factor that may alter the rate of folate catabolism, and therefore concentrations of urinary pABG and apABG (240-242).</td>
</tr>
<tr>
<td><strong>Ferritin</strong></td>
<td>The iron storage protein ferritin catalyzes the oxidation of 5-formyltetrahydrofolate, thus biological states that impact ferritin concentrations may also effect folate catabolism, production of pABG and apABG, and folate status (243).</td>
</tr>
<tr>
<td><strong>Other</strong></td>
<td>Additional biological and contextual factors that may also increase folate catabolism include cancer and anticonvulsant and contraceptive drug use (45).</td>
</tr>
</tbody>
</table>
Supplemental Table 2

Nutrient Review Outline

I. Background about the Nutrient
   - Historical overview
   - Exposure: food sources
   - Public Health significance: including major causes of deficiency/excess
   - Current guidelines for use

II. Biology of the Nutrient
   - Current understanding of the biology: dependent systems
   - Homeostatic controls/metabolism including nutrient/nutrient interactions
   - Role in health and disease

III. Currently Available Biomarkers: Overview
   - Exposure
   - Status: current cut-offs, how to derive at them and relevance to global/population/individuals
   - Function:
     - direct: biomarkers of function of the micronutrients within relevant biological systems;
     - indirect: surrogate markers of function
   - Effect: markers that respond to intervention (supplement and/or food based)

IV. Biomarker Specific issues: for each biomarker listed in III address:
   - Humans versus animal models versus cell/molecular studies?
     - Exposure (short-/long-term?)
     - Status: are there validated norms to define deficiency/adequacy?
     - Function: do biomarkers reflect direct function, e.g., enzyme stimulation assays or indirectly reflect function of biological systems, e.g., vision, cognition/behavior, growth, immune-competence?
     - Effect: are there markers that directly reflect a response to an intervention either positive or negative?
     - Need for use of surrogate markers of all of the above?

   - Population: considerations for each biomarker with regard to:
Online Supporting Material

- Environment: low/middle income, food insecure etc.
- Life stage/gender considerations
- Health considerations: prevalence of infection, NCDs

- Confounders; impact of the following on performance of each biomarker
  - Bioavailability (in case of use in context of exposure)
  - Time of day/time of exposure/meal/intervention
  - Inflammation
  - Sample source (urine, plasma/serum, RBC etc.)
  - Loss (excretion, secretion etc.),
  - Endocrinology (life stage, stress etc.),
  - Pharmacology (treatment interactions including traditional therapies)
  - Nutrient interactions

V. Assay specific queries
Once a candidate is identified based on the above questions, specific details regarding the assay, methods and technology requirements would be provided to the user.

- Specificity/Sensitivity
- Multiple use? (e.g, can it reflect exposure, status, function, effect?)
- Sample collection considerations
- Optimal cut-off points
- Life stage sensitivity?
  - Infants/Children
  - Adolescents
  - Women of reproductive age
  - Pregnancy
  - Elderly
- Laboratory methodology
  - Reagents
  - Laboratory conditions (temp/humidity etc)
  - Equipment
- Field applicability (technical requirements, capacity/resource needs etc.)
- Interpretation in...
Online Supporting Material

- Isolated nutritional deficiency
- The setting of endemic disease, e.g., malaria
- Interpretation in the presence of other infections/conditions
- Utility for targeting interventions

VI. New Direction/technologies: “omics” etc.
VII. Research Gaps/Needs
VIII. Conclusions
Supplemental Literature Cited


